

**NATIONAL TOXICOLOGY PROGRAM**  
**Technical Report Series**  
**No. 267**



**TOXICOLOGY AND CARCINOGENESIS**  
**STUDIES OF**  
**PROPYLENE OXIDE**  
**(CAS NO. 75-56-9)**  
**IN F344/N RATS AND B6C3F<sub>1</sub> MICE**  
**(INHALATION STUDIES)**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES**  
**Public Health Service**  
**National Institutes of Health**

## **NATIONAL TOXICOLOGY PROGRAM**

The National Toxicology Program (NTP), established in 1978, develops and evaluates scientific information about potentially toxic and hazardous chemicals. This knowledge can be used for protecting the health of the American people and for the primary prevention of disease. By bringing together the relevant programs, staff, and resources from the U.S. Public Health Service, DHHS, the National Toxicology Program has centralized and strengthened activities relating to toxicology research, testing and test development/validation efforts, and the dissemination of toxicological information to the public and scientific communities and to the research and regulatory agencies.

The NTP is made up of four charter DHHS agencies: the National Cancer Institute (NCI), National Institutes of Health; the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research, Food and Drug Administration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS.

**NTP TECHNICAL REPORT  
ON THE  
TOXICOLOGY AND CARCINOGENESIS  
STUDIES OF  
PROPYLENE OXIDE  
IN F344/N RATS AND B6C3F<sub>1</sub> MICE  
(INHALATION STUDIES)**



**NATIONAL TOXICOLOGY PROGRAM  
P.O. Box 12233  
Research Triangle Park, NC 27709**

**March 1985**

**NTP TR 267**

**NIH Publication No. 85-2527      NTP-83-020**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Public Health Service  
National Institutes of Health**

## NOTE TO THE READER

These studies are designed and conducted to characterize and evaluate the toxicologic potential, including carcinogenic activity, of selected chemicals in laboratory animals (usually two species, rats and mice). Chemicals selected for testing in the NTP Carcinogenesis Program are chosen primarily on the bases of human exposure, level of production, and chemical structure. Selection per se is not an indicator of a chemical's carcinogenic potential. Negative results, in which the test animals do not have a greater incidence of cancer than control animals, do not necessarily mean that a test chemical is not a carcinogen, inasmuch as the experiments are conducted under a limited set of conditions. Positive results demonstrate that a test chemical is carcinogenic for animals under the conditions of the test and indicate that exposure to the chemical has the potential for hazard to humans. The determination of the risk to humans from chemicals found to be carcinogenic in animals requires a wider analysis which extends beyond the purview of this study.

Five categories of interpretative conclusions were adopted for use in June 1983 in the Technical Reports series to specifically emphasize consistency and the concept of actual evidence of carcinogenicity. For each definitive study result (male rats, female rats, male mice, female mice), one of the following quintet will be selected to describe the findings. These categories refer to the strength of the experimental evidence and not to either potency or mechanism.

- **Clear Evidence of Carcinogenicity** is demonstrated by studies that are interpreted as showing a chemically related increased incidence of malignant neoplasms, studies that exhibit a substantially increased incidence of benign neoplasms, or studies that exhibit an increased incidence of a combination of malignant and benign neoplasms where each increases with dose.
- **Some Evidence of Carcinogenicity** is demonstrated by studies that are interpreted as showing a chemically related increased incidence of benign neoplasms, studies that exhibit marginal increases in neoplasms of several organs/tissues, or studies that exhibit a slight increase in uncommon malignant or benign neoplasms.
- **Equivocal Evidence of Carcinogenicity** is demonstrated by studies that are interpreted as showing a chemically related marginal increase of neoplasms.
- **No Evidence of Carcinogenicity** is demonstrated by studies that are interpreted as showing no chemically related increases in malignant or benign neoplasms.
- **Inadequate Study of Carcinogenicity** demonstrates that because of major qualitative or quantitative limitations, the studies cannot be interpreted as valid for showing either the presence or absence of a carcinogenic effect.

Additionally, the following concepts (as patterned from the International Agency for Research on Cancer Monographs) have been adopted by the NTP to give further clarification of these issues:

The term *chemical carcinogenesis* generally means the induction by chemicals of neoplasms not usually observed, the earlier induction by chemicals of neoplasms that are commonly observed, or the induction by chemicals of more neoplasms than are generally found. Different mechanisms may be involved in these situations. Etymologically, the term *carcinogenesis* means induction of cancer, that is, of malignant neoplasms; however, the commonly accepted meaning is the induction of various types of neoplasms or of a combination of malignant and benign neoplasms. In the Technical Reports, the words *tumor* and *neoplasm* are used interchangeably.

This study was initiated by the National Cancer Institute's Carcinogenesis Testing Program, now part of the National Institute of Environmental Health Sciences, National Toxicology Program. The study described in this Technical Report has been conducted under NTP health and safety requirements and/or guidelines for toxicity studies. Individual toxicology testing contractors are required to demonstrate corporate health and safety programs in compliance with NTP chemical health and safety requirements and to meet or exceed all applicable Federal, state, and local health and safety regulations.

Although every effort is made to prepare the Technical Reports as accurately as possible, mistakes may occur. Readers are requested to identify any mistakes so that corrective action may be taken. Further, anyone who is aware of related ongoing or published studies not mentioned in this report is encouraged to make this information known to the NTP. Comments and questions about the National Toxicology Program Technical Reports on Toxicology and Carcinogenesis Studies should be directed to Dr. J.E. Huff, National Toxicology Program, P.O. Box 12233, Research Triangle Park, NC 27709 (919-541-3780).

These NTP Technical Reports are available for sale from the National Technical Information Service, U.S. Department of Commerce, 5285 Port Royal Road, Springfield, VA 22161 (703-487-4650). Single copies of this Technical Report are available without charge (and while supplies last) from the NTP Public Information Office, National Toxicology Program, P.O. Box 12233, Research Triangle Park, NC 27709.

# CONTENTS

	PAGE
ABSTRACT .....	11
CONTRIBUTORS .....	13
PEER REVIEW PANEL .....	14
SUMMARY OF PEER REVIEW COMMENTS .....	15
I. INTRODUCTION .....	17
II. MATERIALS AND METHODS .....	21
PROCUREMENT AND CHARACTERIZATION OF PROPYLENE OXIDE .....	22
GENERATION AND MEASUREMENT OF CHAMBER CONCENTRATIONS .....	22
SINGLE-EXPOSURE STUDIES .....	22
REPEATED-EXPOSURE STUDIES .....	22
THIRTEEN-WEEK STUDIES .....	26
TWO-YEAR STUDIES .....	26
STUDY DESIGN .....	26
SOURCE AND SPECIFICATIONS OF TEST ANIMALS .....	26
ANIMAL MAINTENANCE .....	26
CLINICAL EXAMINATIONS AND PATHOLOGY .....	27
STATISTICAL METHODS .....	27
III. RESULTS .....	29
RATS .....	30
SINGLE-EXPOSURE STUDIES .....	30
REPEATED-EXPOSURE STUDIES .....	30
THIRTEEN-WEEK STUDIES .....	31
TWO-YEAR STUDIES .....	32
BODY WEIGHTS AND CLINICAL SIGNS .....	32
SURVIVAL .....	32
PATHOLOGY AND STATISTICAL ANALYSES OF RESULTS .....	36
MICE .....	39
SINGLE-EXPOSURE STUDIES .....	39
REPEATED-EXPOSURE STUDIES .....	39
THIRTEEN-WEEK STUDIES .....	40
TWO-YEAR STUDIES .....	41
BODY WEIGHTS AND CLINICAL SIGNS .....	41
SURVIVAL .....	43
PATHOLOGY AND STATISTICAL ANALYSES OF RESULTS .....	45
IV. DISCUSSION AND CONCLUSIONS .....	49
V. REFERENCES .....	55

## TABLES

	PAGE
TABLE 1	INCIDENCES OF MAMMARY TUMORS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE ..... 20
TABLE 2	SUMMARY OF CHAMBER CONCENTRATIONS OF PROPYLENE OXIDE DURING THE TWO-YEAR STUDIES ..... 22
TABLE 3	EXPERIMENTAL DESIGN AND MATERIALS AND METHODS IN THE INHALATION STUDIES OF PROPYLENE OXIDE ..... 23
TABLE 4	SURVIVAL OF RATS IN THE SINGLE FOUR-HOUR-EXPOSURE INHALATION STUDIES OF PROPYLENE OXIDE ..... 30
TABLE 5	SURVIVAL AND MEAN BODY WEIGHTS OF RATS IN THE TWO-WEEK REPEATED-EXPOSURE INHALATION STUDIES OF PROPYLENE OXIDE ..... 30
TABLE 6	SURVIVAL AND MEAN BODY WEIGHTS OF RATS IN THE THIRTEEN-WEEK INHALATION STUDIES OF PROPYLENE OXIDE ..... 31
TABLE 7	MEAN BODY WEIGHTS AND SURVIVAL OF RATS IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE ..... 32
TABLE 8	SURVIVAL OF RATS IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE ..... 34
TABLE 9	INCIDENCES OF NASAL CAVITY LESIONS IN RATS IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE ..... 36
TABLE 10	ANALYSIS OF NASAL CAVITY TUMORS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE ..... 36
TABLE 11	INCIDENCES OF THYROID GLAND LESIONS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE ..... 37
TABLE 12	ANALYSIS OF UTERINE TUMORS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE ..... 38
TABLE 13	ANALYSIS OF PITUITARY TUMORS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE ..... 38
TABLE 14	SURVIVAL OF MICE IN THE SINGLE FOUR-HOUR-EXPOSURE INHALATION STUDIES OF PROPYLENE OXIDE ..... 39

**TABLES (Continued)**

	<b>PAGE</b>
<b>TABLE 15</b>	<b>SURVIVAL AND MEAN BODY WEIGHTS OF MICE IN THE TWO-WEEK REPEATED-EXPOSURE INHALATION STUDIES OF PROPYLENE OXIDE ..... 39</b>
<b>TABLE 16</b>	<b>SURVIVAL AND MEAN BODY WEIGHTS OF MICE IN THE THIRTEEN-WEEK INHALATION STUDIES OF PROPYLENE OXIDE ..... 40</b>
<b>TABLE 17</b>	<b>MEAN BODY WEIGHTS AND SURVIVAL OF MICE IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE ..... 41</b>
<b>TABLE 18</b>	<b>SURVIVAL OF MICE IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE ..... 43</b>
<b>TABLE 19</b>	<b>INCIDENCES OF NASAL CAVITY EPITHELIAL LESIONS IN MICE IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE ..... 45</b>
<b>TABLE 20</b>	<b>ANALYSIS OF VASCULAR TUMORS OF THE NASAL CAVITY IN MICE IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE ..... 46</b>
<b>TABLE 21</b>	<b>ANALYSIS OF MAMMARY GLAND TUMORS IN FEMALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE ..... 47</b>

## FIGURES

	PAGE
<b>FIGURE 1 GROWTH CURVES FOR RATS EXPOSED TO PROPYLENE OXIDE BY INHALATION FOR TWO YEARS .....</b>	<b>33</b>
<b>FIGURE 2 KAPLAN-MEIER SURVIVAL CURVES FOR RATS EXPOSED TO PROPYLENE OXIDE BY INHALATION FOR TWO YEARS .....</b>	<b>35</b>
<b>FIGURE 3 GROWTH CURVES FOR MICE EXPOSED TO PROPYLENE OXIDE BY INHALATION FOR TWO YEARS .....</b>	<b>42</b>
<b>FIGURE 4 KAPLAN-MEIER SURVIVAL CURVES FOR MICE EXPOSED TO PROPYLENE OXIDE BY INHALATION FOR TWO YEARS .....</b>	<b>44</b>
<b>FIGURE 5 INFRARED ABSORPTION SPECTRUM OF PROPYLENE OXIDE (LOT NO. UC 5/10/76) .....</b>	<b>145</b>
<b>FIGURE 6 NUCLEAR MAGNETIC RESONANCE SPECTRUM OF PROPYLENE OXIDE (LOT NO. UC 5/10/76) .....</b>	<b>147</b>
<b>FIGURE 7 INFRARED ABSORPTION SPECTRUM OF PROPYLENE OXIDE (LOT NO. 6477-22) .....</b>	<b>149</b>
<b>FIGURE 8 NUCLEAR MAGNETIC RESONANCE SPECTRUM OF PROPYLENE OXIDE (LOT NO. 6477-22) .....</b>	<b>150</b>
<b>FIGURE 9 PROPYLENE OXIDE VAPOR GENERATION SYSTEM .....</b>	<b>155</b>
<b>FIGURE 10 CUTAWAY DRAWING OF THE LIQUID VAPOR GENERATOR .....</b>	<b>156</b>
<b>FIGURE 11 SCHEMATIC FRONT VIEW OF CHAMBER SHOWING APPROXIMATE SAMPLE SITES .....</b>	<b>157</b>
<b>FIGURE 12 WEEKLY MEAN CONCENTRATION AND STANDARD DEVIATION IN 200-PPM RAT EXPOSURE CHAMBER FOR ENTIRE 103-WEEK STUDY .....</b>	<b>160</b>
<b>FIGURE 13 WEEKLY MEAN CONCENTRATION AND STANDARD DEVIATION IN 400-PPM RAT EXPOSURE CHAMBER FOR ENTIRE 103-WEEK STUDY .....</b>	<b>161</b>
<b>FIGURE 14 WEEKLY MEAN CONCENTRATION AND STANDARD DEVIATION IN 200-PPM MOUSE EXPOSURE CHAMBER FOR ENTIRE 103-WEEK STUDY .....</b>	<b>162</b>
<b>FIGURE 15 WEEKLY MEAN CONCENTRATION AND STANDARD DEVIATION IN 400-PPM MOUSE EXPOSURE CHAMBER FOR ENTIRE 103-WEEK STUDY .....</b>	<b>163</b>



## APPENDIXES

	PAGE
<b>APPENDIX A</b>	
<b>SUMMARY OF THE INCIDENCE OF NEOPLASMS IN RATS IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE</b> .....	<b>59</b>
<b>TABLE A1</b>	
<b>SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE</b> .....	<b>60</b>
<b>TABLE A2</b>	
<b>SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE</b> .....	<b>63</b>
<b>TABLE A3</b>	
<b>INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE</b> .....	<b>66</b>
<b>TABLE A4</b>	
<b>INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE</b> .....	<b>72</b>
<b>APPENDIX B</b>	
<b>SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MICE IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE</b> .....	<b>79</b>
<b>TABLE B1</b>	
<b>SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE</b> .....	<b>81</b>
<b>TABLE B2</b>	
<b>SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE</b> .....	<b>83</b>
<b>TABLE B3</b>	
<b>INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE</b> .....	<b>86</b>
<b>TABLE B4</b>	
<b>INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE</b> .....	<b>92</b>
<b>APPENDIX C</b>	
<b>SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN RATS IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE</b> .....	<b>99</b>
<b>TABLE C1</b>	
<b>SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE</b> .....	<b>100</b>
<b>TABLE C2</b>	
<b>SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE</b> .....	<b>108</b>


**APPENDIXES (Continued)**

	<b>PAGE</b>
<b>APPENDIX D</b>	
<b>SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MICE IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE</b> .....	115
<b>TABLE D1</b>	
<b>SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE</b> .....	116
<b>TABLE D2</b>	
<b>SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE</b> .....	120
<b>APPENDIX E</b>	
<b>ANALYSES OF PRIMARY TUMORS IN RATS AND MICE IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE</b> .....	125
<b>TABLE E1</b>	
<b>ANALYSIS OF PRIMARY TUMORS IN MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE</b> .....	126
<b>TABLE E2</b>	
<b>ANALYSIS OF PRIMARY TUMORS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE</b> .....	129
<b>TABLE E3</b>	
<b>ANALYSIS OF PRIMARY TUMORS IN MALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE</b> .....	131
<b>TABLE E4</b>	
<b>ANALYSIS OF PRIMARY TUMORS IN FEMALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE</b> .....	133
<b>APPENDIX F</b>	
<b>HISTORICAL INCIDENCES OF TUMORS IN F344/N RATS AND B6C3F<sub>1</sub> MICE RECEIVING NO TREATMENT</b> .....	137
<b>TABLE F1</b>	
<b>HISTORICAL INCIDENCE OF INTEGUMENTARY TUMORS IN MALE F344/N RATS RECEIVING NO TREATMENT</b> .....	138
<b>TABLE F2</b>	
<b>HISTORICAL INCIDENCE OF NASAL CAVITY TUMORS IN MALE F344/N RATS RECEIVING NO TREATMENT</b> .....	138
<b>TABLE F3</b>	
<b>HISTORICAL INCIDENCE OF NASAL CAVITY TUMORS IN FEMALE F344/N RATS RECEIVING NO TREATMENT</b> .....	139
<b>TABLE F4</b>	
<b>HISTORICAL INCIDENCE OF CIRCULATORY SYSTEM TUMORS IN MALE F344/N RATS RECEIVING NO TREATMENT</b> .....	139
<b>TABLE F5</b>	
<b>HISTORICAL INCIDENCE OF THYROID GLAND TUMORS IN FEMALE F344/N RATS RECEIVING NO TREATMENT</b> .....	140
<b>TABLE F6</b>	
<b>HISTORICAL INCIDENCE OF UTERINE TUMORS IN FEMALE F344/N RATS RECEIVING NO TREATMENT</b> .....	140

APPENDIXES (Continued)

	PAGE
TABLE F7 HISTORICAL INCIDENCE OF MAMMARY GLAND TUMORS IN FEMALE B6C3F <sub>1</sub> MICE RECEIVING NO TREATMENT .....	141
TABLE F8 HISTORICAL INCIDENCE OF CIRCULATORY SYSTEM TUMORS IN MALE B6C3F <sub>1</sub> MICE RECEIVING NO TREATMENT .....	141
TABLE F9 HISTORICAL INCIDENCE OF CIRCULATORY SYSTEM TUMORS IN FEMALE B6C3F <sub>1</sub> MICE RECEIVING NO TREATMENT .....	142
APPENDIX G CHEMICAL CHARACTERIZATION OF PROPYLENE OXIDE .....	143
APPENDIX H GENERATION AND MEASUREMENT OF CHAMBER CONCENTRATIONS .....	153
TABLE H1 PROPYLENE OXIDE VAPOR CONCENTRATION UNIFORMITY TEST RESULTS ..	158
APPENDIX I SENTINEL ANIMAL PROGRAM .....	165
APPENDIX J DATA AUDIT SUMMARY .....	167





## PROPYLENE OXIDE

CAS NO. 75-56-9

Mol. Wt. 58.08

### ABSTRACT

The 2-year carcinogenesis studies of propylene oxide (greater than 99.9% pure) were conducted by exposing groups of 50 F344/N rats and 50 B6C3F<sub>1</sub> mice of each sex to air containing propylene oxide at concentrations of 0 (chamber control), 200, or 400 ppm for 6 hours per day, 5 days per week, for 103 weeks.

The survival of rats exposed to propylene oxide was comparable with that of the controls; terminal body weights were lower than those of the controls for high dose males (8%) and high dose females (6%). Survival of exposed male and female mice decreased relative to that of the controls (male: control, 42/50; low dose, 34/50; high dose, 29/50; female: 38/50; 29/50; 10/50), but the difference was significant only for animals in the high dose groups. High dose female mice had a mean terminal body weight 10% below that of the controls; high dose male mice had a terminal body weight 22% below that of the controls.

The respiratory epithelium of the nasal turbinates was one of the primary tissues affected in male and female rats; exposure-related increases occurred in the incidences of suppurative inflammation, epithelial hyperplasia, and squamous metaplasia. Papillary adenomas, involving the respiratory epithelium and underlying submucosal glands of the nasal turbinates, were observed in three female rats and two male rats exposed to propylene oxide at 400 ppm. The incidence of adenomas in females was significant by the trend tests.

The proportions of high dose female rats with C-cell adenomas and with C-cell carcinomas of the thyroid gland were increased, but only the combined incidence of these tumors was significant (2/45; 2/35; 7/37). These tumors were not considered to be related to exposure to propylene oxide because there was no other evidence for C-cells' being a target tissue and because there was no increase in C-cell hyperplasia.

The combined incidences of female rats with endometrial stromal polyps and endometrial stromal sarcomas of the uterus were significantly increased in the dosed groups (3/49; 12/50; 10/47). However, the occurrence of these lesions in the dosed groups was similar to the average (306/1,502, 20%) seen in untreated controls in NTP carcinogenesis studies, and hence this increase was not regarded as being related to exposure to propylene oxide.

The respiratory epithelium of the nasal turbinates was also one of the primary tissues affected in male and female mice; exposure-related increases occurred in the incidences of inflammation, and squamous metaplasia was observed in one low dose male and two high dose female mice. One squamous cell carcinoma and one papilloma occurred in the nasal cavity of different high dose male mice, and two high dose female mice had adenocarcinomas of the nasal cavity. The endothelial cells of the submucosal vascular plexus in the nasal turbinates also appeared to be a major site affected in high dose male mice. Three high dose male and three high dose female mice had a saccular dilation (classified as angiectasis) of submucosal turbinate vessels. Further, hemangiomas were seen in the nasal cavity of 5/50 high dose male mice and 3/50 high dose female mice, and hemangiosarcomas were found in the nasal cavity of 5/50 high dose male mice and 2/50 high dose female mice. The increased

incidences of hemangiomas in males and females and of hemangiosarcomas in males were statistically significant. Vascular tumors were not present in the nasal turbinates of any low dose or control mice.

Under the conditions of these studies, there was *some evidence of carcinogenicity\** for F344/N rats, as indicated by increased incidences of papillary adenomas of the nasal turbinates in male and female rats exposed to propylene oxide at 400 ppm. For male and female B6C3F<sub>1</sub> mice, there was *clear evidence of carcinogenicity*, as indicated by increased incidences of hemangiomas or hemangiosarcomas of the nasal turbinates at 400 ppm. In the respiratory epithelium of the nasal turbinates, propylene oxide also caused suppurative inflammation, hyperplasia, and squamous metaplasia in rats and inflammation in mice.

---

\* Categories of evidence of carcinogenicity are defined in the Note to the Reader on page 2.

## CONTRIBUTORS

The NTP Technical Report on the Toxicology and Carcinogenesis Studies of Propylene Oxide is based on the 13-week studies that began in March 1977 and ended in June 1977 at Industrial Biotest Laboratories and the 2-year studies that began in August 1979 and ended in December 1981 at Battelle Pacific Northwest Laboratories.

**National Toxicology Program  
National Toxicology Program, P.O. Box 12233  
Research Triangle Park, NC 27709  
(Evaluated Experiment, Interpreted Results, and Reported Findings)**

Gary A. Boorman, D.V.M., Ph.D. (Chemical Manager)

Rajendra S. Chhabra, Ph.D.  
Joseph K. Haseman, Ph.D.  
James Huff, Ph.D.  
C.W. Jameson, Ph.D.  
E.E. McConnell, D.V.M.

John A. Moore, D.V.M.  
G.N. Rao, D.V.M., Ph.D.  
B.A. Schwetz, D.V.M., Ph.D.  
M.D. Shelby, Ph.D.  
Raymond W. Tennant, Ph.D.  
E. Zeiger, Ph.D.

**NTP Pathology Working Group  
(Evaluated Slides and Prepared Pathology Report on 7/16/82 and 8/17/82)**

G.A. Boorman, D.V.M., Ph.D.  
NTP  
S.L. Eustis, D.V.M., Ph.D.  
NTP

R.M. Kovatch, D.V.M.  
Tracor Jitco, Inc.  
J.A. Popp, D.V.M., Ph.D.  
Chemical Industry Institute of  
Toxicology

**Principal Contributors at Battelle Pacific Northwest Laboratories  
(Conducted Bioassay and Evaluated Tissues)**

William J. Clarke, D.V.M., Ph.D.  
Principal Investigator  
R.A. Renne, D.V.M.  
Pathologist

W. Ellis Giddens, Jr., D.V.M., Ph.D.  
Pathologist  
R.B. Westerberg, Ph.D.  
Chemist

**Principal Contributors at Experimental Pathology Laboratory  
(Provided Pathology Quality Assurance)**

Jerry Hardisty, D.V.M. (mice)

Martin Robl, D.V.M., Ph.D. (rats)

**Principal Contributors at Carltech Associates, Inc.  
(Contractor for Technical Report Preparation)**

William D. Theriault, Ph.D.  
Project Manager  
Abigail C. Jacobs, Ph.D.  
Senior Scientist

John Warner, M.S.  
Chemist/Statistician

## PEER REVIEW PANEL

The members of the Peer Review Panel who evaluated this Technical Report are listed below. Panel members serve as independent scientists, not as representatives of any institution, company, or governmental agency. In this capacity Panel members have five major responsibilities: (a) to ascertain that all relevant literature data have been adequately cited and interpreted, (b) to determine if the design and conditions of the NTP studies were appropriate, (c) to ensure that the Technical Report presents the experimental results and conclusions fully and clearly, (d) to judge the significance of the experimental results by scientific criteria, and (e) to assess the evaluation of the evidence of carcinogenicity and other observed toxic responses.

### National Toxicology Program Board of Scientific Counselors Technical Reports Review Subcommittee

Dr. Jerry B. Hook (Chairperson)  
Vice President, Preclinical Research and Development  
Smith Kline & French Laboratories  
Philadelphia, Pennsylvania

Curtis Harper, Ph.D. (Principal Reviewer)  
Associate Professor of Pharmacology  
School of Medicine  
University of North Carolina  
Chapel Hill, North Carolina

James Swenberg, Ph.D., D.V.M.  
Chief of Pathology  
Chemical Industry Institute of Toxicology  
Research Triangle Park, North Carolina

### Ad Hoc Subcommittee Panel of Experts

Louis S. Beliczky, M.S., M.P.H.  
Director, Department of Industrial Hygiene  
United Rubber Workers International Union  
Akron, Ohio

Tom Slaga, Ph.D. (Principal Reviewer)  
University of Texas System  
Cancer Center  
Science Park, Research Division  
Smithville, Texas

Devra L. Davis, Ph.D.  
Science Policy Director  
Environmental Law Institute  
Washington, D.C.

John R. Van Ryzin, Ph.D.  
Division of Biostatistics  
School of Public Health  
Columbia University  
New York, New York

Robert M. Elashoff, Ph.D.  
University of California at Los Angeles  
Jonsson Comprehensive Cancer Center  
Los Angeles, California

Stan D. Vesselinovitch, Ph.D.\*  
Professor, Departments of  
Radiology and Pathology  
University of Chicago  
Chicago, Illinois

Seymour L. Friess, Ph.D.  
Arlington, Virginia

J. Michael Holland, Ph.D., D.V.M.  
(Principal Reviewer)  
Chevron Environmental Health Center  
Richmond, California

Mary Vore, Ph.D.\*  
Assistant Professor  
Pharmacology Department  
University of Kentucky  
College of Medicine  
Lexington, Kentucky

Robert A. Scala, Ph.D.  
Exxon Corporation  
East Millstone, New Jersey

---

\* Unable to attend June 29, 1983, meeting



## SUMMARY OF PEER REVIEW COMMENTS ON THE CARCINOGENESIS STUDIES OF PROPYLENE OXIDE

On June 29, 1983, the Technical Report on propylene oxide received peer review by the National Toxicology Program Board of Scientific Counselors' Technical Reports Review Subcommittee and associated Panel of Experts. The review meeting began at 9:00 a.m. in the Conference Center, Building 101, South Campus, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina. Members of the subcommittee were: Drs. Jerry Hook (Chairperson), Curtis Harper, and James Swenberg. Members of the Panel were: Mr. Louis Beliczky, and Drs. Devra Davis, Robert Elashoff, Seymour Friess, Michael Holland, Robert Scala, Tom Slaga, John Van Ryzin, Stan Vesselinovich, and Mary Vore. Drs. Vesselinovich and Vore were unable to attend the meeting.

Dr. Holland, a principal reviewer for the Technical Report on the toxicology and carcinogenesis inhalation studies of propylene oxide, agreed in essence with the conclusions. He questioned whether propylene oxide "caused" hemangiomas and hemangiosarcomas in mice and suggested "associated with" the increased incidences as a preferable wording. Given the strong irritant properties of the chemical, tumor formation could be through indirect mechanisms. Dr. Friess agreed that the induction of nasal hemangiomas and hemangiosarcomas should be considered associated with, rather than caused by, the chemical. He suggested also that the tumors may have arisen from an action secondary to irritation, an action expressed only above a threshold level. Dr. Swenberg stated that these types of vascular tumors are so rare that the designation of clear evidence of carcinogenicity was appropriate. Dr. G. Boorman, NTP, noted that the mechanisms of action for most chemical carcinogens are unknown. Further, other evidence indicates that propylene oxide is a site-specific carcinogen.

Dr. Holland recommended that P values for assessing significance of survival between control and exposed groups should be summarized in the Technical Report. Dr. Haseman, NTP, indicated this would be done [see pages 34 and 43].

As a second principal reviewer, Dr. Slaga agreed with the conclusions but requested more discussion about why the increased incidence of adenomas and carcinomas of the thyroid in female rats was not considered chemically related. Dr. Boorman noted that the thyroid C-cell lesions were statistically significant only when combined, but were discounted because no increase in hyperplasias was observed and because no compelling evidence or rationale was apparent for C-cells' being a target tissue.

As a third principal reviewer, Dr. Harper agreed with the conclusions and also stated that the significance of differences in survival should be added routinely to the Technical Reports.

Dr. Davis noted that propylene oxide is an alkylating agent and is mutagenic and requested that nontumor data be given more prominent treatment. Dr. Boorman said this would be done where applicable. Dr. Scala noted the temperature fluctuations that occurred in the inhalation chambers and the variations in the concentrations of propylene oxide in the chamber, which reflected both overexposure and underexposure and which could temper the conclusions attributing a carcinogenic effect to a particular dose concentration. Dr. Boorman replied that there were only three instances of overexposure, the longest being 38 minutes, and he did not think they would influence the interpretations of the studies. Dr. Scala agreed.


Dr. Holland moved that the Technical Report on the toxicology and carcinogenesis studies of propylene oxide be accepted with the revisions discussed. Dr. Harper seconded the motion, and the Technical Report was approved unanimously by the Peer Review Panel.



# I. INTRODUCTION

# I. INTRODUCTION

---



## PROPYLENE OXIDE

CAS NO. 75-56-9

Mol. Wt. 58.08

Propylene oxide is a volatile, colorless liquid used as an intermediate in the production of polyether polyols, polyurethane foams, and unsaturated polyester resins and also as a fumigant for sterilizing a variety of materials ranging from plastic medical instruments to foodstuffs (IARC, 1976). In the United States, propylene oxide is registered as a fumigant for packaged dried prunes and glacé fruits such as candied cherries and as an insecticidal and fungicidal fumigant for bulk quantities of cocoa, gums, and processed spices.

The concentration of propylene oxide residues in food is not to exceed 300 ppm (USCFR, 1979). In Japan, residues of propylene oxide at concentrations ranging from 10 ppm to several thousand parts per million have been measured in various foods fumigated with propylene oxide (Oguma et al., 1968, 1969). Plastic and cellulose products used as food wrappings also were shown to contain up to 6,000 ppm propylene oxide after being fumigated (Hirashima et al., 1970). Total production in the United States in 1980 was 1,767 million kilograms (USITC, 1981). Propylene oxide is also produced in Canada, Japan, and several European countries (IARC, 1976).

Propylene oxide is an irritant, a mild proto-plastic poison, and a mild central nervous system depressant (Hine et al., 1981). Human exposure to propylene oxide vapors has caused corneal burns (McLaughlin, 1946) and contact dermatitis (Jensen, 1981; van Ketel, 1979). The current operating American Conference of Governmental Industrial Hygienists (ACGIH) and Occupational Safety and Health Administration (OSHA) limit for occupational exposure is 100 ppm (ACGIH, 1980). The recommended change is to 50 ppm.

In acute toxicity studies, LD<sub>50</sub> values of 1.14 g/kg for rats and 0.69 g/kg for guinea pigs were

obtained when propylene oxide was administered by gavage as a 5% aqueous solution (Jacobsen et al., 1956).

In inhalation studies, propylene oxide vapors appear to be about one-third as toxic as ethylene oxide (Hine et al., 1981). Groups of rats exposed to propylene oxide once for 30 minutes had 100% mortality at the 14,400-ppm concentration and 50% mortality at 7,200 ppm; a 2-hour exposure at 3,600 ppm killed 4/10 animals (Rowe et al., 1956; Jacobsen et al., 1956). Direct irritation of bronchi, bronchioles, and alveoli was found in animals that died after exposure at high concentrations. Effects included lacrimation, salivation, nasal discharge, and dyspnea; the injuries predisposed the animals to pulmonary infection (Hine et al., 1981).

Propylene oxide has been demonstrated to alkylate DNA in vitro. It reacts preferentially with guanine and adenine to produce hydroxy-propyl adducts (Lawley and Jarman, 1972) and strand breaks (Walles, 1974). The strand breaks are presumably caused by alkylation of the phosphodiester backbone (Walles, 1974). Its alkylating ability has also been demonstrated with 4-(p-nitrobenzyl)pyridine (Hemminki and Falck, 1979; Hemminki et al., 1980). Consistent with this alkylating ability is propylene oxide's induction of mutations in bacteriophage and *Bacillus subtilis* single-stranded DNA in two different bacterial transformation assays (Phillips et al., 1980; Garro and Phillips, 1980). Conflicting results were obtained with respect to strand-breaking ability in both assays. Incubation of *Escherichia coli* bacteriophage T2 with propylene oxide did not produce mutation (Cookson et al., 1971).

Propylene oxide was found to be a direct-acting mutagen in Salmonella assays (Ames et al., 1975) performed in a number of laboratories using spot test, plate assay, and suspension test

protocols (Bootman et al., 1979; Hemminki and Falck, 1979; McMahon et al., 1979; Pfeiffer and Dunkelberg, 1980; Wade et al., 1978). It preferentially mutated strains TA1535 and TA100, indicating that only base-pair substitution mutations were induced. Propylene oxide was also a direct-acting mutagen in *Klebsiella pneumoniae* (Voogd et al., 1981) and *E. coli* (Bootman et al., 1979; Hemminki and Falck, 1979; Hemminki et al., 1980). Mutations were also induced in the yeast, *Schizosaccharomyces pombe* (Heslot, 1962), and in *Neurospora crassa* (Kolmark and Giles, 1955). In *Drosophila*, propylene oxide produced sex-linked recessive lethal mutations (Schalet, 1954; Hardin et al., 1983).

Propylene oxide produced a high frequency of chromatid aberrations (primarily gaps, but some exchanges and deletions) in an "epithelial-like" rat liver cell line that did not undergo exogenous metabolic activation (Dean and Hodson-Walker, 1979). In addition, human lymphocytes exhibited a high frequency of chromatid breaks and gaps following in vitro incubation with propylene oxide (Bootman et al., 1979).

A micronucleus test (i.e., measurement of the production of micronucleated, polychromatic erythrocytes) was negative in male CD-1 mice administered propylene oxide by gavage in two 100, 250, or 500 mg/kg doses (Bootman et al., 1979). A low-level, dose-related response was obtained, however, when two doses of 75 or 300 mg/kg propylene oxide in water were administered intraperitoneally; only the response to the 300 mg/kg dose was significantly elevated. A dominant lethal test in male CD-1 mice produced no decreases in total implants or increases in implant deaths when propylene oxide in 0.5% gum tragacanth was administered by gavage for 14 consecutive days at doses of 50 or 250 mg/kg (Bootman et al., 1979).

No significant increases occurred in the incidences of chromosomal aberrations or sister chromatid exchanges in peripheral lymphocytes from *Cynomolgus* monkeys (*Macaca fascicularis*) exposed to propylene oxide by inhalation. Ethylene oxide produced weakly positive results in the same study (NIOSH, 1983).

Tumors of the forestomach, mainly squamous cell carcinomas, occurred in 4% and 40% of female Sprague-Dawley rats administered

propylene oxide in salad oil by gavage at doses of 15 and 60 mg/kg body weight (Dunkelberg, 1982). Doses were administered twice per week for 150 days. These tumors were seen in 16% and 62% of the animals administered ethylene oxide at doses of 7.5 and 30 mg/kg, respectively, on the same schedule. There was no evidence that either compound induced tumors at sites other than the forestomach.

When administered subcutaneously, propylene oxide has been associated with tumors at the injection site in rats (Walpole, 1958) and mice (Dunkelberg, 1979, 1981). The National Institute for Occupational Safety and Health (NIOSH) concluded that inhalation exposure of male F344 rats to ethylene oxide (50 or 100 ppm) for 2 years was associated with an increased incidence of mesotheliomas (apparently from the tunica vaginalis) and a low incidence of central nervous system gliomas (NIOSH, 1983). Administration of propylene oxide (100 or 300 ppm) to male F344 rats under the same exposure conditions did not produce evidence of exposure-related tumors other than two adenomas of the nasal cavity in the high dose group. These findings were confirmed by an NTP Pathology Working Group.

A joint industry committee on propylene oxide sponsored a 28-month inhalation toxicity/carcinogenicity study of propylene oxide in rats (Reuzel and Kuper, 1983). Groups of 70 male and female rats (Cpb:Wu, Wistar Random) were exposed to propylene oxide at concentrations of 0, 30, 100, or 300 ppm, 6 hours per day, 5 days per week for 124 weeks (males) or 123 weeks (females). Additional groups of 10 animals were exposed and examined at 12, 18, and 24 months. At 300 ppm, there was a slight weight reduction and increased mortality in both males and females as compared with controls. Nonneoplastic compound-related changes were found only in the nasal cavity, where four levels were examined. These changes included degeneration of the olfactory epithelium and hyperplasia of the respiratory epithelium. Squamous metaplasia was not found. Compound-related tumors were restricted to the female rat; both the number of rats bearing mammary tumors and the number of mammary tumors per rat were significantly increased (Table 1).

# I. INTRODUCTION

---

Propylene oxide was tested because of its extensive production, the potential for human exposure in the workplace or in food, the positive

results of short-term genetic assays, and the inadequacy of available animal carcinogenesis data.

**TABLE 1. INCIDENCES OF MAMMARY TUMORS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (a)**

	<b>Concentration Propylene Oxide (ppm)</b>			
	<b>0</b>	<b>30</b>	<b>100</b>	<b>300</b>
No. with benign mammary tumors	32	30	39	47
Av. no. tumors/tumor-bearing animal	1.3	2.1	2.2	2.4
No. with carcinomas	3	6	5	8

(a) Reuzel and Kuper, 1983

## **II. MATERIALS AND METHODS**

### **PROCUREMENT AND CHARACTERIZATION OF PROPYLENE OXIDE**

### **GENERATION AND MEASUREMENT OF CHAMBER CONCENTRATIONS**

### **SINGLE-EXPOSURE STUDIES**

### **REPEATED-EXPOSURE STUDIES**

### **THIRTEEN-WEEK STUDIES**

### **TWO-YEAR STUDIES**

#### **Study Design**

#### **Source and Specifications of Test Animals**

#### **Animal Maintenance**

#### **Clinical Examinations and Pathology**

#### **Statistical Methods**

## II. MATERIALS AND METHODS

### PROCUREMENT AND CHARACTERIZATION OF PROPYLENE OXIDE

Propylene oxide was obtained from Leidy Chemical Corporation (Baltimore, MD) in two lots. Lot no. UC 5/10/76 was used for the single-exposure, repeated-exposure, and 13-week studies; and lot no. 6477-22 was used for the 2-year studies. Purity and identity analyses were conducted at Midwest Research Institute (Kansas City, MO). The identities of both lots of the chemical were confirmed by elemental and spectroscopic analyses (Appendix G). Elemental analyses for carbon and hydrogen agreed with theoretical values. Two gas chromatographic systems indicated only a major peak. Data obtained from these studies indicate that the propylene oxide used in these studies was greater than 99.9% pure.

After the test chemical was received from the analytical contractor, the testing laboratory performing the 2-year studies stored the chemical at room temperature and periodically re-analyzed it by infrared analysis and gas chromatography. These analyses indicated that no degradation of the stored chemical occurred during the course of the 2-year studies (Appendix G).

### GENERATION AND MEASUREMENT OF CHAMBER CONCENTRATIONS

Propylene oxide was vaporized at room temperature, diluted with air, and introduced into the chambers (Appendix H). Concentrations in the exposure chambers were monitored 8-12 times per exposure period by a Hewlett-Packard 5840A Gas Chromatograph. Weekly mean exposure concentrations are presented in Appendix H. The vapor concentrations were within 10% of the mean values of the concentrations at all positions sampled within the chamber. On three occasions, high dose mice were exposed to propylene oxide at concentrations greater than 1,000 ppm. These incidents together with a summary of chamber concentrations for the 2-year studies are presented in Table 2.

### SINGLE-EXPOSURE STUDIES

Male and female F344/N rats and B6C3F<sub>1</sub> mice were obtained from Frederick Cancer Research

TABLE 2. SUMMARY OF CHAMBER CONCENTRATIONS OF PROPYLENE OXIDE DURING THE TWO-YEAR STUDIES

Target Concentration (ppm)	Average Chamber Concentration (a) (ppm)	Total No. of Readings
<b>MICE</b>		
200	198 ± 17	5,419
(b) 400	396 ± 36	5,438
<b>RATS</b>		
200	200 ± 15	5,419
(b) 400	397 ± 30	5,406

(a) ± Standard deviation

(b) The following overexposure incidents occurred during the studies: week 14, 17 min overexposure, ≤4,100 ppm; week 30, 12 min, ≤6,448 ppm; week 82, 38 min, ≤1,091 ppm.

Center and observed before being placed on study. The study was conducted at Industrial Biotest Laboratories.

Groups of five rats of each sex were exposed for 4 hours to air containing 1,277, 2,970, 3,794, or 3,900 ppm propylene oxide. Groups of five mice of each sex were exposed to air containing 387, 859, 1,102, 1,277, or 2,970 ppm propylene oxide on the same schedule.

Animals were observed daily for moribundity and mortality and were weighed on days 0 and 15. Gross necropsies were performed on all animals. Details of animal maintenance are presented in Table 3.

### REPEATED-EXPOSURE STUDIES

Male and female F344/N rats and B6C3F<sub>1</sub> mice were obtained from Frederick Cancer Research Center and observed for 11 days before being placed on study. The animals were approximately 6-8 weeks old when the studies began. The studies were conducted at Industrial Biotest Laboratories.

Groups of five rats of each sex were exposed to air containing propylene oxide at time-weighted average concentrations of 0, 47.2, 98.5, 196, 487, or 1,433 ppm 6 hours per day, 5 days per week for 2 weeks (10 exposures). Groups of five mice of each sex were similarly exposed to air containing propylene oxide at time-weighted average concentrations of 0, 20.1, 47.2, 98.5, 196, or 487 ppm.



**TABLE 3. EXPERIMENTAL DESIGN AND MATERIALS AND METHODS IN THE INHALATION STUDIES OF PROPYLENE OXIDE**

Single-Exposure Studies	Repeated-Exposure Studies	Thirteen-Week Studies	Two-Year Studies
<b>EXPERIMENTAL DESIGN</b>			
<b>Size of Test Groups</b>			
5 males and 5 females of each species	5 males and 5 females of each species	10 males and 10 females of each species	50 males and 50 females of each species
<b>Doses</b>			
Rats--1,277, 2,970, 3,794, or 3,900 ppm propylene oxide by inhalation; mice--387, 859, 1,102, 1,277, or 2,970 ppm by inhalation	Rats--0, 47.2, 98.5, 196, 487, or 1,433 ppm propylene oxide by inhalation; mice--0, 20.1, 47.2, 98.5, 196, or 487 ppm by inhalation	0, 31, 63, 125, 250, or 500 ppm propylene oxide by inhalation	0, 200, or 400 ppm propylene oxide by inhalation
<b>Date of First Exposure</b>			
10/25, 10/26, 10/27, 10/28, and 11/1/76	11/30/76	3/3/77	Rats--8/29/79; mice--8/29/79; low dose restart--12/31/79
<b>Date of Last Exposure</b>			
NA	12/10/76	Rats--6/1/77 Mice--6/2/77	Rats--8/14/81; mice--8/14/81; low dose restart--12/18/81
<b>Duration of Exposure</b>			
4 h	6 h/d, 10 exposures (excluding 12/5/76)	6 h/d, 5 d/wk for 13 wk Rats--62 exposures Mice--63 exposures	6 h/d, 5 d/wk; rats and high dose mice--491 exposure days; low dose mice--495 exposure days
<b>Type and Frequency of Observation</b>			
Observed throughout exposure and 14 d observation period for moribundity and mortality; weighed on d 0 and 15	Observed 1 × d for moribundity and mortality; weighed on d 0, 4, 8, and 12	Observed 1 × d for moribundity and mortality; weighed on d 0 and 1 × wk thereafter	Observed 2 × d for signs of moribundity and mortality; examined 1 × mo for clinical signs of toxicity; all animals weighed 1 × wk for 13 wk, then 1 × mo, finally 2 × mo for remaining 3 mo or 6 mo (restart mice); palpation for tumor masses on 11/5/80 and at each weighing thereafter
<b>Necropsy and Histologic Examination</b>			
Necropsy performed on all animals (gross only)	Necropsy performed on all animals (gross only)	Necropsy performed on all animals; histopathologic exam performed on all control and high dose animals and those that died before final kill; tissues examined are similar to those in the 2-y studies except only one section of nasal turbinate was examined	Necropsy performed on all animals; the following tissues were examined: gross lesions, skin, mandibular lymph nodes, tissue masses and regional lymph nodes, thigh muscle, sciatic nerve, sternbrae, including marrow, costochondral junction (rib), thymus, larynx, pharynx, trachea, lungs and bronchi, heart, thyroid gland, parathyroids, esophagus, stomach, duodenum, jejunum, salivary gland, ileum, colon, cecum, rectum, liver, eyes, pancreas, spleen, kidneys, adrenal glands, urinary bladder, seminal vesicles/prostate/testes or ovaries/uterus, nasal cavity and nasal turbinates (3 sections), brain, pituitary gland, spinal cord, and gallbladder (mice only); histopathologic exam (including blood smear) performed on all above tissues except: thigh muscle, sciatic nerve, costochondral junction (rib), duodenum, jejunum, salivary gland,

**TABLE 3. EXPERIMENTAL DESIGN AND MATERIALS AND METHODS IN THE INHALATION STUDIES OF PROPYLENE OXIDE (Continued)**

Single-Exposure Studies	Repeated-Exposure Studies	Thirteen-Week Studies	Two-Year Studies
<b>Necropsy and Histologic Examination (Continued)</b>			ileum, cecum, rectum, seminal vesicles, and eyes and pharynx unless grossly abnormal
<b>ANIMALS AND ANIMAL MAINTENANCE</b>			
<b>Species</b>			
F344/N rats; B6C3F <sub>1</sub> mice	F344/N rats; B6C3F <sub>1</sub> mice	F344/N rats; B6C3F <sub>1</sub> mice	F344/N rats; B6C3F <sub>1</sub> mice
<b>Animal Source</b>			
Frederick Cancer Research Center (Frederick, MD)	Frederick Cancer Research Center (Frederick, MD)	Frederick Cancer Research Center (Frederick, MD)	Charles River Breeding Labs, Inc. (Portage, MI)
<b>Time Held Before Start of Test</b>			
Data not available	11 d	14 d	21 d; 18 d (restart mice)
<b>Age When Placed on Study</b>			
Data not available	6-8 wk	Data not available	Rats--7-8 wk; mice--7-9 wk
<b>Age When Killed</b>			
Data not available	8-10 wk	Data not available	Rats--111-112 wk; mice--111-113 wk
<b>Necropsy Dates</b>			
Rats--11/9/76-11/16/76; mice--11/9/76-11/13/76	12/11/76	Rats--6/2/77; mice--6/3/77	Rats--8/24-8/26/81; mice--8/27-8/28/81; restart: 12/28/81
<b>Method of Distribution</b>			
Assigned to groups so that average weights were approximately equal	Same as single-exposure studies	Assigned to groups according to a table of random numbers	Stratified by weight; assigned to groups according to a table of random numbers
<b>Feed</b>			
Data not available	Wayne Lab-Blox® (Allied Mills, Inc., Chicago, IL); available ad libitum except during exposure	Same as repeated-exposure studies	Same as repeated-exposure studies
<b>Bedding</b>			
None	None	None	None
<b>Water</b>			
Automatic watering system; available freely	Automatic watering system; available freely	Automatic watering system; available freely	Automatic watering system (Edstrom Industries, Inc., Waterford, WI); filtered, softened tap water; available freely
<b>Cages</b>			
Stainless steel mesh Chamber--stainless steel and glass	Stainless steel mesh Chamber--stainless steel and glass; nominal volume--8 m <sup>3</sup>	Stainless steel mesh (Unifab Corp., Kalamazoo, MI) Chamber--stainless steel and glass, nominal vol--8 m <sup>3</sup> (King-Lar Co., Decatur, IL)	Stainless steel wire cages (Lab Products, Inc., Rochelle Park, NJ); BNW-designed chambers (Hazelton Systems, Inc., Aberdeen, MD)
<b>Animals per Cage</b>			
1	1	1	1

**TABLE 3. EXPERIMENTAL DESIGN AND MATERIALS AND METHODS IN THE INHALATION STUDIES OF PROPYLENE OXIDE (Continued)**

<b>Single-Exposure Studies</b>	<b>Repeated-Exposure Studies</b>	<b>Thirteen-Week Studies</b>	<b>Two-Year Studies</b>
<b>Other Chemicals on Test in Same Room</b>			
Acrylonitrile Methyl methacrylate	Acrylonitrile Methyl methacrylate	Methyl methacrylate	Propylene
<b>Animal Room Environment</b>			
Data not available	Data not available	12 h fluorescent light/d	20 changes room air/h (during nonexposure, chamber door left open); fluorescent light 12 h/d; chamber temp--18.3°-27.8° C (mice); 20.6°-29.4° C (rats); chamber hum--37%-81% (rats); 32%-84% (mice); room temp--21.1° C during exposure; 23.9° C during nonexposure
<b>CHEMISTRY</b>			
<b>Lot Numbers Used</b>			
UC 5/10/76	UC 5/10/76	UC 5/10/76	6477-22
<b>Supplier</b>			
Leidy Chemical Corp. (a division of Union Carbide) (Baltimore, MD)	Same as single-exposure studies	Same as single-exposure studies	Same as single-exposure studies
<b>CHEMICAL/VEHICLE</b>			
<b>Preparation</b>			
Clean dry air (-40° C dew-point) introduced through all-glass impingers containing chemical; desired concentrations were achieved by varying the amount of air which passed through the test material	Same as single-exposure studies	Same as single-exposure studies	Propylene oxide was vaporized at room temp, diluted with air, and introduced into the chamber (Appendix H)

## II. MATERIALS AND METHODS

---

Rats and mice were observed daily for morbidity and mortality and were weighed on days 0, 4, 8, and 12. Necropsies were performed on all animals on day 12. Details of animal maintenance are presented in Table 3.

### THIRTEEN-WEEK STUDIES

Thirteen-week studies were conducted to evaluate the cumulative toxicity of propylene oxide and to determine the concentrations to be used in the 2-year studies. The 13-week studies were conducted at Industrial Biotest Laboratories.

Male and female F344/N rats and B6C3F<sub>1</sub> mice were obtained from Frederick Cancer Research Center, observed for 2 weeks, and then assigned to test groups according to a table of random numbers. (The animals were presumed to be 5-6 weeks old when received. Data on actual ages are not available.) Feed was available freely during nonexposure periods, and water was available freely at all times.

Groups of 10 rats and 10 mice of each sex were exposed to air containing propylene oxide at concentrations of 0, 31, 63, 125, 250, or 500 ppm, 6 hours per day, 5 days per week, for 13 weeks. Animals were checked daily for signs of morbidity and mortality; moribund animals were killed, and necropsies were performed. Clinical examinations were performed weekly. Body weight data were collected weekly.

At the end of the 13-week studies, survivors were killed. Necropsies were performed on all animals, except for those excessively autolyzed or cannibalized. Tissues examined are listed in Table 3.

### TWO-YEAR STUDIES

#### Study Design

These studies were conducted at Battelle Northwest Laboratories. Groups of 50 rats and 50 mice of each sex were exposed to air containing propylene oxide at concentrations of 0 (chamber controls), 200, or 400 ppm, 6 hours per day, 5 days per week for 103 weeks. Groups of low dose mice of each sex were restarted 19 weeks after

the initial start date because a technical error produced excessive chamber concentrations of propylene oxide, which killed all low dose animals.

#### Source and Specifications of Test Animals

Four- to five-week-old male and female F344/N rats and B6C3F<sub>1</sub> mice (C57BL/6N x C3H/HeN MTV<sup>-</sup>) were received from Charles River Breeding Laboratories and held for 21 days before the test began. The rats and mice were assigned to groups according to a table of random numbers.

A quality control skin grafting program has been in effect since early 1978 to monitor the genetic integrity of the inbred mice used to produce the hybrid B6C3F<sub>1</sub> test animal. In mid-1981, data were obtained that showed incompatibility between the NIH C3H reference colony and the C3H colony from a Program supplier. In August 1981, inbred parental lines of mice were further tested for genetic integrity via isozyme and protein electrophoretograms that demonstrate phenotype expressions of known genetic loci.

The C57BL/6 mice were homogeneous at all loci tested. Eighty-five percent of the C3H mice monitored were variant at one to three loci, indicating some heterogeneity in the C3H line from this supplier. Nevertheless, the genome of this line is more homogeneous than those of randomly bred stocks.

Male mice from the C3H colony and female mice from the C57BL/6 colony were used as parents for the hybrid B6C3F<sub>1</sub> mice used in this study. The influence of the potential genetic non-uniformity in the hybrid mice on the results is not known, but results of the studies are not affected because matched concurrent controls were included in each study. The sentinel animal program is described in Appendix I.

#### Animal Maintenance

Rats and mice were housed individually. Food and water were available freely except during exposure periods; during the exposure periods, water but not food was available. Details of animal maintenance are presented in Table 3.

## II. MATERIALS AND METHODS

### Clinical Examinations and Pathology

All animals were observed twice daily for signs of moribundity or mortality. Clinical signs were recorded monthly. Individual animal body weights were recorded every week for the first 13 weeks, then once per month, and finally twice per month for the remaining 3 months or 6 months (restart mice). Mean body weights were calculated for each group. Moribund animals were killed, as were animals that survived to the end of the study. Necropsies were performed on all animals, including those found dead unless they were excessively autolyzed or cannibalized. Thus, the number of animals from which particular organs or tissues were examined microscopically varies and is not necessarily equal to the number of animals that were placed on study in each group.

Examinations for grossly visible lesions were performed on major tissues or organs. Tissues were preserved in 10% neutral buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Tissues examined microscopically are listed in Table 3. The nasal cavities were examined on three levels: just caudal to the incisor teeth, midway between the incisors and the first molar, and at the level of the middle of the second molar.

When the pathology examination was completed, the slides, individual animal data records, and summary tables were sent to an independent quality assurance laboratory. Individual animal records and tables were compared for accuracy, slides and tissue counts were verified, and histotechnique was evaluated. All tumor diagnoses, all target tissues, and all tissues from a randomly selected 10% of the animals were evaluated by a quality assurance pathologist. Slides of all target tissues and those about which the original and quality assurance pathologists disagreed were submitted to the Chairperson of the Pathology Working Group (PWG) for evaluation. Representative slides selected by the PWG Chairperson were reviewed by PWG pathologists, who reached a consensus and compared their findings with the original and quality assurance diagnoses. When diagnostic differences were found, the PWG sent the appropriate slides and comments to the original pathologist for review. This procedure has been described, in part, by Maronpot and Boorman

(1982) and Boorman et al. (1984). The final diagnoses represent a consensus of contractor pathologists and the NTP Pathology Working Group.

Nonneoplastic lesions are not examined routinely by the quality assurance pathologist or the PWG. Certain nonneoplastic findings are reviewed by the quality assurance pathologist and the PWG if they are considered part of the toxic response to a chemical or if they are deemed of special interest.

### Statistical Methods

*Data Recording:* Data on this experiment were recorded in the Carcinogenesis Bioassay Data System (Linhart et al., 1974). The data elements include descriptive information on the chemicals, animals, experimental design, survival, body weight, and individual pathologic results, as recommended by the International Union Against Cancer (Berenblum, 1969).

*Survival Analyses:* The probability of survival was estimated by the product-limit procedure of Kaplan and Meier (1958) and is presented in the form of graphs. Animals were censored from the survival analyses at the time they were found dead of other than natural causes or were found to be missing; animals dying from natural causes were not censored. Statistical analyses for a possible dose-related effect on survival used the method of Cox (1972) for testing two groups for equality and Tarone's (1975) extensions of Cox's method for testing for a dose-related trend. All reported P values for the survival analysis are two-sided.

*Calculation of Incidence Rates:* The incidence of neoplastic or nonneoplastic lesions has been given as the ratio of the number of animals bearing such lesions at a specific anatomic site to the number of animals in which that site was examined. In most instances, the denominators include only those animals for which the site was examined histologically. However, when macroscopic examination was required to detect lesions (e.g., skin or mammary tumors) prior to histologic sampling, or when lesions could have appeared at multiple sites (e.g., lymphomas), the denominators consist of the number of animals on which necropsies were performed.

## II. MATERIALS AND METHODS

---

*Analysis of Tumor Incidence:* Three statistical methods are used to analyze tumor incidence data. The two that adjust for intercurrent mortality employ the classical method for combining contingency tables developed by Mantel and Haenszel (1959). Tests of significance included pairwise comparisons of high dose and low dose groups with chamber controls and tests for overall dose-response trends.

For studies in which compound administration has little effect on survival, the results of the three alternative analyses will generally be similar. When differing results are obtained by the three methods, the final interpretation of the data depends on the extent to which the tumor under consideration is regarded as being the cause of death. All reported P values for tumor analyses are one-sided.

*Life Table Analysis--*The first method of analysis assumed that all tumors of a given type observed in animals dying before the end of the study were "fatal"; i.e., they either directly or indirectly caused the death of the animal. According to this approach, the proportions of tumor-bearing animals in the dosed and control groups were compared at each point in time at which an animal died with a tumor of interest. The denominators of these proportions were the total number of animals in each group examined during the time period. These results, including the data from animals killed at the end of the study, were then combined by the

Mantel-Haenszel method to obtain an overall P value. This method of adjusting for intercurrent mortality is the life table method of Cox (1972) and of Tarone (1975).

*Incidental Tumor Analysis--*The second method of analysis assumed that all tumors of a given type observed in animals that died before the end of the study were "incidental"; i.e., they were merely observed at necropsy in animals dying of an unrelated cause. According to this approach, the proportions of animals found to have tumors in dosed and control groups were compared in each of five time intervals: 0-52 weeks, 53-78 weeks, 79-92 weeks, week 93 to the week before the terminal-kill period, and the terminal-kill period. The denominators of these proportions were the number of animals on which necropsies were actually performed during the time interval. The individual time interval comparisons were then combined by the previously described method to obtain a single overall result. (See Peto et al., 1980, for the computational details of both methods.)

*Unadjusted Analyses--*Primarily, survival-adjusted methods are used to evaluate tumor incidence. In addition, the results of the Fisher's exact test for pairwise comparisons and the Cochran-Armitage linear trend test (Armitage, 1971; Gart et al., 1979) are given. These two tests are based on the overall proportion of tumor-bearing animals and do not adjust for survival differences.

### **III. RESULTS**

#### **RATS**

**SINGLE-EXPOSURE STUDIES**

**REPEATED-EXPOSURE STUDIES**

**THIRTEEN-WEEK STUDIES**

**TWO-YEAR STUDIES**

**Body Weights and Clinical Signs**

**Survival**

**Pathology and Statistical Analyses of Results**

#### **MICE**

**SINGLE-EXPOSURE STUDIES**

**REPEATED-EXPOSURE STUDIES**

**THIRTEEN-WEEK STUDIES**

**TWO-YEAR STUDIES**

**Body Weights and Clinical Signs**

**Survival**

**Pathology and Statistical Analyses of Results**

### III. RESULTS: RATS

#### SINGLE-EXPOSURE STUDIES

Deaths occurred in all exposure groups except those exposed at 1,277 ppm (Table 4). Dyspnea and a red nasal discharge were observed in animals in the three highest exposure groups. No compound-related gross pathologic effects were recorded.

#### REPEATED-EXPOSURE (TWELVE-DAY) STUDIES

One of five male rats exposed at 1,433 ppm died (Table 5). No other deaths occurred.

Dyspnea, hypoactivity, gasping, ataxia, and diarrhea were observed in rats in the highest dose group.

TABLE 4. SURVIVAL OF RATS IN THE SINGLE FOUR-HOUR-EXPOSURE INHALATION STUDIES OF PROPYLENE OXIDE

Concentration (a) (ppm)	Survival (b) (day of death)	
	Male	Female
1,277	5/5	5/5
2,970	4/5 (3)	3/5 (1,2)
3,794	1/5 (1,3,4,5)	1/5 (1,1,3,5)
3,900	2/5 (1,2,2)	2/5 (1,1,2)

(a) Time-averaged mean

(b) Number surviving/number per group

TABLE 5. SURVIVAL AND MEAN BODY WEIGHTS OF RATS IN THE TWO-WEEK REPEATED-EXPOSURE INHALATION STUDIES OF PROPYLENE OXIDE

Concentration (a) (ppm)	Survival (b)	Mean Body Weight (grams)			Final Weight Relative to Controls (d) (percent)
		Initial (c)	Final	Change	
<b>MALE</b>					
0	5/5	106.4 ± 3.2	161.8 ± 4.4	+ 55.4 ± 2.8	--
47.2	5/5	109.6 ± 3.0	163.6 ± 5.0	+ 54.0 ± 3.6	101.1
98.5	5/5	109.2 ± 3.5	165.4 ± 5.0	+ 56.2 ± 2.7	102.2
196	5/5	106.2 ± 2.5	159.8 ± 5.1	+ 53.6 ± 4.0	98.8
487	5/5	104.4 ± 6.6	156.0 ± 7.0	+ 51.6 ± 2.6	96.4
1,433	4/5	106.4 ± 3.2	91.8 ± 1.3	- 13.5 ± 3.2	56.7
<b>FEMALE</b>					
0	5/5	91.2 ± 3.1	121.4 ± 2.0	+ 30.2 ± 1.7	--
47.2	5/5	93.6 ± 2.9	122.8 ± 4.2	+ 29.2 ± 2.1	101.2
98.5	5/5	89.4 ± 2.3	114.4 ± 3.4	+ 25.0 ± 2.6	94.2
196	5/5	91.0 ± 3.6	122.2 ± 4.2	+ 31.2 ± 0.7	100.7
487	5/5	90.6 ± 3.4	117.4 ± 4.3	+ 26.8 ± 1.9	96.7
1,433	5/5	90.2 ± 3.3	91.0 ± 2.6	+ 0.8 ± 1.4	75.0

(a) Time-averaged mean

(b) Number surviving/number initially in the group

(c) Initial mean weight of all animals in the group ± standard error of the mean. Subsequent calculations are based on those animals surviving to the end of the studies.

(d) Final body weight of the dosed group relative to controls =  $\frac{\text{Final Body Weight (Dosed)}}{\text{Final Body Weight (Control Group)}} \times 100$



### III. RESULTS: RATS

#### THIRTEEN-WEEK STUDIES

No rats died. Final mean body weights relative to those of controls were 7.4% lower in males and 5.3% lower in females exposed to air containing 500 ppm propylene oxide (Table 6). No compound-related gross or microscopic pathologic effects were observed. One section of nasal

turbinates per animal was prepared and examined. Chronic murine pneumonia was found in all groups of rats examined histologically.

Because of the weight gain depressions in males exposed at 500 ppm, exposure concentrations of 200 and 400 ppm were selected for rats in the 2-year studies.

TABLE 6. SURVIVAL AND MEAN BODY WEIGHTS OF RATS IN THE THIRTEEN-WEEK INHALATION STUDIES OF PROPYLENE OXIDE

Concentration (ppm)	Survival (a)	Mean Body Weight (grams)			Final Weight Relative to Controls (c) (percent)
		Initial	Final	Change (b)	
<b>MALE</b>					
0	10/10	120.9 ± 3.6	299.3 ± 2.8	+178.4 ± 4.4	--
31	10/10	122.5 ± 2.5	295.7 ± 4.4	+173.2 ± 4.5	98.8
63	10/10	122.4 ± 2.6	305.4 ± 4.8	+183.0 ± 4.7	102.0
125	10/10	121.9 ± 2.7	296.9 ± 5.0	+175.0 ± 5.9	99.2
250	10/10	122.2 ± 2.3	299.2 ± 2.6	+177.0 ± 1.7	100.0
500	10/10	125.2 ± 2.5	277.1 ± 5.0	+151.9 ± 4.5	92.6
<b>FEMALE</b>					
0	10/10	98.7 ± 1.9	177.5 ± 3.5	+ 78.8 ± 2.4	--
31	10/10	98.1 ± 2.1	173.9 ± 1.2	+ 75.8 ± 2.0	98.0
63	10/10	98.6 ± 1.9	176.7 ± 3.0	+ 78.1 ± 2.1	99.5
125	10/10	98.5 ± 1.9	172.4 ± 3.1	+ 73.9 ± 2.6	97.1
250	10/10	99.1 ± 1.8	176.6 ± 2.6	+ 77.5 ± 2.7	99.5
500	10/10	100.7 ± 1.7	168.1 ± 1.1	+ 67.4 ± 1.5	94.7

(a) Number surviving/number initially in the group

(b) Mean weight change of the group ± standard error of the mean

(c) Final body weight of the dosed group relative to controls =  $\frac{\text{Final Body Weight (Dosed)}}{\text{Final Body Weight (Control Group)}} \times 100$

# III. RESULTS: RATS

## TWO-YEAR STUDIES

### Body Weights and Clinical Signs

After week 20 for males and week 40 for females, mean body weights of high dose rats were lower

than those of the controls (Table 7 and Figure 1) No compound-related clinical signs were observed.

TABLE 7. MEAN BODY WEIGHTS AND SURVIVAL OF RATS IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE

Weeks on Study	Control		200 ppm			400 ppm		
	Av. Wt. (grams)	No. of Survivors	Av. Wt. (grams)	Wt. (percent) of Controls	No. of Survivors	Av. Wt. (grams)	Wt. (percent) of Controls	No. of Survivors
<b>MALE</b>								
1	147	50	146	99.3	50	143	97.3	50
2	189	50	179	105.9	50	178	105.3	50
3	195	50	198	101.5	50	193	99.0	50
4	221	50	225	101.8	50	219	99.1	50
5	241	50	242	100.4	50	231	95.9	50
6	280	50	280	100.0	50	251	96.5	50
7	274	50	272	99.3	50	261	95.3	50
8	296	50	295	99.7	50	283	95.6	50
9	305	50	303	99.3	50	286	93.8	50
10	319	50	310	97.2	50	300	94.0	50
11	321	50	327	101.9	50	306	95.0	50
12	330	50	327	99.1	50	313	94.8	50
13	341	50	342	100.3	50	320	93.8	50
17	366	50	367	100.3	50	343	93.7	50
22	375	50	364	97.1	50	356	94.9	50
26	406	50	385	95.1	50	376	92.8	50
29	397	50	390	98.2	50	352	96.2	50
33	411	50	402	97.8	50	365	98.1	50
38	411	50	403	98.1	50	384	95.9	50
42	412	50	402	97.6	50	360	94.7	50
47	411	50	403	98.1	49	395	96.1	50
51	433	50	428	98.8	49	413	95.4	50
55	437	50	435	99.5	49	419	95.9	50
60	461	50	448	99.3	49	431	95.8	50
64	449	50	448	99.8	49	433	96.4	50
68	461	49	455	98.7	49	438	95.0	50
73	460	48	457	99.3	49	443	96.3	50
77	467	46	455	99.6	49	437	95.6	50
81	454	44	444	97.8	49	425	93.8	49
86	436	42	435	99.8	47	417	95.6	49
90	442	38	435	98.4	44	409	92.5	46
92	437	38	436	99.8	43	409	93.6	44
94	431	37	428	99.3	42	401	93.0	41
96	439	35	439	100.0	39	405	92.3	39
98	439	34	449	102.3	39	408	92.9	34
100	438	31	433	98.9	35	408	93.2	32
102	432	30	429	99.3	33	396	91.7	31
<b>FEMALE</b>								
1	116	50	117	100.9	50	114	98.3	50
2	129	50	134	103.9	50	133	103.1	50
3	140	50	143	102.1	50	136	97.1	50
4	153	50	156	102.0	50	151	98.7	50
5	162	50	161	99.4	50	158	97.5	50
6	171	50	170	99.4	50	164	95.9	50
7	176	50	174	98.9	50	167	94.9	50
8	183	50	181	98.9	50	178	97.3	50
9	185	50	184	99.5	50	179	96.8	50
10	190	50	189	99.5	50	184	96.8	50
11	192	50	195	101.6	50	186	96.9	50
12	198	50	199	100.6	50	191	96.5	50
13	200	50	201	100.5	50	195	97.5	50
17	209	50	208	99.5	50	204	97.6	50
22	213	50	215	100.9	50	211	99.1	50
26	223	50	229	102.7	50	221	99.1	50
29	226	50	228	100.9	50	222	98.2	50
33	235	50	235	100.0	50	228	97.0	50
38	234	50	239	102.1	50	232	99.1	50
42	244	50	244	100.0	50	234	95.9	50
47	248	50	244	98.4	50	238	96.0	50
51	254	49	255	100.4	50	247	97.2	50
55	262	49	262	100.0	50	251	95.8	50
60	282	49	273	96.8	49	264	93.6	49
64	288	49	279	96.9	48	272	94.4	49
68	291	49	288	99.0	48	279	95.9	49
73	302	48	298	98.7	48	286	94.7	49
77	301	48	296	98.3	47	282	93.7	49
81	299	48	298	99.7	47	283	94.6	48
86	308	43	295	95.8	46	282	91.6	47
90	309	39	291	94.2	43	284	91.9	45
92	307	38	289	94.1	43	285	92.8	44
94	310	38	290	93.5	41	289	93.2	44
96	313	38	300	95.8	36	290	92.7	39
98	311	37	301	96.8	35	299	95.1	35
100	314	37	303	96.5	34	291	92.7	34
102	312	35	304	97.4	32	293	93.9	32





FIGURE 1. GROWTH CURVES FOR RATS EXPOSED TO PROPYLENE OXIDE BY INHALATION FOR TWO YEARS

### III. RESULTS: RATS

---

#### Survival

Estimates of the probabilities of the survival of male and female rats exposed to propylene oxide at the concentrations of these studies and those of the controls are shown in the Kaplan and

Meier curves in Figure 2. No significant differences in survival were observed between any groups of either sex (Table 8).

**TABLE 8. SURVIVAL OF RATS IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE**

	Control	200 ppm	400 ppm
<b>MALE (a)</b>			
Animals initially in study	50	50	50
Nonaccidental deaths before termination (b)	21	19	21
Killed at termination	29	30	29
Died during termination period	0	1	0
Survival P values (c)	0.834	0.717	0.881
<b>FEMALE (a)</b>			
Animals initially in study	50	50	50
Nonaccidental deaths before termination (b)	15	18	19
Killed at termination	35	31	31
Died during termination period	0	1	0
Survival P values (c)	0.628	0.624	0.682

(a) Terminal kill period: week 104

(b) Includes animals killed in a moribund condition

(c) The result of the life table trend test is in the control column, and those of the life table exact pairwise comparisons with the controls are in the dosed columns.





FIGURE 2. KAPLAN-MEIER SURVIVAL CURVES FOR RATS EXPOSED TO PROPYLENE OXIDE BY INHALATION FOR TWO YEARS

### III. RESULTS: RATS

#### Pathology and Statistical Analyses of Results

This section describes the significant or noteworthy changes in the incidence of rats with neoplastic or nonneoplastic lesions. Histopathologic findings on neoplasms in rats are summarized in Appendix A, Tables A1 and A2; Tables A3 and A4 give the survival and tumor status for individual male and female rats. Findings on nonneoplastic lesions are summarized in Appendix C, Tables C1 and C2. Appendix E, Tables E1 and E2, contain the statistical analyses of those primary tumors that occurred with an incidence of at least 5% in one of the three groups. The statistical analyses used are discussed in Chapter II (Statistical Methods) and Appendix E (footnotes). Historical incidences of tumors in control animals are listed in Appendix F.

**Nasal Cavity:** A dose-related increase occurred in the incidences of suppurative inflammation of the mucosa and submucosa and of squamous metaplasia of the respiratory epithelium (Table 9). These lesions were evident in the most anterior section of the nasal cavity (at the level of the

incisor teeth). The squamous metaplasia was usually observed on the greater curvatures of the nasal and maxillary turbinates and on the lateral wall of the nasal cavity between the nasal and maxillary turbinates. A small increase in the incidence of squamous metaplasia was observed in the nasolacrimal ducts of exposed rats (male: control, 4/50, 8%; low dose, 8/50, 16%; high dose, 9/50, 18%; female: control, 3/50, 6%; low dose, 9/50, 18%; high dose, 0/50). This lesion was also observed in the anterior section of the nasal cavity. Lesions of the nasolacrimal duct (squamous metaplasia or inflammation) were diagnosed only when the adjacent epithelium of the nasal mucosa was not similarly involved. A diagnosis of squamous metaplasia of the nasal cavity may include lesions of the nasolacrimal duct, but a lesion of the nasolacrimal duct per se was not diagnosed as squamous metaplasia.

Proliferation of the nasal cavity epithelial cells was seen mainly in animals exposed to propylene oxide at the highest concentration (Table 10). Papillary adenomas involving the

TABLE 9. INCIDENCES OF NASAL CAVITY LESIONS IN RATS IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE (a)

Lesion	Male			Female		
	Control	200 ppm	400 ppm	Control	200 ppm	400 ppm
Suppurative inflammation	(b) 9	(b) 21	(b) 38	3	5	(b) 23
Epithelial hyperplasia	0	1	(b) 11	1	0	(b) 5
Squamous metaplasia	1	3	21	1	2	11
Papillary adenoma	0	0	2	0	0	3

(a) Fifty animals were examined histologically in each group.

(b) Because these incidence figures represent both the specific nonneoplastic effect and those recorded under multiple organs, the numbers do not correspond fully with those listed in Appendix C.

TABLE 10. ANALYSIS OF NASAL CAVITY TUMORS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (a)

	Control	200 ppm	400 ppm
<b>Papillary Adenoma</b>			
Overall Rates	0/50 (0%)	0/50 (0%)	3/50 (6%)
Adjusted Rates	0.0%	0.0%	9.7%
Terminal Rates	0/35 (0%)	0/32 (0%)	3/31 (10%)
Life Table Tests	P=0.031	(b)	P=0.100
Incidental Tumor Tests	P=0.031	(b)	P=0.100
Cochran-Armitage Trend Test	P=0.037		
Fisher Exact Tests		(b)	P=0.121

(a) The statistical analyses used are discussed in Chapter II (Statistical Methods) and Appendix E (footnotes).

(b) No P value is presented because no tumors were observed in the control and 200-ppm groups.

respiratory epithelium and the underlying sub-mucosal glands were observed in three female rats and two male rats exposed at 400 ppm; the incidences in the females were significant by the trend tests. Most of these proliferative lesions appeared to originate in the mucosa of the lateral wall of the nasal cavity on or near the nasal turbinates.

**Thyroid Gland:** C-cell adenomas or carcinomas (combined) occurred in female rats with a significant positive trend, and the incidence in the high dose group was significantly greater than that in the controls (Table 11). Neither lesion occurred alone at an incidence that was significantly greater than that in the controls. All the C-cell adenomas and all but one of the C-cell carcinomas were observed after the terminal kill at week 104. The incidence of C-cell hyperplasia showed a slight, but not significant, decrease in dosed female rats. The incidence of C-cell adenomas or carcinomas in dosed male rats was greater than that in the controls, but the results of the statistical tests were not significant (Appendix E, Table E1). A dose-related decrease in C-cell hyperplasia also occurred in male rats.

C-cell lesions were classified as hyperplasia when the proliferating C-cells were interspersed among follicles and when there was no compression or distortion of the normal follicular architecture. The diagnosis of C-cell adenoma was based on the presence of a discrete nodule of C-cells which distorted the normal follicular architecture. Metastases or invasion of adjacent tissue, the thyroid capsule, or vessels were considered indicators of C-cell carcinoma.

**Pancreas:** Increased incidences of acinar cell atrophy occurred in dosed male rats (control, 1/47, 2%; low dose, 12/49, 24%; high dose, 17/47, 36%).

**Adrenal Gland:** Cytomegaly in the adrenal cortex was observed at increased incidences in dosed females (control, 1/48, 2%; low dose, 6/49, 12%; high dose, 11/48, 23%).

**Testis:** Testicular atrophy was observed at increased incidences in dosed male rats (controls, 18/49, 37%; low dose, 40/50, 80%; high dose, 24/50, 48%).

**TABLE 11. ANALYSIS OF THYROID GLAND LESIONS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE**

	Control	200 ppm	400 ppm
<b>C-Cell Hyperplasia</b>	7/45 (16%)	6/35 (17%)	5/37 (14%)
<b>C-Cell Adenoma</b>			
Overall Rates	1/45 (2%)	1/35 (3%)	4/37 (11%)
Adjusted Rates	3.0%	4.8%	16.7%
Terminal Rates	1/33 (3%)	1/21 (5%)	4/24 (17%)
Life Table Tests	P=0.056	P=0.658	P=0.095
Incidental Tumor Tests	P=0.056	P=0.658	P=0.095
Cochran-Armitage Trend Test	P=0.072		
Fisher Exact Tests		P=0.687	P=0.125
<b>C-Cell Carcinoma</b>			
Overall Rates	1/45 (2%)	1/35 (3%)	3/37 (8%)
Adjusted Rates	3.0%	4.8%	10.3%
Terminal Rates	1/33 (3%)	1/21 (5%)	2/24 (8%)
Life Table Tests	P=0.149	P=0.658	P=0.234
Incidental Tumor Tests	P=0.103	P=0.658	P=0.155
Cochran-Armitage Trend Test	P=0.156		
Fisher Exact Tests		P=0.687	P=0.238
<b>C-Cell Adenoma or Carcinoma</b>			
Overall Rates	2/45 (4%)	2/35 (6%)	7/37 (19%)
Adjusted Rates	6.1%	9.5%	26.6%
Terminal Rates	2/33 (6%)	2/21 (10%)	6/24 (25%)
Life Table Tests	P=0.017	P=0.523	P=0.031
Incidental Tumor Tests	P=0.011	P=0.523	P=0.019
Cochran-Armitage Trend Test	P=0.023		
Fisher Exact Tests		P=0.592	P=0.041

### III. RESULTS: RATS

*Uterus:* Endometrial stromal polyps or sarcomas (combined) occurred with a significant positive trend, and the incidences in the dosed groups were significantly greater than that in the controls (Table 12).

The incidences of cystic endometrial hyperplasia were increased in dosed females (control, 0/49; low dose, 9/50, 18%; high dose, 6/47, 13%).

*Skin:* Keratoacanthomas occurred in male rats with a significant positive trend (control, 1/50, 2%; low dose, 1/50, 2%; high dose, 5/50, 10%).

*Pituitary:* Adenomas occurred in female rats with a significant negative trend, and the incidence in the high dose group was significantly lower than that in the controls (Table 13).

**TABLE 12. ANALYSIS OF UTERINE TUMORS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE**

	Control	200 ppm	400 ppm
<b>Endometrial Stromal Polyp</b>			
Overall Rates	3/49 (6%)	8/50 (16%)	8/47 (17%)
Adjusted Rates	8.1%	24.1%	21.5%
Terminal Rates	2/35 (6%)	7/32 (22%)	4/31 (13%)
Life Table Tests	P=0.073	P=0.082	P=0.095
Incidental Tumor Tests	P=0.131	P=0.085	P=0.209
Cochran-Armitage Trend Test	P=0.074		
Fisher Exact Tests		P=0.106	P=0.087
<b>Endometrial Stromal Sarcoma</b>			
Overall Rates	0/49 (0%)	4/50 (8%)	2/47 (4%)
Adjusted Rates	0.0%	11.5%	6.5%
Terminal Rates	0/35 (0%)	2/32 (6%)	2/31 (6%)
Life Table Tests	P=0.196	P=0.057	P=0.212
Incidental Tumor Tests	P=0.301	P=0.139	P=0.212
Cochran-Armitage Trend Test	P=0.208		
Fisher Exact Tests		P=0.061	P=0.237
<b>Endometrial Stromal Polyp or Sarcoma</b>			
Overall Rates	3/49 (6%)	12/50 (24%)	10/47 (21%)
Adjusted Rates	8.1%	34.1%	27.4%
Terminal Rates	2/35 (6%)	9/32 (28%)	6/31 (19%)
Life Table Tests	P=0.031	P=0.010	P=0.034
Incidental Tumor Tests	P=0.077	P=0.019	P=0.079
Cochran-Armitage Trend Test	P=0.032		
Fisher Exact Tests		P=0.013	P=0.029

**TABLE 13. ANALYSIS OF PITUITARY TUMORS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE**

	Control	200 ppm	400 ppm
<b>Adenoma</b>			
Overall Rates	25/48 (52%)	18/47 (38%)	14/46 (30%)
Adjusted Rates	60.5%	48.9%	43.6%
Terminal Rates	18/34 (53%)	13/31 (42%)	12/30 (40%)
Life Table Tests	P=0.041N	P=0.193N	P=0.052N
Incidental Tumor Tests	P=0.023N	P=0.123N	P=0.036N
Cochran-Armitage Trend Test	P=0.021N		
Fisher Exact Tests		P=0.126N	P=0.027N



#### SINGLE-EXPOSURE STUDIES

Dyspnea was observed in all exposed groups; sedation occurred in the two highest dose groups; and lacrimation occurred in the highest dose groups. All mice exposed at 2,970 ppm, 2/5 males and 5/5 females exposed at 1,277 ppm, and 2/5 males and 4/5 females exposed at 1,102 ppm

died (Table 14). No compound-related effects were recorded at necropsy.

#### REPEATED-EXPOSURE STUDIES

No mice died (Table 15). Dyspnea occurred in the two highest exposure groups (196 and 487 ppm). Animals in the highest exposure groups were hypoactive.

**TABLE 14. SURVIVAL OF MICE IN THE SINGLE FOUR-HOUR-EXPOSURE INHALATION STUDIES OF PROPYLENE OXIDE**

Concentration (a) (ppm)	Survival (b) (Day of Death)	
	Male	Female
387	5/5	4/5 (6)
859	5/5	5/5
1,102	3/5 (1,1)	1/5 (1,1,1,2)
1,277	3/5 (1,1)	0/5 (1,1,1,1,1)
2,970	0/5 (1,1,1,1,1)	0/5 (1,1,1,1,1)

(a) Time-averaged mean

(b) Number surviving/number per group

**TABLE 15. SURVIVAL AND MEAN BODY WEIGHTS OF MICE IN THE TWO-WEEK REPEATED-EXPOSURE INHALATION STUDIES OF PROPYLENE OXIDE**

Concentration (a) (ppm)	Survival (b)	Mean Body Weight (grams)			Final Weight Relative to Controls (d) (percent)
		Initial (c)	Final	Change	
<b>MALE</b>					
0	5/5	23.8 ± 1.2	25.6 ± 0.6	+1.8 ± 0.7	--
20.1	5/5	23.4 ± 0.9	27.2 ± 0.9	+3.8 ± 0.6	106.2
47.2	5/5	22.6 ± 0.9	24.0 ± 1.5	+1.4 ± 1.7	93.8
98.5	5/5	23.6 ± 0.5	25.6 ± 1.0	+2.0 ± 0.9	100.0
196	5/5	21.8 ± 0.6	25.0 ± 0.3	+3.2 ± 0.5	97.7
487	5/5	22.2 ± 0.5	23.4 ± 0.5	+1.2 ± 0.2	91.4
<b>FEMALE</b>					
0	5/5	17.6 ± 0.7	22.4 ± 0.5	+4.8 ± 0.4	--
20.1	5/5	19.2 ± 0.7	23.4 ± 1.3	+4.2 ± 1.6	104.5
47.2	5/5	18.2 ± 0.4	20.8 ± 0.6	+2.6 ± 0.4	92.9
98.5	5/5	18.8 ± 0.7	21.0 ± 0.8	+2.2 ± 0.6	93.8
196	5/5	17.6 ± 0.2	20.0 ± 0.9	+2.4 ± 1.1	89.3
487	5/5	18.4 ± 0.5	20.4 ± 0.5	+2.0 ± 0.5	91.1

(a) Time-averaged mean

(b) Number surviving/number initially in the group

(c) Initial mean weight of all animals in the group ± standard error of the mean

(d) Final body weight of the dosed group relative to controls =  $\frac{\text{Final Body Weight (Dosed)}}{\text{Final Body Weight (Control Group)}} \times 100$

### III. RESULTS: MICE

#### THIRTEEN-WEEK STUDIES

One male mouse in the 125-ppm group died (Table 16). Final mean body weights relative to those of the controls were depressed 12.9% in male mice exposed at 500 ppm and 14.6% in female mice exposed at 500 ppm. No compound-related gross or microscopic pathologic effects

were observed. One section of nasal turbinate was prepared and examined.

Because of the depressions in weight gain observed in mice exposed at 500 ppm, exposure concentrations of 200 and 400 ppm propylene oxide were selected for mice in the 2-year studies.

TABLE 16. SURVIVAL AND MEAN BODY WEIGHTS OF MICE IN THE THIRTEEN-WEEK INHALATION STUDIES OF PROPYLENE OXIDE

Concentration (ppm)	Survival (a)	Mean Body Weight (grams)			Final Weight Relative to Controls (c) (percent)
		Initial	Final	Change (b)	
<b>MALE</b>					
0	10/10	22.8 ± 0.4	31.1 ± 0.5	+8.3 ± 0.7	--
31	10/10	22.9 ± 0.4	32.3 ± 0.5	+9.4 ± 0.6	103.9
63	10/10	23.0 ± 0.4	31.0 ± 0.5	+8.0 ± 0.7	99.7
125	(d) 9/10	22.8 ± 0.5	31.1 ± 0.5	+8.3 ± 0.7	100.0
250	10/10	22.9 ± 0.3	30.3 ± 0.4	+7.4 ± 0.5	97.4
500	10/10	23.3 ± 0.4	27.1 ± 0.3	+3.8 ± 0.5	87.1
<b>FEMALE</b>					
0	10/10	17.8 ± 0.3	26.1 ± 0.5	+8.3 ± 0.4	--
31	10/10	17.9 ± 0.3	24.4 ± 0.5	+6.5 ± 0.3	93.5
63	10/10	17.9 ± 0.3	25.1 ± 0.4	+7.2 ± 0.4	96.2
125	10/10	17.8 ± 0.3	24.7 ± 0.3	+6.9 ± 0.3	94.6
250	10/10	17.8 ± 0.3	25.4 ± 0.3	+7.6 ± 0.2	97.3
500	10/10	18.1 ± 0.2	22.3 ± 0.3	+4.2 ± 0.2	85.4

(a) Number surviving/number initially in the group

(b) Mean weight change of the survivors of the group ± standard error of the mean

(c) Final body weight of the dosed group relative to controls =  $\frac{\text{Final Body Weight (Dosed)}}{\text{Final Body Weight (Control Group)}} \times 100$

(d) Death occurred on day 14 of the study.

#### TWO-YEAR STUDIES



##### Body Weights and Clinical Signs

Mean body weights of high dose male and female mice were lower than those of the controls after week 29 (Table 17 and Figure 3). Mean

body weights of low dose male mice were greater than those of the controls, except for the last 3 months of the study. Mean body weights of low dose female mice were lower than those of the controls after week 68. No compound-related clinical signs were recorded.

TABLE 17. MEAN BODY WEIGHTS AND SURVIVAL OF MICE IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE

Weeks on Study	Control		200 ppm			400 ppm		
	Av. Wt. (grams)	No. of Survivors	Av. Wt. (grams)	Wt. (percent) of Controls	No. of Survivors	Av. Wt. (grams)	Wt. (percent) of Controls	No. of Survivors
<b>MALE</b>								
1	27	50	29	107.4	50	27	100.0	50
2	28	50	30	107.1	50	29	103.6	50
3	30	50	31	103.3	50	28	86.7	50
4	29	50	31	106.9	50	28	96.6	50
5	30	50	31	103.3	50	29	96.7	50
6	30	50	32	106.7	50	28	93.3	50
7	31	50	32	103.2	50	29	93.5	50
8	29	50	32	110.3	50	31	106.9	50
9	31	50	34	109.7	50	32	103.2	50
10	31	50	33	106.5	50	30	96.8	50
11	31	50	33	106.5	50	31	100.0	50
12	31	50	33	106.5	50	31	100.0	50
13	32	50	-	-	-	33	103.1	50
17	32	50	-	-	-	31	96.9	50
26	32	50	-	-	-	33	103.1	50
29	35	50	37	105.7	50	33	94.3	50
33	36	50	38	105.6	50	34	94.4	49
36	36	50	-	-	-	35	97.2	49
42	36	50	39	108.3	50	34	94.4	49
47	35	50	-	-	-	35	100.0	49
51	36	50	-	-	-	33	91.7	49
55	37	50	40	108.1	50	34	91.9	49
60	38	49	-	-	-	31	81.6	49
64	38	49	-	-	-	32	84.2	49
68	38	49	40	105.3	48	31	81.6	47
73	38	48	-	-	-	30	78.9	47
77	38	48	-	-	-	31	81.6	44
81	38	48	-	-	-	32	84.2	44
86	38	48	36	94.7	45	30	78.9	43
90	38	43	37	97.4	40	30	78.9	43
92	37	43	37	100.0	39	29	78.4	41
94	37	43	37	100.0	39	29	78.4	39
96	38	43	36	100.0	37	31	86.1	37
98	37	43	34	91.9	36	29	78.4	34
100	36	43	36	100.0	34	30	83.3	32
102	37	43	35	94.6	34	29	78.4	30
<b>FEMALE</b>								
1	21	50	23	109.5	50	21	100.0	50
2	23	50	23	100.0	50	23	100.0	49
3	24	50	23	95.8	50	21	87.5	48
4	23	49	24	104.3	50	22	95.7	48
5	25	49	24	96.0	50	24	96.0	48
6	25	49	25	100.0	50	24	96.0	47
7	25	49	26	100.0	50	24	92.3	47
8	25	48	25	100.0	50	25	100.0	47
9	25	48	25	96.2	50	26	100.0	46
10	25	48	25	100.0	50	25	100.0	46
11	26	48	26	100.0	50	26	100.0	46
12	26	48	27	103.8	50	26	100.0	46
13	27	48	-	-	-	27	100.0	46
17	28	48	-	-	-	26	92.9	46
22	29	48	-	-	-	28	96.6	46
29	28	47	28	100.0	49	28	100.0	45
33	30	47	29	96.7	49	28	93.3	45
38	31	46	-	-	-	28	90.3	45
42	29	46	30	103.4	49	28	96.6	45
47	29	46	-	-	-	28	96.6	45
51	30	46	-	-	-	29	96.7	45
55	31	46	30	96.8	48	30	96.8	44
60	33	46	-	-	-	28	84.8	44
64	31	46	-	-	-	29	93.5	43
68	31	46	31	100.0	48	27	87.1	40
73	33	46	-	-	-	26	78.8	38
77	32	46	-	-	-	25	78.1	38
81	31	46	-	-	-	27	87.1	34
86	31	45	29	93.5	43	27	87.1	28
90	32	43	30	93.8	38	27	84.4	23
92	32	43	29	90.6	38	22	68.8	21
94	30	40	29	96.7	38	22	73.3	19
96	31	40	29	93.5	35	25	80.6	18
98	31	39	27	87.1	33	23	74.2	14
100	31	39	27	87.1	32	21	67.7	13
102	30	39	28	93.3	30	27	90.0	10



**FIGURE 3. GROWTH CURVES FOR MICE EXPOSED TO PROPYLENE OXIDE BY INHALATION FOR TWO YEARS**

#### Survival

Estimates of the probabilities of survival of male and female mice exposed to air containing propylene oxide at the concentrations in these studies and those of the controls are shown in the Kaplan and Meier curves in Figure 4. The

survival of high dose male mice was significantly lower than that of the controls ( $P=0.006$ ). Survival of high dose female mice was significantly lower than that in the low dose and control groups ( $P<0.001$ ). (Table 18)



**TABLE 18. SURVIVAL OF MICE IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE**

	Control	200 ppm	400 ppm
<b>MALE (a)</b>			
Animals initially in study	50	50	50
Nonaccidental deaths before termination (b)	8	16	20
Accidentally killed	0	0	1
Killed at termination	42	34	27
Died during termination period	0	0	2
Survival P values (c)	0.006	0.105	0.006
<b>FEMALE (a)</b>			
Animals initially in study	50	50	50
Nonaccidental deaths before termination (b)	12	20	39
Accidentally killed	0	1	1
Killed at termination	37	29	10
Died during termination period	1	0	0
Survival P values (c)	<0.001	0.207	<0.001

(a) Terminal kill period: week 104

(b) Includes animals killed in a moribund condition

(c) The result of the life table trend test is in the control column, and those of the life table exact pairwise comparisons with the controls are in the dosed columns.



**FIGURE 4. KAPLAN-MEIER SURVIVAL CURVES FOR MICE EXPOSED TO PROPYLENE OXIDE BY INHALATION FOR TWO YEARS**

#### Pathology and Statistical Analyses of Results

This section describes the significant or noteworthy changes in the incidences of mice with neoplastic and nonneoplastic lesions. Histopathologic findings on neoplasms in mice are summarized in Appendix B, Tables B1 and B2; Tables B3 and B4 give the survival and tumor status for individual male and female mice. Findings on nonneoplastic lesions are summarized in Appendix D, Tables D1 and D2. Appendix E, Tables E3 and E4, contain the statistical analyses of those primary tumors that occurred with an incidence of at least 5% in one of the three groups. The statistical analyses used are discussed in Chapter II (Statistical Methods) and Appendix E (footnotes). Historical incidences of tumors in control animals are listed in Appendix F.

*Nasal Cavity:* The incidences of lesions affecting the respiratory epithelium of the nasal mucosa

are shown in Table 19. The mildest recognized change was the accumulation of protein-rich fluid in the nasal cavity surrounding the turbinates. The fluid was usually acellular; however, the lesion was diagnosed as a serous inflammation because granulocytes were occasionally present in the respiratory mucosa, suggesting that a mild inflammatory change had occurred. Lesions that were almost entirely granulocytic occurred with a dose-related increase; these were diagnosed as suppurative inflammation. Lesions that also contained lymphocytes and macrophages were classified as acute/chronic inflammation. A papilloma and a squamous cell carcinoma were found in two separate high dose male mice. Two high dose female mice had adenocarcinomas of the nasal turbinates. The carcinoma and the adenocarcinomas appeared to arise from the submucosal glands; they were not exophytic, and they spread deeply along the nerve sheaths.

**TABLE 19. INCIDENCES OF NASAL CAVITY EPITHELIAL LESIONS IN MICE IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE (a)**

Lesion	Male			Female		
	Control	200 ppm	400 ppm	Control	200 ppm	400 ppm
Serous inflammation	0	13	2	2	(b) 6	(b) 2
Suppurative inflammation	0	8	4	0	(b) 16	(b) 23
Acute/chronic inflammation	1	(b) 14	38	(b) 0	(b) 14	(b) 18
Squamous metaplasia	0	1	0	0	0	2
Papilloma	0	0	1	0	0	0
Squamous cell carcinoma	0	0	1	0	0	0
Adenocarcinoma	0	0	0	0	0	2

(a) Fifty animals were examined histologically in each group.

(b) Because these incidence figures represent both the specific nonneoplastic effect and those recorded under multiple organs, the numbers do not correspond fully with those listed in Appendix D.

### III. RESULTS: MICE

The endothelium of the vascular plexus beneath the respiratory epithelium also appeared to be affected. Angiectasis characterized by saccular dilation of submucosal vessels was found in three high dose males and three high dose females. In addition, hemangiomas in males and

females plus hemangiosarcomas in males occurred with significant positive trends; the incidences in the high dose groups were significantly greater than those in the controls (Table 20).

**TABLE 20. ANALYSIS OF VASCULAR TUMORS OF THE NASAL CAVITY IN MICE IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE (a)**

	Control	200 ppm	400 ppm
<b>MALE</b>			
<b>Hemangioma</b>			
Overall Rates	0/50 (0%)	0/50 (0%)	5/50 (10%)
Adjusted Rates	0.0%	0.0%	17.2%
Terminal Rates	0/42 (0%)	0/34 (0%)	5/29 (17%)
Life Table Tests	P=0.002	(a)	P=0.011
Incidental Tumor Tests	P=0.002	(b)	P=0.011
Cochran-Armitage Trend Test	P=0.006		
Fisher Exact Tests		(b)	P=0.028
<b>Hemangiosarcoma</b>			
Overall Rates (b)	0/50 (0%)	0/50 (0%)	5/50 (10%)
Adjusted Rates (b)	0.0%	0.0%	15.6%
Terminal Rates (c)	0/42 (0%)	0/34 (0%)	4/29 (14%)
Life Table Tests (d)	P=0.003	(b)	P=0.015
Incidental Tumor Tests (d)	P=0.004	(b)	P=0.021
Cochran-Armitage Trend Test (d)	P=0.006		
Fisher Exact Tests		(b)	P=0.028
<b>Hemangioma or Hemangiosarcoma</b>			
Overall Rates	0/50 (0%)	0/50 (0%)	10/50 (20%)
Adjusted Rates	0.0%	0.0%	32.4%
Terminal Rates	0/42 (0%)	0/34 (0%)	9/29 (31%)
Life Table Tests	P<0.001	(b)	P<0.001
Incidental Tumor Tests	P<0.001	(b)	P<0.001
Cochran-Armitage Trend Test	P<0.001		
Fisher Exact Tests		(b)	P=0.001
<b>FEMALE</b>			
<b>Hemangioma</b>			
Overall Rates	0/50 (0%)	0/50 (0%)	3/50 (6%)
Adjusted Rates	0.0%	0.0%	20.7%
Terminal Rates	0/38 (0%)	0/29 (0%)	0/10 (0%)
Life Table Tests	P=0.004	(b)	P=0.012
Incidental Tumor Tests	P=0.091	(b)	P=0.336
Cochran-Armitage Trend Test	P=0.037		
Fisher Exact Tests		(b)	P=0.121
<b>Hemangiosarcoma</b>			
Overall Rates	0/50 (0%)	0/50 (0%)	2/50 (4%)
<b>Hemangioma or Hemangiosarcoma</b>			
Overall Rates	0/50 (0%)	0/50 (0%)	5/50 (10%)
Adjusted Rates	0.0%	0.0%	32.2%
Terminal Rates	0/38 (0%)	0/29 (0%)	1/10 (10%)
Life Table Tests	P<0.001	(b)	P<0.001
Incidental Tumor Tests	P=0.008	(b)	P=0.062
Cochran-Armitage Trend Test	P=0.006		
Fisher Exact Tests		(a)	P=0.028

(a) The statistical analyses used are discussed in Chapter II (Statistical Methods) and Appendix E (footnotes).

(b) No P value is presented because no tumors were observed in the control and 200-ppm groups.



The differentiation between hemangioma and hemangiosarcoma was based primarily on the degree of anaplasia in the neoplastic cells. Cytologic details of neoplasms with obvious features of malignancy (e.g., invasion of the maxillary sinus, bone marrow of the maxilla, or bone marrow and subcutis) were used as the standard by which malignancy was determined. Hemangiosarcomas were composed of endothelial cells with large vesicular nuclei and a high mitotic index. They formed smaller vascular channels and sinusoids. Hemangiomas were usually composed of more well-differentiated endothelial cells; these cells were flattened, had smaller nuclei, had fewer or no mitotic figures, and formed larger vascular channels.

*Circulatory System (all sites except nasal cavity):* No evidence of exposure-related vascular tumors was found outside the nasal cavity. Hemangiosarcomas were found in the livers of two control male mice and at multiple sites in two low dose male mice. Vascular tumors outside the nasal cavity were not found in high dose males. One

control and one high dose female mouse had a hemangioma of the uterus; a low dose female had a hemangiosarcoma of the liver, and a high dose female had a hemangiosarcoma of the urinary bladder.

*Ovary:* The incidences of ovarian atrophy were increased in dosed mice: control, 6/48 (13%); low dose, 8/46 (17%); high dose, 20/37 (54%).

*Uterus:* Suppurative inflammation of the uterus, peritoneum, or multiple organs or ovarian abscesses were observed in 2 control, 8 low dose, and 15 high dose female mice. Uterine endometrial hyperplasia occurred at a decreased incidence in dosed female mice: control, 24/48 (50%); low dose, 13/50 (26%); high dose, 1/48 (2%).

*Mammary Gland:* Adenocarcinomas (all types) occurred in females with a statistically significant positive trend, and the incidence in the high dose group was significantly greater than that in the controls (only by the life table test) (Table 21).

**TABLE 21. ANALYSIS OF MAMMARY GLAND TUMORS IN FEMALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE**

	Control	200 ppm	400 ppm
<b>Adenocarcinoma</b>			
Overall Rates	0/50 (0%)	3/50 (6%)	3/50 (6%)
Adjusted Rates	0.0%	8.1%	14.5%
Terminal Rates	0/38 (0%)	1/29 (3%)	1/10 (10%)
Life Table Tests	P=0.025	P=0.105	P=0.047
Incidental Tumor Tests	P=0.362	P=0.290	P=0.236
Cochran-Armitage Trend Test	P=0.101		
Fisher Exact Tests		P=0.121	P=0.121



## **IV. DISCUSSION AND CONCLUSIONS**

## IV. DISCUSSION AND CONCLUSIONS

---

F344/N rats and B6C3F<sub>1</sub> mice were exposed to propylene oxide vapors in air for 103 weeks. Inhalation was chosen as the route of exposure, since the most common potential human exposure would be to propylene oxide vapors. The concentrations of 200 and 400 ppm were chosen because in short-term studies the compound at higher concentrations produced weight loss. Rats appeared to tolerate exposure well, for mortality was not increased in exposed animals and final weights were within 10% of control values. The excessive mortality and weight loss in high dose mice suggest that toxic levels were reached: 29/50 (58%) of the males and 10/50 (20%) of the females survived to the end of the study; mean body weights of males and females were 21% and 10% below those of the controls.

On three occasions, high dose mice were exposed for 12-38 minutes at concentrations exceeding 1,000 ppm; concentrations in one exposure period exceeded 6,000 ppm. Only one male (at week 31) and one female (at week 83) died during the 2-week periods following these incidents. Thus, these increases were not considered to increase mortality or to influence the findings in these studies.

Toxic effects in rats and mice were restricted to the nasal cavity, which was the primary site exposed in these inhalation studies. This finding is consistent with results of other studies in which propylene oxide was observed to act as an irritant and a carcinogen only at the site of administration. Propylene oxide produced squamous cell carcinomas, papillomas, and hyperplasia of the forestomach when administered for up to 150 weeks by gavage to fasted Sprague-Dawley rats (Dunkelberg, 1982). All reported effects in that study were restricted to the forestomach. Similarly, propylene oxide administered subcutaneously produced sarcomas at the injection site in rats (strain unknown) (Walpole, 1958) and in NMRI mice (Dunkelberg, 1979, 1981).

In the present studies, the irritant effects of propylene oxide on the respiratory epithelium of the nasal mucosa were shown by marked suppurative inflammation, epithelial hyperplasia, and squamous metaplasia. The lesions were most evident in the anterior portion of the nasal cavity and on the greater curvatures of the nasal and maxillary turbinates.

Papillary adenomas of the nasal cavity were found in two male and three female F344/N rats exposed to propylene oxide at concentrations of 400 ppm. The incidence of papillary adenomas in female rats was significant by the trend tests. The lesions appeared to arise from the respiratory epithelium of the submucosal glands and were generally in the lateral wall of the nasal turbinates. The glandular tumors were well differentiated, often projecting into the lumen of the nasal cavity. Exposed rats also had epithelial hyperplasia. These lesions were less focal and smaller than the papillary adenomas but were morphologically similar.

The significance of finding adenomas in the turbinates of only high dose (400 ppm) rats and the relationship of these lesions to administration of propylene oxide are not clear. In an inhalation study undertaken by the National Institute for Occupational Safety and Health, two nasal adenomas were found in a group of 80 male F344 rats exposed to propylene oxide at a concentration of 300 ppm (NIOSH, 1983). The chances of detecting microscopic tumors in that study were increased because three sections of turbinate were examined from each control and exposed rat, as is done for the NTP studies, including these on propylene oxide. Much of the NTP historical data on nasal tumors is based on a single section of turbinate.

High dose animals in the current study also had irritation of the respiratory mucosa. Irritation per se may affect the incidence of adenomas. Research on nasal tumors induced in rats by 1,4-dinitrosopiperazine suggests that nodular hyperplasia may be more important than papillomas of the nasal turbinate as a precursor of carcinoma development (Takano et al., 1982). For these reasons, the evidence for carcinogenicity of propylene oxide for the nasal turbinate of rats is not clear.

Mice had similar inflammatory changes of the respiratory epithelium of the nasal cavity. Mice dying early in the study had rhinitis characterized primarily by an accumulation of neutrophils in the lumen of the nasal cavity. Lymphocytes, histiocytes, plasma cells, and mild squamous metaplasia were found in mice surviving to at least week 72 of the studies. Incidences of inflammation in males and females were comparable.

## IV. DISCUSSION AND CONCLUSIONS

Rhinitis was found in 4/100 control mice (both sexes), 69/100 low dose mice, and 88/100 high dose mice. One squamous cell carcinoma and one papilloma were found in the nasal cavity of high dose male mice, and two adenocarcinomas were seen in the nasal cavities of high dose female mice. The lesions were not exophytic; they appeared to arise from the submucosal glands, spread into the adjacent musculature, and grow along nerve sheaths. No lesions were observed in low dose and control mice. Squamous cell papillomas, carcinomas, and adenocarcinomas in the nasal cavity are rare in untreated mice and have not been observed in 1,615 male untreated control B6C3F<sub>1</sub> mice or in 1,668 female untreated control B6C3F<sub>1</sub> mice in the NTP carcinogenesis program. Therefore, the lesions observed in mice in the current study are considered to be related to exposure to propylene oxide.

Three levels of turbinates were examined in mice for this study. Although nasal tumors have not been found in historical control mice, an examination of turbinates is not required for all studies, and they are usually not examined unless a lesion is noted grossly. In inhalation studies, where examination of turbinates is required, recent studies include three sections and older studies, only one. Since turbinates have not been consistently examined in previous studies, historical data should be used with caution.

In the CIVO study of 28-month inhalation exposure of rats to propylene oxide (Reuzel and Kuper, 1983), 47 high dose (300 ppm) animals had slight-to-marked hyperplasia of the respiratory epithelium whereas only four controls were noted to have slight hyperplasia. Adenomas of the nasal cavity were not diagnosed in that study, but one high dose animal was found to have a squamous cell carcinoma of the nose, one of the trachea, and one of the larynx/pharynx with one animal having an adenocarcinoma of the larynx/pharynx. Tumors at these sites were not found in controls. Because these tumors occurred in one animal at each site, they were not statistically significant, but taken together they may have some biologic significance, since squamous cell carcinomas of the upper respiratory tract are uncommon in the rat.

Hemangiomas or hemangiosarcomas (combined) of the nasal cavity occurred at significantly

increased incidences in high dose (400 ppm) mice (male: control, 0/50; low dose, 0/50; high dose, 10/50; female: control, 0/50; low dose, 0/50; high dose, 5/50). Reduced survival among high dose female mice may explain the lower incidence of these neoplasms compared with male mice. The earliest recognizable lesion was classified as angiectasis and was found in three high dose males and in three high dose females. The lesion consisted of saccular dilatation of submucosal vessels in the nasal turbinates. Hemangiomas consisted of numerous small vascular channels lined by flattened endothelial cells. In the hemangiosarcomas, endothelial cells were prominent and had a higher mitotic rate. Obvious malignant properties were demonstrated by invasion of bones of the skull. A few vascular tumors were found at other sites (e.g., spleen or subcutis) in both exposed and control mice; they were considered to be unrelated to propylene oxide exposure. The only effect that was clearly carcinogenic occurred in high dose mice at the site of exposure.

Since propylene oxide is a direct-acting alkylating agent, a direct-acting mutagen in microorganisms, and a clastogen in cultured mammalian cells, it is not surprising that propylene oxide is tumorigenic at the site of exposure. Thus, the relatively weak response produced in exposed rats is unexpected. The tumorigenicity at the site of exposure has its parallel in the finding that propylene oxide did not induce micronuclei in mouse erythrocytes following gavage but did so following intraperitoneal injection (Bootman et al., 1979).

Propylene oxide was found to be the weakest alkylating agent and mutagen when compared with other epoxides, including epichlorohydrin, styrene oxide, and ethylene glycol. Comparisons were based on the rate and extent of the chemicals' reaction with 4-(*p*-nitrobenzyl)pyridine and their mutagenicity in *Escherichia coli* and *Salmonella typhimurium* strains. Compared with epichlorohydrin, the alkylating ability of propylene oxide was 17.2%-20% and the mutagenicity was 3.2% in *Salmonella* and 2%-10% in *E. coli* (Hemminki and Falck, 1979; Hemminki et al., 1980). Propylene oxide was also less mutagenic than epichlorohydrin in *Klebsiella* (Voogd et al., 1981) and *Neurospora* (Kolmark and Giles, 1955); however, propylene oxide did induce higher levels of chromatid

## IV. DISCUSSION AND CONCLUSIONS

---

breaks and exchanges than did epichlorohydrin in cultures of rat liver cells (Dean and Hodson-Walker, 1979).

The mutagenicity of propylene oxide and ethylene oxide differed, depending on the systems tested. Both epoxides failed to mutate *E. coli* T2 bacteriophage (Cookson et al., 1971), but they were equally mutagenic in a preincubation modification of the Ames Salmonella test (Pfeiffer and Dunkelberg, 1980). Ethylene oxide induced low levels of chromatid aberrations in peripheral lymphocytes of monkeys exposed by inhalation, whereas propylene oxide did not (NIOSH, 1983).

Other tumors found in rats in the present study were considered to be unrelated to propylene oxide exposure. The incidence of female rats with C-cell adenomas or carcinomas (combined) of the thyroid gland occurred with a statistically significant trend, and the incidence in the high dose group was significantly greater than that of the controls (Table 11); however, the incidences of C-cell hyperplasia in the dosed groups were comparable to that in the controls. Proliferation of C-cells in the thyroid gland of aging rats is not uncommon and appears to begin as mild, diffuse, or small focal collections of C-cells adjacent to the follicular epithelium. As the proliferation continues, the follicular epithelium is compressed and contiguous follicles become involved. Lesions smaller than three follicles are arbitrarily classified as hyperplasia. Lesions that are larger and restricted to one lobe are adenomas; and lesions involving the thyroid capsule, invading adjacent tissue, or having obvious malignant characteristics (such as metastases) are classified as C-cell carcinomas. Since these lesions are relatively common in female F344/N rats (122/1,472, 8%) (Appendix F, Table F5) and the distinction between hyperplasia and adenoma is one of degree, the combined incidence of C-cell adenomas and carcinomas in this study is considered to be unrelated to administration of propylene oxide.

Incidences of cystic endometrial stromal polyps, endometrial stromal polyps, and endometrial stromal sarcomas of the uterus were increased in

dosed female rats. The increase in the number of animals with sarcomas was not significant, but the incidence was significant when combined with polyps (Table 12). Historically, the incidences of endometrial stromal sarcomas are low and the incidences of endometrial stromal polyps are great in untreated female F344/N rats (Appendix F, Table F6). Since the progression from endometrial stromal polyps to sarcomas has not been established and the incidences of the tumors were low, these lesions cannot be clearly attributed to propylene oxide exposure.

Pituitary adenomas or adenomas and carcinomas (combined) occurred in female rats with significant negative trends. The incidences in the high dose groups were significantly lower than those in the controls. Lower tumor incidence and delay in the onset of tumors were reported for rats when feed consumption had been restricted (Ross and Bras, 1973; Tucker, 1979). Although the decreased weight gain in high dose female rats in the present study suggests that their feed consumption may have been reduced, this parameter was not measured. The lower incidence of pituitary tumors in the high dose female rats is consistent with decreased feed consumption.

Mammary gland adenocarcinomas occurred at significantly increased incidences in dosed female mice by the life table test, but these incidences are within the range found in untreated controls (Appendix F, Table F7). Thus, the incidence of this tumor is not considered to be related to exposure to propylene oxide.

Ovarian abscesses and suppurative inflammation of the uterus or peritoneum were observed in 2 control, 8 low dose, and 15 high dose female mice. *Klebsiella pneumonia* and *K. oxytoca* have been isolated from these mice and from mice in other NTP carcinogenesis studies at several laboratories. The presence of various serotypes of *Klebsiella* and the presence of other organisms such as *E. coli* suggest that the *Klebsiella* may be a secondary infection. The infection is definitely not related to propylene oxide exposure.

## IV. DISCUSSION AND CONCLUSIONS

---

*Conclusions:* Under the conditions of these studies, there was *some evidence of carcinogenicity\** for F344/N rats, as indicated by increased incidences of papillary adenomas of the nasal turbinates in male and female rats exposed to propylene oxide at 400 ppm. For male and female B6C3F<sub>1</sub> mice, there was *clear evidence of*

*carcinogenicity*, as indicated by increased incidences of hemangiomas or hemangiosarcomas of the nasal turbinates at 400 ppm. In the respiratory epithelium of the nasal turbinates, propylene oxide also caused suppurative inflammation, hyperplasia, and squamous metaplasia in rats and inflammation in mice.

---

\* Categories of evidence of carcinogenicity are defined in the Note to the Reader on page 2.





## **V. REFERENCES**

## V. REFERENCES

---

1. Aldrich Library of Nuclear Magnetic Resonance Spectra, Vol. 1., NMR No. 145A.
2. American Conference of Governmental Industrial Hygienists (ACGIH) (1980) Threshold Limit Values for Chemical Substances in Workroom Air Adopted by ACGIH for 1980. ISBN: 0-936712-29-5. Cincinnati: ACGIH, pp. 38-39.
3. Ames, B.N.; McCann, J.; Yamasaki, E. (1975) Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. *Mutat. Res.* 31:347-363.
4. Armitage, P. (1971) *Statistical Methods in Medical Research*. New York: John Wiley & Sons, Inc., pp. 362-365.
5. Berenblum, I., Ed. (1969) *Carcinogenicity Testing: A Report of the Panel on Carcinogenicity of the Cancer Research Commission of UICC, Vol. 2*. Geneva: International Union Against Cancer.
6. Boorman, G.; Montgomery, C., Jr.; Hardisty, J.; Eustis, S.; Wolfe, M.; McConnell, E. (1984): *Quality assurance in pathology for rodent toxicology and carcinogenicity tests*. Milman, H.; Weisburger, E., Eds.: *Handbook of Carcinogen Testing*. Park Ridge, NJ: Noyes Publications (in press).
7. Bootman, J.; Lodge, D.C.; Whalley, H.E. (1979) Mutagenic activity of propylene oxide in bacterial and mammalian systems. *Mutat. Res.* 67:101-112.
8. Cookson, M.J.; Sims, P.; Grover, P.L. (1971) Mutagenicity of epoxides of polycyclic hydrocarbons correlates with carcinogenicity of parent hydrocarbons. *Nature New Biol.* 234:186-187.
9. Cox, D. (1972) Regression models and life tables. *J. R. Stat. Soc.* B34:187-220.
10. Dean, B.J.; Hodson-Walker, G. (1979) An *in vitro* chromosome assay using cultured rat-liver cells. *Mutat. Res.* 64:329-337.
11. Dunkelberg, H. (1979) On the oncogenic activity of ethylene oxide and propylene oxide in mice. *Br. J. Cancer* 39:588-589.
12. Dunkelberg, H. (1981) Kanzerogene Aktivitat von Ethylenoxid und seinen Reaktionsprodukten 2-Chlorethanol, 2-Bromomethanol, Ethylenglykol und im Vergleich zu 1,2-Propylenoxid bei Subkutaner Applikation an Mäusen. *Zentralbl. Bakteriol. Mikrobiol. Hyg. (B)* 174:383-404.
13. Dunkelberg, H. (1982) Carcinogenicity of ethylene oxide and 1,2-propylene oxide upon intragastric administration to rats. *Br. J. Cancer* 46:924.
14. Elleman, D.D.; Manatt, S.L.; Pearce, C.D. (1965) Relative signs of nuclear magnetic resonance coupling constants in propylene oxide and indene oxide. *J. Chem. Phys.* 42:650-667.
15. Garro, A.J.; Phillips, R.A. (1980) Detection of mutagen-induced lesions in isolated DNA by marker rescue of *Bacillus subtilis* phage 105. *Mutat. Res.* 73:1-13.
16. Gart, J.; Chu, K.; Tarone, R. (1979) Statistical issues in interpretation of chronic bioassay tests for carcinogenicity. *J. Natl. Cancer Inst.* 62(4):957-974.
17. Goto, K.; Maeda, S.; Kano, Y.; Sugimura, T. (1978) Factors involved in differential Giemsa-staining of sister chromatids. *Chromosoma* 66:351-359.
18. Hardin, B.; Schuler, R.; McGinnis, P.; Niemeier, R.; Smith, R. (1983) Evaluation of propylene oxide for mutagenic activity in 3 *in vivo* test systems. *Mutat. Res.* 117:337-344.
19. Hemminki, K.; Falck, K. (1979) Correlation of mutagenicity and 4-(p-nitrobenzyl)pyridine alkylation by epoxides. *Toxicol. Lett.* 4:103-106.
20. Hemminki, K.; Falck, K.; Vainio, H. (1980) Comparison of alkylation rates and mutagenicity of directly acting industrial and laboratory chemicals. *Arch. Toxicol.* 46:277-285.
21. Henry, C. (1903) *Chem. Zentr.* 2:486.
22. Heslot, H. (1962) Etude quantitative de reversion biochimiques induites chez la levure *Schizo-saccharomyces pombe* par des radiations et des substances radiomimetiques. *Abh. Dtsch. Akad. Wiss., Berlin Kl. Med.* 1:193-228.

## V. REFERENCES

23. Hine, C.; Rowe, V.; White, E.; Darmer, K.; Youngblood, G. (1981) Epoxy compounds. *Patty's Industrial Hygiene and Toxicology*, 3rd ed. Vol. 2A. New York: John Wiley & Sons, p. 2141.
24. Hirashima, T.; Oguma, T.; Hosogai, Y.; Fujii, S. (1970) Studies on gaseous antimicrobial agent. III. Determination of propylene oxide residue in food wrappings and containers. *J. Food Hyg. Soc.* 11(3):161-163.
25. International Agency for Research on Cancer (IARC) (1976) Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man: Cadmium, Nickel, Some Epoxides, Miscellaneous Industrial Chemicals and General Considerations on Volatile Anaesthetics, Vol. 11. Lyon, France.
26. Jacobsen, K.; Hackley, E.; Feinsilver, L. (1956) Toxicity of inhaled ethylene oxide and propylene oxide vapors: acute and chronic toxicity of ethylene oxide and acute toxicity of propylene oxide. *AMA Arch. Ind. Health* 13:237-244.
27. Jensen, O. (1981) Contact allergy to propylene oxide and isopropyl alcohol in a skin disinfectant swab. *Contact Dermatitis* 7:148-150.
28. Kaplan, E.; Meier, P. (1958) Nonparametric estimation of incomplete observations. *J. Am. Stat. Assoc.* 53:457-481.
29. Kolmark, G.; Giles, N.H. (1955) Comparative studies of mono epoxides as inducers of reverse mutations in neurospora. *Genetics* 40:890-902.
30. Lawley, P.D.; Jarman, M. (1972) Alkylation by propylene oxide of deoxyribonucleic acid, adenine, guanosine and deoxyguanylic acid. *Biochem. J.* 126:893-900.
31. Linhart, M.; Cooper, J.; Martin, R.; Page, N.; Peters, J. (1974) Carcinogenesis bioassay data system. *Comp. Biomed. Res.* 7:230-248.
32. Mantel, N.; Haenszel, W. (1959) Statistical aspects of the analysis of data from retrospective studies of disease. *J. Natl. Cancer Inst.* 22:719-748.
33. Maronpot, R.R.; Boorman, G.A. (1982) Interpretation of rodent hepatocellular proliferative alterations and hepatocellular tumors in chemical safety assessment. *Toxicol. Path.* 10:70-81.
34. McLaughlin, R.S. (1946) Chemical burns of the human cornea. *Am. J. Ophthal.* 29:1355-1362.
35. McMahon, R.E.; Cline, J.C.; Thompson, C.Z. (1979) Assay of 855 test chemicals in ten tester strains using a new modification of the Ames test for bacterial mutagens. *Cancer Res.* 39:682-693.
36. National Institute for Occupational Safety and Health (NIOSH) (1983) Study. Preliminary results presented by T. Lewis at the Subcommittee on Environmental Mutagenesis, Bethesda, MD.
37. National Academy of Sciences (NAS) (1980) Histologic typing of liver tumors of the rat. *J. Natl. Cancer Inst.* 64:179-206.
38. Oguma, T.; Hosogai, Y.; Fujii, S.; Kawashiro, I. (1968) Studies on gaseous antimicrobial agent. I. Determination of propylene oxide residue in foods. *J. Food Hyg. Soc. Japan* 9:395-398.
39. Oguma, T.; Hosogai, Y.; Fujii, S. (1969) Studies on gaseous antimicrobial agents. II. Determination of propylene oxide residue in fats and oils. *J. Food Hyg. Soc. Japan* 10:37-39.
40. Perry, P.; Wolff, S (1974).: New Giemsa method for the differential staining of sister chromatids. *Nature (London)* 251:156-158.
41. Peto, R.; Pike, M.; Day, N.; Gray, R.; Lee, P.; Parish, S.; Peto, J.; Richards, S.; Wahrendorf, J. (1980) Annex. Guidelines for simple, sensitive, significance tests for carcinogenic effects in long-term animal experiments. *Long-Term and Short-Term Screening Assays for Carcinogens: A Critical Appraisal. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Supplement 2--International Agency for Research on Cancer. Lyon, France, pp. 311-426.*

## V. REFERENCES

---

42. Pfeiffer, E.H.; Dunkelberg, H. (1980) Mutagenicity of ethylene oxide and propylene oxide and of the glycols and halohydrins formed from them during the fumigation of foodstuffs. *Food Cosmet. Toxicol.* 18:115-118.
43. Phillips, R.A.; Zahler, S.A.; Garro, A.J. (1980) Detection of mutagen-induced lesions in isolated DNA using a new *Bacillus subtilis* transformation-based assay. *Mutat. Res.* 74:267-281.
44. Ross, M.H.; Bras, G. (1973) Influence of protein under- and overnutrition on spontaneous tumor prevalence in the rat. *J. Nutr.* 103:944-963.
45. Reuzel, P.; Kuper, C. (1983) Chronic Inhalation Toxicity/Carcinogenicity Study of 1,2-Propylene Oxide in Rats. Zeist, The Netherlands: CIVO Institutes TNO, Report No. V82.215/280853. 34 p.
46. Rowe, V.K.; Hollingsworth, R.L.; Oyen, F.; McCollister, D.D.; Spencer, H.C. (1956) Toxicity of propylene oxide determined on experimental animals. *AMA Arch. Ind. Health*, pp. 228-236.
47. Sadtler Standard Spectra. IR No. 387. NMR No. 10797. Philadelphia: Sadtler Research Laboratories.
48. Schalet, A. (1954) The mutagenic action of 1,2-propylene oxide and ethyl sulfate on mature sperm. *Drosophila Information Service* 28:155.
49. Smyth, H.F., Jr.; Seaton, J.; Fischer, L. (1941) The single dose toxicity of some glycols and derivatives. *J. Ind. Hyg. Toxicol.* 23:259-268.
50. Squire, R.; Levitt, M. (1975) Report of a workshop on classification of specific hepatocellular lesions in rats. *Cancer Res.* 35:3214-3223.
51. Takano, T.; Shiri, T.; Ogiso, T.; Tsuda, M.; Baba, S.; Ito, N. (1982) Sequential changes in tumor development induced by 1,4-nitrosopiperazine in the nasal cavity of F344 rats. *Cancer Res.* 42:4236-4240.
52. Tarone, R. (1975) Tests for trend in life table analysis. *Biometrika* 62:679-682.
53. Tucker, M.J. (1979) The effect of long-term food restriction on tumours in rodents. *Int. J. Cancer* 23:803-807.
54. U.S. Code of Federal Regulations (USCFR), 1979.
55. U.S. International Trade Commission (USITC) (1981) Synthetic Organic Chemicals, United States Production and Sales 1980. USITC Publication No. 1183, Washington, D.C.: Government Printing Office.
56. van Ketel, W.G. (1979) Contact dermatitis from propylene oxide. *Contact Dermatitis* 5(3):191-192.
57. Voogd, C.E.; van der Stel, J.J.; Jacobs, J.J. (1981) The mutagenic action of aliphatic epoxides. *Mutat. Res.* 89:269-282
58. Wade, D.R.; Airy, S.C.; Sinsheimer, J.E. (1978) Mutagenicity of aliphatic epoxides. *Mutat. Res.* 58:217-223.
59. Walles, S. (1974) The influence of some alkylating agents on the structure of DNA *in vitro*. *Chem.-Biol. Interact.* 9:97-103.
60. Walpole, A.L. (1958) Carcinogenic action of alkylating agents. *Ann. N.Y. Acad. Sci.* 68:750-761.
61. Yahagi, T.; Degawa, M.; Seino, Y.; Matsushima, T.; Nagao, M.; Sugimura, T.; Hashimoto, Y. (1975) Mutagenicity of carcinogenic azo dyes and their derivatives. *Cancer Lett.* 1:91-96.
62. Zimakov, P.; Sakolova, V. (1953) Physical properties of propylene oxide. *Zhur. Fiz. Khim.* 27:1079-1080.

**APPENDIX A**

**SUMMARY OF THE INCIDENCE OF NEOPLASMS IN RATS  
IN THE TWO-YEAR INHALATION STUDIES OF  
PROPYLENE OXIDE**

TABLE A1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
<b>INTEGUMENTARY SYSTEM</b>			
*SKIN	(50)	(50)	(50)
PAPILLOMA, NOS		1 (2%)	1 (2%)
KERATOACANTHOMA	1 (2%)	1 (2%)	5 (10%)
FIBROMA			1 (2%)
*SUBCUT TISSUE	(50)	(50)	(50)
FIBROMA	3 (6%)	2 (4%)	3 (6%)
LIPOMA			1 (2%)
OSTEOSARCOMA	1 (2%)		
NEURILEMOMA		1 (2%)	
<b>RESPIRATORY SYSTEM</b>			
*NASAL CAVITY	(50)	(50)	(50)
PAPILLARY ADENOMA			2 (4%)
#LUNG	(50)	(47)	(49)
ALVEOLAR/BRONCHIOLAR CARCINOMA	2 (4%)		2 (4%)
FOLLICULAR-CELL CARCINOMA, METAS		1 (2%)	
C-CELL CARCINOMA, METASTATIC			1 (2%)
<b>HEMATOPOIETIC SYSTEM</b>			
*MULTIPLE ORGANS	(50)	(50)	(50)
MALIGNANT LYMPHOMA, NOS	2 (4%)		
LEUKEMIA, NOS	1 (2%)	3 (6%)	1 (2%)
LEUKEMIA, MONONUCLEAR CELL	19 (38%)	23 (46%)	22 (44%)
*THYMUS	(31)	(26)	(37)
SQUAMOUS CELL CARCINOMA	1 (3%)		
<b>CIRCULATORY SYSTEM</b>			
*DIAPHRAGM	(50)	(50)	(50)
HEMANGIOMA			1 (2%)
*SPLEEN	(50)	(47)	(48)
HEMANGIOMA		1 (2%)	
<b>DIGESTIVE SYSTEM</b>			
#LIVER	(50)	(50)	(49)
NEOPLASTIC NODULE		2 (4%)	2 (4%)
HEPATOCELLULAR CARCINOMA	1 (2%)		1 (2%)
#DUODENUM	(46)	(48)	(48)
MUCINOUS ADENOCARCINOMA		1 (2%)	
#ILEUM	(46)	(48)	(48)
MUCINOUS ADENOCARCINOMA		1 (2%)	
<b>URINARY SYSTEM</b>			
*KIDNEY/MEDULLA	(50)	(50)	(50)
SARCOMA, NOS			1 (2%)
*URINARY BLADDER	(48)	(48)	(45)
TRANSITIONAL-CELL CARCINOMA	1 (2%)		
SARCOMA, NOS		1 (2%)	
MESOTHELIOMA, NOS	1 (2%)		

TABLE A1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>ENDOCRINE SYSTEM</b>			
#PITUITARY	(47)	(47)	(48)
ADENOMA, NOS	19 (40%)	13 (28%)	12 (25%)
ADENOCARCINOMA, NOS			1 (2%)
#ANTERIOR PITUITARY	(47)	(47)	(48)
ADENOMA, NOS	2 (4%)	2 (4%)	3 (6%)
#ADRENAL	(48)	(49)	(49)
CORTICAL ADENOMA			1 (2%)
PHEOCHROMOCYTOMA	3 (6%)	3 (6%)	2 (4%)
#ADRENAL MEDULLA	(48)	(49)	(49)
PHEOCHROMOCYTOMA		2 (4%)	2 (4%)
#THYROID	(44)	(41)	(49)
CARCINOMA, NOS	1 (2%)		
FOLLICULAR-CELL ADENOMA	1 (2%)		2 (4%)
FOLLICULAR-CELL CARCINOMA		1 (2%)	
C-CELL ADENOMA	1 (2%)	1 (2%)	2 (4%)
C-CELL CARCINOMA		1 (2%)	2 (4%)
#PANCREATIC ISLETS	(47)	(49)	(47)
ISLET-CELL ADENOMA	1 (2%)	3 (6%)	1 (2%)
ISLET-CELL CARCINOMA	1 (2%)	1 (2%)	
<b>REPRODUCTIVE SYSTEM</b>			
*MAMMARY GLAND	(50)	(50)	(50)
FIBROMA			1 (2%)
FIBROADENOMA		2 (4%)	1 (2%)
#TESTIS	(49)	(50)	(50)
INTERSTITIAL-CELL TUMOR	29 (59%)	36 (72%)	35 (70%)
MESOTHELIOMA, NOS	1 (2%)	1 (2%)	1 (2%)
*VAS DEFERENS	(50)	(50)	(50)
CARCINOMA, NOS			1 (2%)
<b>NERVOUS SYSTEM</b>			
#BRAIN	(47)	(50)	(49)
GLIOMA, NOS	1 (2%)	2 (4%)	
<b>SPECIAL SENSE ORGANS</b>			
*ZYMBAL'S GLAND	(50)	(50)	(50)
PAPILLOMA, NOS			1 (2%)
SQUAMOUS CELL CARCINOMA			1 (2%)
<b>MUSCULOSKELETAL SYSTEM</b>			
*SKULL	(50)	(50)	(50)
OSTEOMA	1 (2%)		
<b>BODY CAVITIES</b>			
*PERITONEAL CAVITY	(50)	(50)	(50)
LIPOMA			1 (2%)
*MESENTERY	(50)	(50)	(50)
FIBROSARCOMA		1 (2%)	
<b>ALL OTHER SYSTEMS</b>			
*MULTIPLE ORGANS	(50)	(50)	(50)
MESOTHELIOMA, NOS		1 (2%)	
MESOTHELIOMA, MALIGNANT			2 (4%)

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
 \* NUMBER OF ANIMALS NECROPSIED

**TABLE A1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>ANIMAL DISPOSITION SUMMARY</b>			
ANIMALS INITIALLY IN STUDY	50	50	50
NATURAL DEATH@	14	16	13
MORIBUND SACRIFICE	7	4	8
SCHEDULED SACRIFICE			
TERMINAL SACRIFICE	29	30	29
DOSING ACCIDENT			
ACCIDENTALLY KILLED, NDA			
ACCIDENTALLY KILLED, NOS			
ANIMAL MISSING			
ANIMAL MISSEXED			
OTHER CASES			
@ INCLUDES AUTOLYZED ANIMALS			
<b>TUMOR SUMMARY</b>			
TOTAL ANIMALS WITH PRIMARY TUMORS**	47	49	48
TOTAL PRIMARY TUMORS	94	107	115
TOTAL ANIMALS WITH BENIGN TUMORS	41	46	45
TOTAL BENIGN TUMORS	61	68	78
TOTAL ANIMALS WITH MALIGNANT TUMORS	29	30	30
TOTAL MALIGNANT TUMORS	31	35	34
TOTAL ANIMALS WITH SECONDARY TUMORS##		1	1
TOTAL SECONDARY TUMORS		1	1
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT	1	4	3
TOTAL UNCERTAIN TUMORS	2	4	3
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PRIMARY OR METASTATIC			
TOTAL UNCERTAIN TUMORS			
** PRIMARY TUMORS: ALL TUMORS EXCEPT SECONDARY TUMORS			
## SECONDARY TUMORS: METASTATIC TUMORS OR TUMORS INVASIVE INTO AN ADJACENT ORGAN			



TABLE A2. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
<b>INTEGUMENTARY SYSTEM</b>			
*SKIN	(50)	(50)	(50)
PAPILLOMA, NOS		1 (2%)	
BASAL-CELL CARCINOMA			1 (2%)
*SUBCUT TISSUE	(50)	(50)	(50)
SARCOMA, NOS		1 (2%)	1 (2%)
FIBROMA	1 (2%)		1 (2%)
LIPOMA	1 (2%)		
RHABDOMYOSARCOMA	1 (2%)		
<b>RESPIRATORY SYSTEM</b>			
*NASAL CAVITY	(50)	(50)	(50)
PAPILLARY ADENOMA			3 (6%)
#LUNG	(48)	(48)	(50)
TUBULAR-CELL ADENOCARCINOMA, MET	1 (2%)		
C-CELL CARCINOMA, METASTATIC			2 (4%)
GRANULOSA-CELL CARCINOMA, METAST	1 (2%)		
<b>HEMATOPOIETIC SYSTEM</b>			
*MULTIPLE ORGANS	(50)	(50)	(50)
MALIGNANT LYMPHOMA, NOS	1 (2%)		
MALIG. LYMPHOMA, HISTIOCYTIC TYPE		1 (2%)	
LEUKEMIA, NOS	3 (6%)	3 (6%)	6 (12%)
LEUKEMIA, MONONUCLEAR CELL	11 (22%)	20 (40%)	15 (30%)
<b>CIRCULATORY SYSTEM</b>			
NONE			
<b>DIGESTIVE SYSTEM</b>			
*TONGUE	(50)	(50)	(50)
PAPILLOMA, NOS	1 (2%)		
#LIVER	(50)	(49)	(49)
NEOPLASTIC NODULE	1 (2%)		
#FORESTOMACH	(49)	(48)	(47)
SQUAMOUS CELL PAPILLOMA			1 (2%)
*RECTUM	(50)	(50)	(50)
SARCOMA, NOS, INVASIVE			1 (2%)
<b>URINARY SYSTEM</b>			
#KIDNEY	(50)	(50)	(49)
TUBULAR-CELL ADENOMA		1 (2%)	
TUBULAR-CELL ADENOCARCINOMA	1 (2%)		
#URINARY BLADDER	(44)	(46)	(40)
SARCOMA, NOS, INVASIVE			1 (3%)
ENDOMETRIAL STROMAL SARCOMA, INV		1 (2%)	

TABLE A2. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>ENDOCRINE SYSTEM</b>			
#PITUITARY	(48)	(47)	(46)
ADENOMA, NOS	17 (35%)	13 (28%)	13 (28%)
#ANTERIOR PITUITARY	(48)	(47)	(46)
CARCINOMA, NOS		2 (4%)	
ADENOMA, NOS	8 (17%)	5 (11%)	1 (2%)
#ADRENAL	(48)	(49)	(48)
CORTICAL ADENOMA	1 (2%)	1 (2%)	
CORTICAL CARCINOMA		1 (2%)	
PHEOCHROMOCYTOMA			1 (2%)
#ADRENAL MEDULLA	(48)	(49)	(48)
PHEOCHROMOCYTOMA	1 (2%)	1 (2%)	
#THYROID	(45)	(35)	(37)
ADENOMA, NOS			1 (3%)
FOLLICULAR-CELL ADENOMA		1 (3%)	
FOLLICULAR-CELL CARCINOMA		1 (3%)	1 (3%)
C-CELL ADENOMA	1 (2%)	1 (3%)	4 (11%)
C-CELL CARCINOMA	1 (2%)	1 (3%)	3 (8%)
#PANCREATIC ISLETS	(47)	(48)	(46)
ISLET-CELL ADENOMA		1 (2%)	1 (2%)
<b>REPRODUCTIVE SYSTEM</b>			
*MAMMARY GLAND	(50)	(50)	(50)
ADENOCARCINOMA, NOS	1 (2%)	1 (2%)	1 (2%)
FIBROADENOMA	7 (14%)	13 (26%)	13 (26%)
*CLITORAL GLAND	(50)	(50)	(50)
SQUAMOUS CELL CARCINOMA			1 (2%)
PAPILLARY ADENOMA			1 (2%)
#UTERUS	(49)	(50)	(47)
ADENOCARCINOMA, NOS			1 (2%)
SARCOMA, NOS			1 (2%)
ENDOMETRIAL STROMAL POLYP	3 (6%)	8 (16%)	7 (15%)
ENDOMETRIAL STROMAL SARCOMA		4 (8%)	2 (4%)
#CERVIX UTERI	(49)	(50)	(47)
ENDOMETRIAL STROMAL POLYP			1 (2%)
#OVARY	(48)	(50)	(46)
TUBULAR-CELL ADENOCARCINOMA, MET	1 (2%)		
GRANULOSA-CELL CARCINOMA	1 (2%)		
<b>NERVOUS SYSTEM</b>			
#CEREBRUM	(49)	(50)	(49)
CARCINOMA, NOS, INVASIVE		1 (2%)	
#BRAIN	(49)	(50)	(49)
GLIOMA, NOS			2 (4%)
OLIGODENDROGLIOMA		1 (2%)	
<b>SPECIAL SENSE ORGANS</b>			
*EYE/LACRIMAL GLAND	(50)	(50)	(50)
CARCINOMA, NOS			1 (2%)
*ZYMBAL'S GLAND	(50)	(50)	(50)
CARCINOMA, NOS	1 (2%)		
SQUAMOUS CELL CARCINOMA		1 (2%)	
<b>MUSCULOSKELETAL SYSTEM</b>			
NONE			
<b>BODY CAVITIES</b>			
NONE			
<b>ALL OTHER SYSTEMS</b>			
NONE			

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
 \* NUMBER OF ANIMALS NECROPSIED

**TABLE A2. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>ANIMAL DISPOSITION SUMMARY</b>			
ANIMALS INITIALLY IN STUDY	50	50	50
NATURAL DEATH@	10	10	13
MORIBUND SACRIFICE	5	9	6
SCHEDULED SACRIFICE			
TERMINAL SACRIFICE	35	31	31
DOSING ACCIDENT			
ACCIDENTALLY KILLED, NDA			
ACCIDENTALLY KILLED, NOS			
ANIMAL MISSING			
ANIMAL MISSEXED			
OTHER CASES			
@ INCLUDES AUTOLYZED ANIMALS			
<b>TUMOR SUMMARY</b>			
TOTAL ANIMALS WITH PRIMARY TUMORS**	38	46	44
TOTAL PRIMARY TUMORS	63	83	84
TOTAL ANIMALS WITH BENIGN TUMORS	30	34	33
TOTAL BENIGN TUMORS	41	46	48
TOTAL ANIMALS WITH MALIGNANT TUMORS	19	28	30
TOTAL MALIGNANT TUMORS	21	37	36
TOTAL ANIMALS WITH SECONDARY TUMORS##	2	2	3
TOTAL SECONDARY TUMORS	3	2	4
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT	1		
TOTAL UNCERTAIN TUMORS	1		
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PRIMARY OR METASTATIC			
TOTAL UNCERTAIN TUMORS			
** PRIMARY TUMORS: ALL TUMORS EXCEPT SECONDARY TUMORS			
## SECONDARY TUMORS: METASTATIC TUMORS OR TUMORS INVASIVE INTO AN ADJACENT ORGAN			



TABLE A3. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE RATS: CHAMBER CONTROL (Continued)

ANIMAL NUMBER	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
WEEKS ON STUDY	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	
TOTAL TISSUES TUMORS																																																																																																					
<b>INTEGUMENTARY SYSTEM</b>																																																																																																					
SKIN KERATOCANTHOMA																																																																																																					
SUBCUTANEOUS TISSUE FIBROMA																																																																																																					
OSTEOSARCOMA																																																																																																					
<b>RESPIRATORY SYSTEM</b>																																																																																																					
LUNGS AND BRONCHI ALVEOLAR/BRONCHIOLAR CARCINOMA																																																																																																					
TRACHEA																																																																																																					
<b>HEMATOPOIETIC SYSTEM</b>																																																																																																					
BONE MARROW																																																																																																					
SPLEEN																																																																																																					
LYMPH NODES																																																																																																					
THYMUS SQUAMOUS CELL CARCINOMA																																																																																																					
<b>CIRCULATORY SYSTEM</b>																																																																																																					
HEART																																																																																																					
<b>DIGESTIVE SYSTEM</b>																																																																																																					
SALIVARY GLAND																																																																																																					
LIVER HEPATOCELLULAR CARCINOMA																																																																																																					
BILE DUCT																																																																																																					
GALLBLADDER & COMMON BILE DUCT																																																																																																					
PANCREAS																																																																																																					
ESOPHAGUS																																																																																																					
STOMACH																																																																																																					
SMALL INTESTINE																																																																																																					
LARGE INTESTINE																																																																																																					
<b>URINARY SYSTEM</b>																																																																																																					
KIDNEY																																																																																																					
URINARY BLADDER TRANSITIONAL-CELL CARCINOMA MESOTHELIOA, NOS																																																																																																					
<b>ENDOCRINE SYSTEM</b>																																																																																																					
PITUITARY ADENOMA, NOS																																																																																																					
ADRENAL PHEOCHROMOCYTOMA																																																																																																					
THYROID CARCINOMA, NOS FOLLICULAR-CELL ADENOMA C-CELL ADENOMA																																																																																																					
PARATHYROID																																																																																																					
PANCREATIC ISLETS ISLET-CELL ADENOMA ISLET-CELL CARCINOMA																																																																																																					
<b>REPRODUCTIVE SYSTEM</b>																																																																																																					
MAMMARY GLAND																																																																																																					
TESTIS INTERSTITIAL-CELL TUMOR MESOTHELIOA, NOS																																																																																																					
PROSTATE																																																																																																					
<b>NERVOUS SYSTEM</b>																																																																																																					
BRAIN GLIOMA, NOS																																																																																																					
<b>MUSCULOSKELETAL SYSTEM</b>																																																																																																					
BONE OSTEOA																																																																																																					
<b>ALL OTHER SYSTEMS</b>																																																																																																					
MULTIPLE ORGANS NOS MALIGNANT LYMPHOMA, NOS LEUKEMIA, NOS LEUKEMIA, MONONUCLEAR CELL																																																																																																					

\* ANIMALS NECROPSIED



TABLE A3. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE RATS: LOW-DOSE (Continued)

ANIMAL NUMBER	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
WEEKS ON STUDY	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	
TOTAL TISSUES TUMORS																																																																																																					
<b>INTEGUMENTARY SYSTEM</b>																																																																																																					
SKIN PAPILLOMA, NOS																																																																																																					
SKIN KERATOCANTHOMA																																																																																																					
SUBCUTANEOUS TISSUE FIBROMA																																																																																																					
SUBCUTANEOUS TISSUE NEURILEIOMA																																																																																																					
<b>RESPIRATORY SYSTEM</b>																																																																																																					
LUNGS AND BRONCHI FOLLICULAR-CELL CARCINOMA, METAST																																																																																																					
TRACHEA																																																																																																					
<b>HEMATOPOIETIC SYSTEM</b>																																																																																																					
BONE MARROW																																																																																																					
SPLEEN HEMANGIOMA																																																																																																					
LYMPH NODES																																																																																																					
THYMUS																																																																																																					
<b>CIRCULATORY SYSTEM</b>																																																																																																					
HEART																																																																																																					
<b>DIGESTIVE SYSTEM</b>																																																																																																					
SALIVARY GLAND																																																																																																					
LIVER NEOPLASTIC NODULE																																																																																																					
BILE DUCT																																																																																																					
GALLBLADDER & COMMON BILE DUCT																																																																																																					
PANCREAS																																																																																																					
ESOPHAGUS																																																																																																					
STOMACH																																																																																																					
SMALL INTESTINE MUCINOUS ADENOCARCINOMA																																																																																																					
LARGE INTESTINE																																																																																																					
<b>URINARY SYSTEM</b>																																																																																																					
KIDNEY																																																																																																					
URINARY BLADDER SARCOMA, NOS																																																																																																					
<b>ENDOCRINE SYSTEM</b>																																																																																																					
PITUITARY ADENOMA, NOS																																																																																																					
ADRENAL PHEOCHROMOCYTOMA																																																																																																					
THYROID FOLLICULAR-CELL CARCINOMA																																																																																																					
THYROID C-CELL ADENOMA																																																																																																					
THYROID C-CELL CARCINOMA																																																																																																					
PARATHYROID																																																																																																					
PANCREATIC ISLETS ISLET-CELL ADENOMA																																																																																																					
PANCREATIC ISLETS ISLET-CELL CARCINOMA																																																																																																					
<b>REPRODUCTIVE SYSTEM</b>																																																																																																					
MAMMARY GLAND FIBROADENOMA																																																																																																					
TESTIS INTERSTITIAL-CELL TUMOR																																																																																																					
TESTIS MESOTHELIOMA, NOS																																																																																																					
PROSTATE																																																																																																					
<b>NERVOUS SYSTEM</b>																																																																																																					
BRAIN GLIOMA, NOS																																																																																																					
<b>BODY CAVITIES</b>																																																																																																					
MESENTERY FIBROSARCOMA																																																																																																					
<b>ALL OTHER SYSTEMS</b>																																																																																																					
MULTIPLE ORGANS NOS																																																																																																					
MESOTHELIOMA, NOS																																																																																																					
LEUKEMIA, NOS																																																																																																					
LEUKEMIA, MONONUCLEAR CELL																																																																																																					

\* ANIMALS NECROPSIED

TABLE A3. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE: HIGH DOSE

ANIMAL NUMBER	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25			
WEEKS ON STUDY	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25				
<b>INTEGUMENTARY SYSTEM</b>																													
SKIN PAPILLOMA, NOS KERATOCANTHOMA FIBROMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
						X										X													
SUBCUTANEOUS TISSUE FIBROMA LIPOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
						X																				X			
<b>RESPIRATORY SYSTEM</b>																													
LUNGS AND BRONCHI ALVEOLAR/BRONCHIOLAR CARCINOMA C-CELL CARCINOMA, METASTATIC	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
						X																							
TRACHEA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
NASAL CAVITY PAPILLARY ADENOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
											X																		
<b>HEMATOPOIETIC SYSTEM</b>																													
BONE MARROW	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
SPLEEN	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
LYMPH NODES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
THYMUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
<b>CIRCULATORY SYSTEM</b>																													
HEART	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
<b>DIGESTIVE SYSTEM</b>																													
SALIVARY GLAND	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
LIVER NEOPLASTIC NODULE HEPATOCELLULAR CARCINOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
											X																		
BILE DUCT	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
GALLBLADDER & COMMON BILE DUCT	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N			
PANCREAS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
ESOPHAGUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
STOMACH	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
SMALL INTESTINE	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
LARGE INTESTINE	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
<b>URINARY SYSTEM</b>																													
KIDNEY SARCOMA, NOS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
						X																							
URINARY BLADDER	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
<b>ENDOCRINE SYSTEM</b>																													
PITUITARY ADENOMA, NOS ADENOCARCINOMA, NOS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
						X					X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X			
ADRENAL CORTICAL ADENOMA PHEOCHROMOCYTOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
						X										X									X				
THYROID FOLLICULAR-CELL ADENOMA C-CELL ADENOMA C-CELL CARCINOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
	X															X									X				
PARATHYROID	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
PANCREATIC ISLETS ISLET-CELL ADENOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
																X													
<b>REPRODUCTIVE SYSTEM</b>																													
MAMMARY GLAND FIBROMA FIBROADENOMA	+	N	N	N	N	N	N	N	+	N	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
																X													
TESTIS INTERSTITIAL-CELL TUMOR MESOTHELIOA, NOS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
	X		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X			
PROSTATE	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
VAS DEFERNES, SPERMATIC CORD CARCINOMA, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N			
																X													
<b>NERVOUS SYSTEM</b>																													
BRAIN	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
<b>SPECIAL SENSE ORGANS</b>																													
ZYMBAL'S GLAND PAPILLOMA, NOS SQUAMOUS CELL CARCINOMA	N	N	+	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	+	N	N	N	N
																X													
<b>BODY CAVITIES</b>																													
PERITONEUM LIPOMA	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
<b>ALL OTHER SYSTEMS</b>																													
MULTIPLE ORGANS NOS MESOTHELIOA, MALIGNANT LEUKEMIA, NOS LEUKEMIA, MONONUCLEAR CELL	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
	X					X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
DIAPHRAGM NOS HEMANGIOMA																													





**TABLE A4. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE: CHAMBER CONTROL**

ANIMAL NUMBER	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	
WEEKS ON STUDY	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
<b>INTEGUMENTARY SYSTEM</b>																															
SUBCUTANEOUS TISSUE	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
FIBROMA																															
LIPOMA																															
RHABDOMYOSARCOMA																															
<b>RESPIRATORY SYSTEM</b>																															
LUNGS AND BRONCHI	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
TUBULAR-CELL ADENOCARCINOMA, META																															
GRANULOSA-CELL CARCINOMA, METASTA																															
TRACHEA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
<b>HEMATOPOIETIC SYSTEM</b>																															
BONE MARROW	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
SPLEEN	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
LYMPH NODES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
THYMUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
<b>CIRCULATORY SYSTEM</b>																															
HEART	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
<b>DIGESTIVE SYSTEM</b>																															
ORAL CAVITY																															
PAPILLOMA, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
SALIVARY GLAND	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
LIVER	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
NEOPLASTIC NODULE																															
BILE DUCT	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
GALLBLADDER & COMMON BILE DUCT	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
PANCREAS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
ESOPHAGUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
STOMACH	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
SMALL INTESTINE	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
LARGE INTESTINE	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
<b>URINARY SYSTEM</b>																															
KIDNEY	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
TUBULAR-CELL ADENOCARCINOMA																															
URINARY BLADDER	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
<b>ENDOCRINE SYSTEM</b>																															
PITUITARY	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
ADENOMA, NOS	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
ADRENAL	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
CORTICAL ADENOMA																															
PHEOCHROMOCYTOMA																															
THYROID	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
C-CELL ADENOMA																															
C-CELL CARCINOMA																															
PARATHYROID	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
<b>REPRODUCTIVE SYSTEM</b>																															
MAMMARY GLAND	+	+	N	+	N	+	+	+	N	+	+	+	N	+	+	+	N	+	+	N	+	+	N	+	+	N	+	+	+	+	
ADENOCARCINOMA, NOS																															
FIBROADENOMA	X	X																													
UTERUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
ENDOMETRIAL STROMAL POLYP																															
OVARY	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
TUBULAR-CELL ADENOCARCINOMA, META																															
GRANULOSA-CELL CARCINOMA																															
<b>NERVOUS SYSTEM</b>																															
BRAIN	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
<b>SPECIAL SENSE ORGANS</b>																															
ZYMBAL'S GLAND	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
CARCINOMA, NOS																															
<b>ALL OTHER SYSTEMS</b>																															
MULTIPLE ORGANS NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
MALIGNANT LYMPHOMA, NOS																															
LEUKEMIA, NOS																															
LEUKEMIA, MONONUCLEAR CELL	X									X	X																				

+: TISSUE EXAMINED MICROSCOPICALLY  
 -: REQUIRED TISSUE NOT EXAMINED MICROSCOPICALLY  
 X: TUMOR INCIDENCE  
 N: NECROPSY, NO AUTOLYSIS, NO MICROSCOPIC EXAMINATION  
 S: ANIMAL MIS-SEXED  
 1: NO TISSUE INFORMATION SUBMITTED  
 C: NECROPSY, NO HISTOLOGY DUE TO PROTOCOL  
 A: AUTOLYSIS  
 M: ANIMAL MISSING  
 B: NO NECROPSY PERFORMED





TABLE A4. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE RATS: LOW-DOSE (Continued)

ANIMAL NUMBER																					TOTAL TISSUES TUMORS
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
WEEKS ON STUDY	2	2	2	3	3	3	3	3	3	3	3	3	3	4	4	4	4	4	4	4	5
<b>INTEGUMENTARY SYSTEM</b>																					
SKIN PAPILLOMA, NOS	+	+	+	N	N	+	+	+	+	N	N	+	+	+	+	+	+	N	+	+	+
SUBCUTANEOUS TISSUE SARCOMA, NOS	+	+	+	N	N	+	+	+	+	N	N	+	+	+	+	+	+	N	+	+	+
<b>RESPIRATORY SYSTEM</b>																					
LUNGS AND BRONCHI	+	+	+	+	+	+	+	+	+	-	+	+	-	+	+	+	+	+	+	+	+
TRACHEA	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
<b>HEMATOPOIETIC SYSTEM</b>																					
BONE MARROW	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
SPLEEN	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	+	+
LYMPH NODES	-	+	+	+	-	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+
THYMUS	-	+	-	-	-	+	+	-	-	+	+	-	+	-	+	-	-	+	-	+	-
<b>CIRCULATORY SYSTEM</b>																					
HEART	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
<b>DIGESTIVE SYSTEM</b>																					
SALIVARY GLAND	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	+	+	+	+
LIVER	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+
BILE DUCT	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+
GALLBLADDER & COMMON BILE DUCT	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
PANCREAS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ESOPHAGUS	+	-	-	+	+	-	+	+	-	+	+	+	+	+	+	-	+	-	-	-	-
STOMACH	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
SMALL INTESTINE	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
LARGE INTESTINE	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	-	+	+	+
<b>URINARY SYSTEM</b>																					
KIDNEY TUBULAR-CELL ADENOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
URINARY BLADDER ENDOMETRIAL STROMAL SARCOMA, INVA	+	-	+	+	+	+	+	+	+	+	+	+	+	X	+	+	+	+	+	+	-
<b>ENDOCRINE SYSTEM</b>																					
PITUITARY CARCINOMA, NOS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ADENOMA, NOS	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
ADRENAL CORTICAL ADENOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
CORTICAL CARCINOMA													X								
PHEOCHROMOCYTOMA														X							
THYROID FOLLICULAR-CELL ADENOMA	+	-	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	+
FOLLICULAR-CELL CARCINOMA																		X			
C-CELL ADENOMA																					
C-CELL CARCINOMA																					
PARATHYROID	+	-	-	+	+	+	+	-	-	+	-	-	-	-	-	-	-	-	-	-	-
PANCREATIC ISLETS ISLET-CELL ADENOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
<b>REPRODUCTIVE SYSTEM</b>																					
MAMMARY GLAND ADENOCARCINOMA, NOS	+	+	+	+	+	+	+	+	+	N	+	N	+	N	+	+	N	+	+	+	N
FIBROADENOMA	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
UTERUS ENDOMETRIAL STROMAL POLYP	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ENDOMETRIAL STROMAL SARCOMA	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
OVARY	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
<b>NERVOUS SYSTEM</b>																					
BRAIN CARCINOMA, NOS, INVASIVE OLIGODENDROGLIOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
<b>SPECIAL SENSE ORGANS</b>																					
ZYMBAL'S GLAND SQUAMOUS CELL CARCINOMA	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
<b>ALL OTHER SYSTEMS</b>																					
MULTIPLE ORGANS NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
MALIG. LYMPHOMA, HISTIOCYTIC TYPE																					
LEUKEMIA, NOS																					
LEUKEMIA, MONONUCLEAR CELL			X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X

\* ANIMALS NECROPSIED

**TABLE A4. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE: HIGH DOSE**

ANIMAL NUMBER	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25
WEEKS ON STUDY	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	
<b>INTEGUMENTARY SYSTEM</b>																										
SKIN BASAL-CELL CARCINOMA	+	+	+	+	N	+	+	+	+	+	+	+	+	+	+	+	+	N	N	+	+	+	+	+	+	+
SUBCUTANEOUS TISSUE SARCOMA, NOS FIBROMA	+	+	+	+	N	+	+	+	+	+	+	+	+	+	+	+	+	N	N	+	+	+	+	+	+	+
<b>RESPIRATORY SYSTEM</b>																										
LUNGS AND BRONCHI C-CELL CARCINOMA, METASTATIC	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
TRACHEA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
NASAL CAVITY PAPILLARY ADENOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	N	+	+	+	+	+	+	N	+	X
<b>HEMATOPOIETIC SYSTEM</b>																										
BONE MARROW	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
SPLEEN	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
LYMPH NODES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
THYMUS	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
<b>CIRCULATORY SYSTEM</b>																										
HEART	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
<b>DIGESTIVE SYSTEM</b>																										
SALIVARY GLAND	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
LIVER	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
BILE DUCT	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
GALLBLADDER & COMMON BILE DUCT	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
PANCREAS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ESOPHAGUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
STOMACH SQUAMOUS CELL PAPILLOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
SMALL INTESTINE	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
LARGE INTESTINE	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
RECTUM SARCOMA, NOS, INVASIVE	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
<b>URINARY SYSTEM</b>																										
KIDNEY	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
URINARY BLADDER SARCOMA, NOS, INVASIVE	-	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
<b>ENDOCRINE SYSTEM</b>																										
PITUITARY ADENOMA, NOS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ADRENAL PHEOCHROMOCYTOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
THYROID ADENOMA, NOS FOLLICULAR-CELL CARCINOMA C-CELL ADENOMA C-CELL CARCINOMA	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PARATHYROID	-	+	-	-	+	-	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PANCREATIC ISLETS ISLET-CELL ADENOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
<b>REPRODUCTIVE SYSTEM</b>																										
MAMMARY GLAND ADENOCARCINOMA, NOS FIBROADENOMA	N	+	+	+	N	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PREPUTIAL/CLITORAL GLAND SQUAMOUS CELL CARCINOMA PAPILLARY ADENOMA	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
UTERUS ADENOCARCINOMA, NOS SARCOMA, NOS ENDOMETRIAL STROMAL POLYP ENDOMETRIAL STROMAL SARCOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
OVARY	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
<b>NERVOUS SYSTEM</b>																										
BRAIN GLIOMA, NOS	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
<b>SPECIAL SENSE ORGANS</b>																										
LACRIMAL GLAND CARCINOMA, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
<b>ALL OTHER SYSTEMS</b>																										
MULTIPLE ORGANS NOS LEUKEMIA, NOS LEUKEMIA, MONONUCLEAR CELL	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N







**APPENDIX B**

**SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MICE  
IN THE TWO-YEAR INHALATION STUDIES OF  
PROPYLENE OXIDE**



TABLE B1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
<b>INTEGUMENTARY SYSTEM</b>			
*SKIN	(50)	(50)	(50)
ADNEXAL ADENOMA		1 (2%)	
<b>RESPIRATORY SYSTEM</b>			
*NASAL CAVITY	(50)	(50)	(50)
PAPILLOMA, NOS			1 (2%)
SQUAMOUS CELL CARCINOMA			1 (2%)
#LUNG	(50)	(50)	(50)
HEPATOCELLULAR CARCINOMA, METAST		2 (4%)	
ALVEOLAR/BRONCHIOLAR ADENOMA	14 (28%)	12 (24%)	8 (16%)
ALVEOLAR/BRONCHIOLAR CARCINOMA	2 (4%)	2 (4%)	
<b>HEMATOPOIETIC SYSTEM</b>			
*MULTIPLE ORGANS	(50)	(50)	(50)
MALIGNANT LYMPHOMA, NOS	4 (8%)	2 (4%)	4 (8%)
MALIGNANT LYMPHOMA, MIXED TYPE		3 (6%)	
LEUKEMIA, NOS	1 (2%)		
#LYMPH NODE	(44)	(48)	(42)
MALIGNANT LYMPHOMA, MIXED TYPE	1 (2%)		
<b>CIRCULATORY SYSTEM</b>			
*SUBCUT TISSUE	(50)	(50)	(50)
HEMANGIOSARCOMA		1 (2%)	
#SPLEEN	(48)	(50)	(47)
HEMANGIOMA			1 (2%)
HEMANGIOSARCOMA		1 (2%)	
*NASAL CAVITY	(50)	(50)	(50)
HEMANGIOMA			5 (10%)
HEMANGIOSARCOMA			5 (10%)
#HEART	(50)	(50)	(50)
HEMANGIOSARCOMA		1 (2%)	
#LIVER	(50)	(50)	(50)
HEMANGIOSARCOMA	2 (4%)	1 (2%)	
<b>DIGESTIVE SYSTEM</b>			
*TOOTH	(50)	(50)	(50)
ODONTOMA	1 (2%)	1 (2%)	1 (2%)
#LIVER	(50)	(50)	(50)
HEPATOCELLULAR ADENOMA	8 (16%)	6 (12%)	5 (10%)
HEPATOCELLULAR CARCINOMA	6 (12%)	10 (20%)	5 (10%)
<b>URINARY SYSTEM</b>			
#KIDNEY/TUBULE	(50)	(50)	(50)
CYSTADENOMA, NOS			1 (2%)
<b>ENDOCRINE SYSTEM</b>			
#ADRENAL	(50)	(43)	(49)
CORTICAL ADENOMA		2 (5%)	
CORTICAL CARCINOMA	1 (2%)		
#THYROID	(43)	(48)	(46)
FOLLICULAR-CELL ADENOMA		1 (2%)	

**TABLE B1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>REPRODUCTIVE SYSTEM</b>			
#TESTIS	(48)	(49)	(49)
INTERSTITIAL-CELL TUMOR		1 (2%)	
<b>NERVOUS SYSTEM</b>			
NONE			
<b>SPECIAL SENSE ORGANS</b>			
*EYE/LACRIMAL GLAND	(50)	(50)	(50)
ADENOCARCINOMA, NOS	1 (2%)		
*HARDERIAN GLAND	(50)	(50)	(50)
ADENOMA, NOS		1 (2%)	
PAPILLARY CYSTADENOMA, NOS	1 (2%)		
<b>MUSCULOSKELETAL SYSTEM</b>			
NONE			
<b>BODY CAVITIES</b>			
NONE			
<b>ALL OTHER SYSTEMS</b>			
NONE			
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			
<b>ANIMAL DISPOSITION SUMMARY</b>			
ANIMALS INITIALLY IN STUDY	50	50	50
NATURAL DEATH@	7	14	17
MORIBUND SACRIFICE	1	2	5
SCHEDULED SACRIFICE			
TERMINAL SACRIFICE	42	34	27
DOSING ACCIDENT			
ACCIDENTALLY KILLED, NDA			1
ACCIDENTALLY KILLED, NOS			
ANIMAL MISSING			
ANIMAL MISSEXED			
OTHER CASES			
@ INCLUDES AUTOLYZED ANIMALS			
<b>TUMOR SUMMARY</b>			
TOTAL ANIMALS WITH PRIMARY TUMORS**	29	31	27
TOTAL PRIMARY TUMORS	42	46	37
TOTAL ANIMALS WITH BENIGN TUMORS	20	21	17
TOTAL BENIGN TUMORS	23	24	21
TOTAL ANIMALS WITH MALIGNANT TUMORS	17	17	14
TOTAL MALIGNANT TUMORS	18	21	15
TOTAL ANIMALS WITH SECONDARY TUMORS##		2	
TOTAL SECONDARY TUMORS		2	
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT	1	1	1
TOTAL UNCERTAIN TUMORS	1	1	1
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PRIMARY OR METASTATIC			
TOTAL UNCERTAIN TUMORS			
** PRIMARY TUMORS: ALL TUMORS EXCEPT SECONDARY TUMORS			
## SECONDARY TUMORS: METASTATIC TUMORS OR TUMORS INVASIVE INTO AN ADJACENT ORGAN			

**TABLE B2. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
<b>INTEGUMENTARY SYSTEM</b>			
*SUBCUT TISSUE	(50) (50)	(50)	
FIBROMA			1 (2%)
<b>RESPIRATORY SYSTEM</b>			
*NASAL CAVITY	(50)	(50)	(50)
ADENOCARCINOMA, NOS			2 (4%)
OSTEOMA	1 (2%)		
#LUNG	(50)	(50)	(50)
ADENOCARCINOMA, NOS, METASTATIC		1 (2%)	
ALVEOLAR/BRONCHIOLAR ADENOMA	4 (8%)	7 (14%)	6 (12%)
ADENOSQUAMOUS CARCINOMA, METASTA			1 (2%)
<b>HEMATOPOIETIC SYSTEM</b>			
*MULTIPLE ORGANS	(50)	(50)	(50)
MALIGNANT LYMPHOMA, NOS	7 (14%)	3 (6%)	5 (10%)
MALIG.LYMPHOMA, UNDIFFER-TYPE			1 (2%)
MALIG.LYMPHOMA, HISTIOCYTIC TYPE	1 (2%)	3 (6%)	
MALIGNANT LYMPHOMA, MIXED TYPE	3 (6%)	4 (8%)	1 (2%)
#SPLEEN	(48)	(49)	(44)
ADENOCARCINOMA, NOS, METASTATIC		1 (2%)	
MALIGNANT LYMPHOMA, MIXED TYPE	1 (2%)		
<b>CIRCULATORY SYSTEM</b>			
*NASAL CAVITY	(50)	(50)	(50)
HEMANGIOMA			3 (6%)
HEMANGIOSARCOMA			2 (4%)
#HEART	(50)	(50)	(48)
ADENOCARCINOMA, NOS, METASTATIC		1 (2%)	
#LIVER	(50)	(50)	(49)
HEMANGIOSARCOMA		1 (2%)	
#URINARY BLADDER	(44)	(47)	(42)
HEMANGIOSARCOMA			1 (2%)
#UTERUS	(48)	(50)	(48)
HEMANGIOMA	1 (2%)		1 (2%)
<b>DIGESTIVE SYSTEM</b>			
*TOOTH	(50)	(50)	(50)
ODONTOMA	1 (2%)		
#LIVER	(50)	(50)	(49)
HEPATOCELLULAR ADENOMA	1 (2%)	3 (6%)	2 (4%)
HEPATOCELLULAR CARCINOMA	2 (4%)	4 (8%)	1 (2%)
<b>URINARY SYSTEM</b>			
#KIDNEY	(50)	(50)	(49)
ADENOCARCINOMA, NOS, METASTATIC		1 (2%)	
SARCOMA, NOS			1 (2%)
<b>ENDOCRINE SYSTEM</b>			
#PITUITARY	(46)	(48)	(38)
CARCINOMA,NOS	1 (2%)		
ADENOMA, NOS	8 (17%)	6 (13%)	1 (3%)
#ADRENAL	(48)	(48)	(48)
PHEOCHROMOCYTOMA	1 (2%)		
SARCOMA, NOS			1 (2%)
#THYROID	(45)	(50)	(43)
FOLLICULAR-CELL ADENOMA	1 (2%)	1 (2%)	

**TABLE B2. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>REPRODUCTIVE SYSTEM</b>			
*MAMMARY GLAND	(50)	(50)	(50)
ADENOCARCINOMA, NOS		3 (6%)	
ADENOSQUAMOUS CARCINOMA			3 (6%)
#UTERUS	(48)	(50)	(48)
ADENOCARCINOMA, NOS		1 (2%)	
LEIOMYOMA		1 (2%)	
LEIOMYOSARCOMA		1 (2%)	
ENDOMETRIAL STROMAL POLYP	2 (4%)	1 (2%)	
#UTERUS/ENDOMETRIUM	(48)	(50)	(48)
ADENOMA, NOS		1 (2%)	
#OVARY	(48)	(46)	(37)
ADENOMA, NOS	1 (2%)		
GRANULOSA-CELL TUMOR		1 (2%)	
TERATOMA, NOS	1 (2%)		
<b>NERVOUS SYSTEM</b>			
NONE			
<b>SPECIAL SENSE ORGANS</b>			
*HARDERIAN GLAND	(50)	(50)	(50)
ADENOMA, NOS		1 (2%)	
<b>MUSCULOSKELETAL SYSTEM</b>			
*SKULL	(50)	(50)	(50)
OSTEOSARCOMA		1 (2%)	
<b>BODY CAVITIES</b>			
NONE			
<b>ALL OTHER SYSTEMS</b>			
*MULTIPLE ORGANS	(50)	(50)	(50)
SARCOMA, NOS, METASTATIC			1 (2%)
OSTEOSARCOMA, METASTATIC		1 (2%)	
LEG			
OSTEOSARCOMA		1	

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
 \* NUMBER OF ANIMALS NECROPSIED

**TABLE B2. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>ANIMAL DISPOSITION SUMMARY</b>			
ANIMALS INITIALLY IN STUDY	50	50	50
NATURAL DEATH@	12	14	36
MORIBUND SACRIFICE	1	6	3
SCHEDULED SACRIFICE			
TERMINAL SACRIFICE	37	29	10
DOSING ACCIDENT			
ACCIDENTALLY KILLED, NDA			1
ACCIDENTALLY KILLED, NOS		1	
ANIMAL MISSING			
ANIMAL MISSEXED			
OTHER CASES			
@ INCLUDES AUTOLYZED ANIMALS			
<b>TUMOR SUMMARY</b>			
TOTAL ANIMALS WITH PRIMARY TUMORS**	28	35	23
TOTAL PRIMARY TUMORS	37	44	32
TOTAL ANIMALS WITH BENIGN TUMORS	16	18	12
TOTAL BENIGN TUMORS	20	21	14
TOTAL ANIMALS WITH MALIGNANT TUMORS	13	20	16
TOTAL MALIGNANT TUMORS	15	22	18
TOTAL ANIMALS WITH SECONDARY TUMORS##		3	2
TOTAL SECONDARY TUMORS		5	2
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT	2	1	
TOTAL UNCERTAIN TUMORS	2	1	
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PRIMARY OR METASTATIC			
TOTAL UNCERTAIN TUMORS			
** PRIMARY TUMORS: ALL TUMORS EXCEPT SECONDARY TUMORS			
## SECONDARY TUMORS: METASTATIC TUMORS OR TUMORS INVASIVE INTO AN ADJACENT ORGAN			

**TABLE B3. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE: CHAMBER CONTROL**

ANIMAL NUMBER	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	
WEEKS ON STUDY	1	6	11	16	21	26	31	36	41	46	51	56	61	66	71	76	81	86	91	96	101	106	111	116	121	126	
<b>RESPIRATORY SYSTEM</b>																											
LUNGS AND BRONCHI ALVEOLAR/BRONCHIOLAR ADENOMA ALVEOLAR/BRONCHIOLAR CARCINOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
TRACHEA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
<b>HEMATOPOIETIC SYSTEM</b>																											
BONE MARROW	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
SPLEEN	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
LYMPH NODES MALIGNANT LYMPHOMA, MIXED TYPE	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	
THYMUS	-	-	+	+	+	-	-	-	+	+	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
<b>CIRCULATORY SYSTEM</b>																											
HEART	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
<b>DIGESTIVE SYSTEM</b>																											
ORAL CAVITY ODONTOMA	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
SALIVARY GLAND	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
LIVER HEPATOCELLULAR ADENOMA HEPATOCELLULAR CARCINOMA HEMANGIOSARCOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
BILE DUCT	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
GALLBLADDER & COMMON BILE DUCT	N	N	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	N	
<b>PANCREAS</b>																											
ESOPHAGUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
STOMACH	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
SMALL INTESTINE	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
LARGE INTESTINE	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
<b>URINARY SYSTEM</b>																											
KIDNEY	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
URINARY BLADDER	+	-	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
<b>ENDOCRINE SYSTEM</b>																											
PITUITARY	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	
ADRENAL CORTICAL CARCINOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
THYROID	+	+	+	+	-	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
PARATHYROID	-	-	-	-	-	-	-	+	-	-	+	-	+	-	-	-	-	-	-	-	-	-	-	-	+		
<b>REPRODUCTIVE SYSTEM</b>																											
MAMMARY GLAND	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
TESTIS	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
PROSTATE	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
<b>NERVOUS SYSTEM</b>																											
BRAIN	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
<b>SPECIAL SENSE ORGANS</b>																											
LACRIMAL GLAND ADENOCARCINOMA, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
MARBERIAN GLAND PAPILLARY CYSTADENOMA, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	
<b>ALL OTHER SYSTEMS</b>																											
MULTIPLE ORGANS NOS MALIGNANT LYMPHOMA, NOS LEUKEMIA, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	

+: TISSUE EXAMINED MICROSCOPICALLY  
 -: REQUIRED TISSUE NOT EXAMINED MICROSCOPICALLY  
 X: TUMOR INCIDENCE  
 N: NECROPSY, NO AUTOLYSIS, NO MICROSCOPIC EXAMINATION  
 S: ANIMAL MIS-SEXED  
 I: NO TISSUE INFORMATION SUBMITTED  
 C: NECROPSY, NO HISTOLOGY DUE TO PROTOCOL  
 A: AUTOLYSIS  
 M: ANIMAL MISSING  
 B: NO NECROPSY PERFORMED







TABLE B3. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE MICE: LOW-DOSE (Continued)

ANIMAL NUMBER	WEEKS ON STUDY																				TOTAL TISSUES TUMORS	
	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24		
<b>INTEGUMENTARY SYSTEM</b>																						
SKIN ADHESAL ADENOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50	1
SUBCUTANEOUS TISSUE HEMANGIOSARCOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50	1
<b>RESPIRATORY SYSTEM</b>																						
LUNGS AND BRONCHI HEPATOCELLULAR CARCINOMA, METASTA ALVEOLAR/BRONCHIOLAR ADENOMA ALVEOLAR/BRONCHIOLAR CARCINOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50	2
	X	X		X	X		X	X		X				X					X		12	2
TRACHEA	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46	
<b>HEMATOPOIETIC SYSTEM</b>																						
BONE MARROW	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49	
SPLEEN HEMANGIOSARCOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50	1
LYMPH NODES	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48	
THYMUS	-	+	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	19	
<b>CIRCULATORY SYSTEM</b>																						
HEART HEMANGIOSARCOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50	1
<b>DIGESTIVE SYSTEM</b>																						
ORAL CAVITY ODONTOMA	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	50	1
SALIVARY GLAND	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50	
LIVER HEPATOCELLULAR ADENOMA HEPATOCELLULAR CARCINOMA HEMANGIOSARCOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50	6
				X	X					X			X	X	X						10	1
BILE DUCT	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50	
GALLBLADDER & COMMON BILE DUCT	N	+	N	+	+	+	+	+	+	+	+	+	+	+	+	N	+	+	N	+	50	
PANCREAS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49	
ESOPHAGUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49	
STOMACH	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48	
SMALL INTESTINE	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47	
LARGE INTESTINE	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46	
<b>URINARY SYSTEM</b>																						
KIDNEY	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50	
URINARY BLADDER	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46	
<b>ENDOCRINE SYSTEM</b>																						
PITUITARY	-	+	+	+	+	+	-	+	+	-	+	+	+	+	+	+	+	+	+	+	44	
ADRENAL CORTICAL ADENOMA	+	+	+	+	+	-	+	+	+	-	+	+	+	+	+	+	+	+	+	+	43	2
THYROID FOLLICULAR-CELL ADENOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48	1
PARATHYROID	-	-	+	+	+	+	+	-	+	+	+	-	+	-	+	+	+	-	+	+	30	
<b>REPRODUCTIVE SYSTEM</b>																						
MAMMARY GLAND	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	50	
TESTIS INTERSTITIAL-CELL TUMOR	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49	1
PROSTATE	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49	
<b>NERVOUS SYSTEM</b>																						
BRAIN	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50	
<b>SPECIAL SENSE ORGANS</b>																						
HARDERIAN GLAND ADENOMA, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	50	1
<b>ALL OTHER SYSTEMS</b>																						
MULTIPLE ORGANS NOS MALIGNANT LYMPHOMA, NOS MALIGNANT LYMPHOMA, MIXED TYPE	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	50	2
										X				X							1	1

\* ANIMALS NECROPSIED







TABLE B4. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE: CHAMBER CONTROL  
(Continued)

ANIMAL NUMBER																					TOTAL TISSUES TUMORS					
	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46		47	48	49	50	
WEEKS ON STUDY	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	50	
<b>RESPIRATORY SYSTEM</b>																										
LUNGS AND BRONCHI ALVEOLAR/BRONCHIOLAR ADENOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 4
TRACHEA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
NASAL CAVITY OSTEOOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
<b>HEMATOPOIETIC SYSTEM</b>																										
BONE MARROW	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	57
SPLEEN MALIGNANT LYMPHOMA, MIXED TYPE	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48 1
LYMPH NODES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	56
THYMUS	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	34
<b>CIRCULATORY SYSTEM</b>																										
HEART	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
<b>DIGESTIVE SYSTEM</b>																										
ORAL CAVITY ODONTOMA	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	50 1
SALIVARY GLAND	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	59
LIVER HEPATOCELLULAR ADENOMA HEPATOCELLULAR CARCINOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1 2
BILE DUCT	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
GALLBLADDER & COMMON BILE DUCT	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 N
PANCREAS	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	58
ESOPHAGUS	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	59
STOMACH	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	59
SMALL INTESTINE	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	57
LARGE INTESTINE	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
<b>URINARY SYSTEM</b>																										
KIDNEY	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
URINARY BLADDER	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	44
<b>ENDOCRINE SYSTEM</b>																										
PITUITARY CARCINOMA, NOS ADENOMA, NOS	+	+	-	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46 1 8
ADRENAL PHEOCHROMOCYTOMA	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48 1
THYROID FOLLICULAR-CELL ADENOMA	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	45 1
PARATHYROID	-	-	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20	
<b>REPRODUCTIVE SYSTEM</b>																										
MAMMARY GLAND	+	N	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 N
UTERUS ENDOMETRIAL STROMAL POLYP HEMANGIOMA	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48 2 1
OVARY ADENOMA, NOS TERATOMA, NOS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48 1 1
<b>NERVOUS SYSTEM</b>																										
BRAIN	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
<b>ALL OTHER SYSTEMS</b>																										
MULTIPLE ORGANS NOS MALIGNANT LYMPHOMA, NOS MALIG. LYMPHOMA, HISTIOCYTIC TYPE MALIGNANT LYMPHOMA, MIXED TYPE	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	50 7 1 3

\* ANIMALS NECROPSIED





TABLE B4. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE: LOW-DOSE (Continued)

ANIMAL NUMBER	5208	5209	5210	5211	5212	5213	5214	5215	5216	5217	5218	5219	5220	5221	5222	5223	5224	5225	5226	5227	5228	5229	5230	TOTAL TISSUES TUMORS
WEEKS ON STUDY	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	
<b>RESPIRATORY SYSTEM</b>																								
LUNGS AND BRONCHI ADENOCARCINOMA, NOS, METASTATIC ALVEOLAR/BRONCHIOLAR ADENOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 7
TRACHEA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
<b>HEMATOPOIETIC SYSTEM</b>																								
BONE MARROW	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
SPLEEN ADENOCARCINOMA, NOS, METASTATIC	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
LYMPH NODES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
THYMUS	-	-	+	-	+	+	+	+	+	-	-	+	-	-	+	-	-	+	-	-	+	-	+	22
<b>CIRCULATORY SYSTEM</b>																								
HEART ADENOCARCINOMA, NOS, METASTATIC	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
<b>DIGESTIVE SYSTEM</b>																								
SALIVARY GLAND	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
LIVER HEPATOCELLULAR ADENOMA HEPATOCELLULAR CARCINOMA HEMANGIOSARCOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 3 4 1
BILE DUCT	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
GALLBLADDER & COMMON BILE DUCT	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
PANCREAS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
ESOPHAGUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
STOMACH	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
SMALL INTESTINE	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
LARGE INTESTINE	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
<b>URINARY SYSTEM</b>																								
KIDNEY ADENOCARCINOMA, NOS, METASTATIC	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
URINARY BLADDER	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
<b>ENDOCRINE SYSTEM</b>																								
PITUITARY ADENOMA, NOS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48 6
ADRENAL	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
THYROID FOLLICULAR-CELL ADENOMA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1
PARATHYROID	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25
<b>REPRODUCTIVE SYSTEM</b>																								
MAMMARY GLAND ADENOCARCINOMA, NOS	+	N	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1 3
UTERUS ADENOMA, NOS ADENOCARCINOMA, NOS LEIOMYOMA LEIOMYOSARCOMA ENDOMETRIAL STROMAL POLYP	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50 1 1 1 1
OVARY GRANULOSA-CELL TUMOR	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	46 1
<b>NERVOUS SYSTEM</b>																								
BRAIN	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
<b>SPECIAL SENSE ORGANS</b>																								
HARDERIAN GLAND ADENOMA, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	50 1
<b>MUSCULOSKELETAL SYSTEM</b>																								
BONE OSTEOSARCOMA	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	50 1
<b>ALL OTHER SYSTEMS</b>																								
MULTIPLE ORGANS NOS OSTEOSARCOMA, METASTATIC MALIGNANT LYMPHOMA, NOS MALIGNANT LYMPHOMA, HISTIOCYTIC TYPE MALIGNANT LYMPHOMA, MIXED TYPE	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	50 1 3 4
LEG NOS OSTEOSARCOMA	X																							1

\* ANIMALS NECROPSIED







## **APPENDIX C**

# **SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN RATS IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE**

**TABLE C1. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
<b>INTEGUMENTARY SYSTEM</b>			
*SKIN	(50)	(50)	(50)
EPIDERMAL INCLUSION CYST			2 (4%)
INFLAMMATION, CHRONIC FOCAL	1 (2%)		
INFLAMMATION, PYOGRANULOMATOUS		1 (2%)	
ACANTHOSIS	1 (2%)		
*SUBCUT TISSUE	(50)	(50)	(50)
EPIDERMAL INCLUSION CYST	1 (2%)		
INFLAMMATION, CHRONIC FOCAL	1 (2%)	1 (2%)	
GRANULOMA, FOREIGN BODY			1 (2%)
NECROSIS, FAT		1 (2%)	
<b>RESPIRATORY SYSTEM</b>			
*NASAL CAVITY	(50)	(50)	(50)
FOREIGN BODY, NOS	1 (2%)	4 (8%)	3 (6%)
CONGESTION, NOS		1 (2%)	1 (2%)
CONGESTION, ACUTE			1 (2%)
HEMORRHAGE	1 (2%)		
INFLAMMATION, SUPPURATIVE	7 (14%)	19 (38%)	33 (66%)
INFLAMMATION, ACUTE			1 (2%)
INFLAMMATION, ACUTE FOCAL			1 (2%)
INFLAMMATION, ACUTE SUPPURATIVE	1 (2%)		
DEGENERATION, NOS		3 (6%)	
HYPERPLASIA, EPITHELIAL		1 (2%)	9 (18%)
HYPERPLASIA, FOCAL			2 (4%)
HYPERKERATOSIS			1 (2%)
METAPLASIA, SQUAMOUS	1 (2%)	3 (6%)	21 (42%)
*LARYNX	(50)	(50)	(50)
FOREIGN BODY, NOS	1 (2%)		
VEGETABLE FOREIGN BODY	1 (2%)		
ULCER, NOS			1 (2%)
INFLAMMATION, SUPPURATIVE	2 (4%)	8 (16%)	7 (14%)
INFLAMMATION, NECROTIZING			1 (2%)
INFLAMMATION, CHRONIC		1 (2%)	
INFLAMMATION, CHRONIC FOCAL	1 (2%)		2 (4%)
HYPERPLASIA, EPITHELIAL		1 (2%)	2 (4%)
HYPERPLASIA, FOCAL		1 (2%)	
*SUBMUCOSA OF LARYNX	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE		1 (2%)	2 (4%)
#TRACHEA	(49)	(46)	(49)
INFLAMMATION, SUPPURATIVE		1 (2%)	
INFLAMMATION, ACUTE/CHRONIC		1 (2%)	
INFLAMMATION, CHRONIC FOCAL		1 (2%)	
HYPERPLASIA, EPITHELIAL			2 (4%)
#TRACHEAL SUBMUCOSA	(49)	(46)	(49)
INFLAMMATION, SUPPURATIVE		3 (7%)	1 (2%)
#LUNG/BRONCHUS	(50)	(47)	(49)
BRONCHIECTASIS			1 (2%)
#LUNG/BRONCHIOLE	(50)	(47)	(49)
INFLAMMATION, SUPPURATIVE		1 (2%)	
HYPERPLASIA, EPITHELIAL			2 (4%)

TABLE C1. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
#LUNG	(50)	(47)	(49)
FOREIGN BODY, NOS	1 (2%)		
CONGESTION, NOS	5 (10%)	3 (6%)	3 (6%)
HEMORRHAGE	1 (2%)	4 (9%)	6 (12%)
INFLAMMATION, INTERSTITIAL	1 (2%)	2 (4%)	1 (2%)
INFLAMMATION, SUPPURATIVE	1 (2%)	5 (11%)	4 (8%)
INFLAMMATION, ACUTE SUPPURATIVE			1 (2%)
INFLAMMATION, CHRONIC FOCAL	6 (12%)	3 (6%)	7 (14%)
GRANULOMA, NOS	1 (2%)		
FIBROSIS, FOCAL	1 (2%)		2 (4%)
FIBROSIS, MULTIFOCAL			1 (2%)
NECROSIS, FOCAL	1 (2%)		1 (2%)
CALCIFICATION, FOCAL			4 (8%)
ALVEOLAR MACROPHAGES	4 (8%)	3 (6%)	4 (8%)
HYPERPLASIA, ALVEOLAR EPITHELIUM	7 (14%)	4 (9%)	10 (20%)
#LUNG/ALVEOLI	(50)	(47)	(49)
HEMORRHAGE	1 (2%)		
INFLAMMATION, CHRONIC FOCAL			1 (2%)
FIBROSIS, FOCAL	2 (4%)	1 (2%)	2 (4%)
FIBROSIS, MULTIFOCAL	1 (2%)		5 (10%)
HISTIOCYTOSIS	1 (2%)	1 (2%)	
<b>HEMATOPOIETIC SYSTEM</b>			
#BONE MARROW	(49)	(49)	(48)
FIBROSIS			1 (2%)
HYPOPLASIA, NOS	2 (4%)		
ATROPHY, NOS	1 (2%)		2 (4%)
HYPERPLASIA, NOS	2 (4%)		
#SPLEEN	(50)	(47)	(48)
HEMORRHAGE	3 (6%)		
FIBROSIS	1 (2%)	1 (2%)	
FIBROSIS, FOCAL	3 (6%)	7 (15%)	4 (8%)
FIBROSIS, MULTIFOCAL			1 (2%)
FIBROSIS, DIFFUSE			2 (4%)
NECROSIS, NOS			1 (2%)
NECROSIS, FOCAL	1 (2%)	3 (6%)	2 (4%)
INFARCT, NOS			1 (2%)
PIGMENTATION, NOS	1 (2%)	1 (2%)	1 (2%)
HEMOSIDEROSIS		1 (2%)	
HYPERPLASIA, LYMPHOID	2 (4%)	1 (2%)	3 (6%)
HEMATOPOIESIS	1 (2%)		
#SPLENIC FOLLICLES	(50)	(47)	(48)
NECROSIS, NOS	1 (2%)		
#LYMPH NODE	(44)	(49)	(46)
INFLAMMATION, ACUTE/CHRONIC	2 (5%)	4 (8%)	1 (2%)
PLASMOCYTOSIS		1 (2%)	
#MANDIBULAR L. NODE	(44)	(49)	(46)
FIBROSIS			1 (2%)
#BRONCHIAL LYMPH NODE	(44)	(49)	(46)
HEMORRHAGE	2 (5%)		2 (4%)
INFLAMMATION, ACUTE			2 (4%)
ANGIECTASIS			7 (15%)
#AXILLARY LYMPH NODE	(44)	(49)	(46)
HEMORRHAGE		1 (2%)	
#LIVER	(50)	(50)	(49)
HEMATOPOIESIS			1 (2%)
#THYMUS	(31)	(26)	(37)
ATROPHY, NOS	1 (3%)	2 (8%)	1 (3%)

**TABLE C1. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>CIRCULATORY SYSTEM</b>			
#BRAIN/MENINGES	(47)	(50)	(49)
THROMBOSIS, NOS	1 (2%)		
*NASAL CAVITY	(50)	(50)	(50)
THROMBOSIS, NOS	1 (2%)		
#LUNG	(50)	(47)	(49)
THROMBOSIS, NOS	1 (2%)		
#HEART	(50)	(50)	(49)
THROMBOSIS, NOS	1 (2%)		
INFLAMMATION, CHRONIC	1 (2%)		
INFLAMMATION, CHRONIC FOCAL FIBROSIS	1 (2%)	2 (4%) 1 (2%)	1 (2%)
FIBROSIS, MULTIFOCAL	1 (2%)		
HEMOSIDEROSIS	1 (2%)		
METAPLASIA, CARTILAGINOUS	1 (2%)		
#HEART/ATRIUM	(50)	(50)	(49)
THROMBOSIS, NOS		3 (6%)	
#HEART/VENTRICLE	(50)	(50)	(49)
DILATATION, NOS			1 (2%)
#MYOCARDIUM	(50)	(50)	(49)
INFLAMMATION, INTERSTITIAL	1 (2%)		
INFLAMMATION, CHRONIC	1 (2%)		1 (2%)
INFLAMMATION, CHRONIC FOCAL FIBROSIS	3 (6%)		2 (4%)
FIBROSIS	11 (22%)	19 (38%)	13 (27%)
FIBROSIS, FOCAL	6 (12%)	1 (2%)	
FIBROSIS, MULTIFOCAL	4 (8%)	1 (2%)	
FIBROSIS, DIFFUSE	1 (2%)		
DEGENERATION, NOS	1 (2%)		
NECROSIS, FOCAL	1 (2%)		
#ENDOCARDIUM	(50)	(50)	(49)
HYPERPLASIA, FOCAL			1 (2%)
#CARDIAC VALVE	(50)	(50)	(49)
THROMBOSIS, NOS	1 (2%)		
METAPLASIA, CARTILAGINOUS	3 (6%)	4 (8%)	7 (14%)
#AORTIC VALVE	(50)	(50)	(49)
METAPLASIA, CARTILAGINOUS	2 (4%)		
*AORTA	(50)	(50)	(50)
CALCIFICATION, FOCAL		1 (2%)	
*CORONARY ARTERY	(50)	(50)	(50)
METAPLASIA, CARTILAGINOUS			1 (2%)
*PULMONARY ARTERY	(50)	(50)	(50)
THROMBOSIS, NOS			1 (2%)
CALCIFICATION, NOS		2 (4%)	4 (8%)
CALCIFICATION, FOCAL	7 (14%)	7 (14%)	8 (16%)
*ARTERY OF HEAD NECK	(50)	(50)	(50)
THROMBOSIS, NOS			1 (2%)
*PANCREATIC ARTERY	(50)	(50)	(50)
CALCIFICATION, NOS			1 (2%)
#PANCREAS	(47)	(49)	(47)
PERIARTERITIS	1 (2%)		
#COLON	(48)	(48)	(48)
PERIARTERITIS			1 (2%)
#TESTIS	(49)	(50)	(50)
PERIARTERITIS			1 (2%)
<b>DIGESTIVE SYSTEM</b>			
#SALIVARY GLAND	(46)	(49)	(47)
METAMORPHOSIS FATTY		1 (2%)	
ATROPHY, FOCAL		1 (2%)	
#LIVER	(50)	(50)	(49)
CONGESTION, NOS	1 (2%)		
INFLAMMATION, FOCAL			1 (2%)
INFLAMMATION, SUPPURATIVE	2 (4%)		



TABLE C1. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
DIGESTIVE SYSTEM (Continued)			
#LIVER (Continued)	(50)	(50)	(50)
INFLAMMATION, ACUTE/CHRONIC	1 (2%)		
INFLAMMATION, CHRONIC FOCAL	2 (4%)		
FIBROSIS	1 (2%)		
DEGENERATION, NOS	1 (2%)	1 (2%)	
DEGENERATION, LIPOID	2 (4%)	1 (2%)	
NECROSIS, FOCAL	5 (10%)	3 (6%)	6 (12%)
NECROSIS, CENTRAL	2 (4%)	3 (6%)	
PIGMENTATION, NOS		1 (2%)	
CYTOPLASMIC VACUOLIZATION	8 (16%)	7 (14%)	5 (10%)
BASOPHILIC CYTO CHANGE		9 (18%)	2 (4%)
EOSINOPHILIC CYTO CHANGE		2 (4%)	5 (10%)
CLEAR-CELL CHANGE		1 (2%)	
HEPATOCTOME GALY	4 (8%)	1 (2%)	3 (6%)
HYPERPLASIA, NODULAR	1 (2%)		
ANGIECTASIS	1 (2%)		1 (2%)
#PORTAL TRACT	(50)	(50)	(49)
FIBROSIS	5 (10%)	19 (38%)	9 (18%)
FIBROSIS, FOCAL			4 (8%)
FIBROSIS, MULTIFOCAL	2 (4%)		1 (2%)
#LIVER/CENTRIOBULAR	(50)	(50)	(49)
DEGENERATION, NOS	2 (4%)	1 (2%)	1 (2%)
#LIVER/HEPATOCTES	(50)	(50)	(49)
CYTOPLASMIC VACUOLIZATION	1 (2%)	2 (4%)	
BASOPHILIC CYTO CHANGE	3 (6%)		1 (2%)
EOSINOPHILIC CYTO CHANGE		1 (2%)	4 (8%)
CLEAR-CELL CHANGE	1 (2%)		
HYPERPLASIA, NODULAR			1 (2%)
#BILE DUCT	(50)	(50)	(49)
INFLAMMATION, MULTIFOCAL	1 (2%)		
INFLAMMATION, CHRONIC FOCAL	1 (2%)		
HYPERPLASIA, NOS	30 (60%)	46 (92%)	41 (84%)
HYPERPLASIA, FOCAL	6 (12%)	1 (2%)	1 (2%)
HYPERPLASIA, DIFFUSE	2 (4%)		
#PANCREAS	(47)	(49)	(47)
HEMORRHAGE	1 (2%)		
INFLAMMATION, FOCAL GRANULOMATOUS			1 (2%)
GRANULOMA, FOREIGN BODY			1 (2%)
FIBROSIS			1 (2%)
FIBROSIS, FOCAL	4 (9%)		2 (4%)
FIBROSIS, MULTIFOCAL	1 (2%)		1 (2%)
FIBROSIS, DIFFUSE	3 (6%)		2 (4%)
NECROSIS, NOS	1 (2%)		
ATROPHY, NOS	3 (6%)		
ATROPHY, FOCAL	7 (15%)	1 (2%)	
#PANCREATIC ACINUS	(47)	(49)	(47)
ATROPHY, NOS	1 (2%)	11 (22%)	12 (26%)
ATROPHY, FOCAL		1 (2%)	5 (11%)
#STOMACH	(49)	(49)	(50)
ULCER, NOS	1 (2%)	1 (2%)	
INFLAMMATION, FOCAL		2 (4%)	
INFLAMMATION, SUPPURATIVE	1 (2%)		
ULCER, ACUTE	1 (2%)		
INFLAMMATION, ACUTE NECROTIZING			1 (2%)
NECROSIS, NOS	1 (2%)		
NECROSIS, FOCAL			2 (4%)
HYPERPLASIA, EPITHELIAL			1 (2%)
ACANTHOSIS		1 (2%)	2 (4%)
#GASTRIC MUCOSA	(49)	(49)	(50)
ULCER, NOS		2 (4%)	
HYPERKERATOSIS		1 (2%)	
ACANTHOSIS		1 (2%)	

**TABLE C1. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>DIGESTIVE SYSTEM (Continued)</b>			
#GASTRIC SUBMUCOSA	(49)	(49)	(50)
HEMORRHAGE	1 (2%)		
#COLON	(48)	(48)	(48)
PARASITISM	4 (8%)	3 (6%)	3 (6%)
#CECUM	(48)	(48)	(48)
NECROSIS, FOCAL	1 (2%)		
INFARCT, FOCAL	1 (2%)		
<b>URINARY SYSTEM</b>			
#KIDNEY	(50)	(50)	(50)
PYELONEPHRITIS, ACUTE	2 (4%)		
INFLAMMATION, CHRONIC FOCAL	1 (2%)		
FIBROSIS, FOCAL			1 (2%)
NEPHROPATHY	45 (90%)	48 (96%)	48 (96%)
NEPHROSIS, NOS	1 (2%)	1 (2%)	
PIGMENTATION, NOS	1 (2%)		
#KIDNEY/CORTEX	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE		1 (2%)	1 (2%)
FIBROSIS, DIFFUSE	1 (2%)		
NECROSIS, DIFFUSE			2 (4%)
METAMORPHOSIS FATTY		1 (2%)	
#KIDNEY/MEDULLA	(50)	(50)	(50)
METAMORPHOSIS FATTY		1 (2%)	
<b>URINARY SYSTEM (Continued)</b>			
#KIDNEY/TUBULE	(50)	(50)	(50)
DILATATION, NOS	1 (2%)		
DEGENERATION, NOS	1 (2%)		2 (4%)
NECROSIS, NOS	1 (2%)		
NECROSIS, DIFFUSE		1 (2%)	
PIGMENTATION, NOS	6 (12%)	2 (4%)	2 (4%)
REGENERATION, NOS	3 (6%)		
#KIDNEY/PELVIS	(50)	(50)	(50)
DILATATION, NOS			1 (2%)
CALCIFICATION, FOCAL			1 (2%)
HYPERPLASIA, EPITHELIAL			2 (4%)
HYPERPLASIA, FOCAL			1 (2%)
#URINARY BLADDER	(48)	(48)	(45)
CALCULUS, UNKN GROSS OR MICRO	1 (2%)		
INFLAMMATION, SUPPURATIVE	1 (2%)		
HYPERPLASIA, EPITHELIAL	3 (6%)	3 (6%)	
<b>ENDOCRINE SYSTEM</b>			
#PITUITARY	(47)	(47)	(48)
CYST, NOS	6 (13%)	2 (4%)	3 (6%)
CALCIFICATION, FOCAL			1 (2%)
HYPERPLASIA, NOS	2 (4%)	3 (6%)	1 (2%)
HYPERPLASIA, FOCAL		1 (2%)	
ANGIECTASIS			1 (2%)
#ANTERIOR PITUITARY	(47)	(47)	(48)
HYPERPLASIA, NOS			2 (4%)
#ADRENAL	(48)	(49)	(49)
DEGENERATION, LIPOID	3 (6%)		
NECROSIS, FOCAL	1 (2%)		
#ADRENAL CORTEX	(48)	(49)	(49)
DEGENERATION, LIPOID		3 (6%)	
NECROSIS, FOCAL		1 (2%)	
CYTOPLASMIC VACUOLIZATION	3 (6%)	5 (10%)	7 (14%)
CYTOMEGALY	2 (4%)	6 (12%)	6 (12%)
HYPERPLASIA, FOCAL	2 (4%)		2 (4%)
ANGIECTASIS			1 (2%)

TABLE C1. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>ENDOCRINE SYSTEM (Continued)</b>			
#ADRENAL MEDULLA	(48)	(49)	(49)
HYPERPLASIA, FOCAL	2 (4%)	2 (4%)	10 (20%)
ANGIECTASIS			1 (2%)
#THYROID	(44)	(41)	(49)
THYROGLOSSAL DUCT CYST	1 (2%)		
CYSTIC FOLLICLES			1 (2%)
HYPERPLASIA, C-CELL	8 (18%)	5 (12%)	4 (8%)
HYPERPLASIA, FOLLICULAR-CELL		1 (2%)	3 (6%)
#PARATHYROID	(26)	(28)	(31)
CYTOMEGALY			1 (3%)
HYPERPLASIA, NOS			1 (3%)
#PANCREATIC ISLETS	(47)	(49)	(47)
HYPERPLASIA, FOCAL		1 (2%)	2 (4%)
<b>REPRODUCTIVE SYSTEM</b>			
*MAMMARY GLAND	(50)	(50)	(50)
GALACTOCELE			1 (2%)
HYPERPLASIA, NOS		1 (2%)	1 (2%)
HYPERPLASIA, FOCAL	1 (2%)		
HYPERPLASIA, CYSTIC			1 (2%)
*PREPUTIAL GLAND	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE	1 (2%)		
ABSCCESS, NOS			1 (2%)
INFLAMMATION, CHRONIC SUPPURATIVE			1 (2%)
HYPERKERATOSIS		1 (2%)	
METAPLASIA, SQUAMOUS			1 (2%)
#PROSTATE	(38)	(39)	(28)
INFLAMMATION, SUPPURATIVE	7 (18%)	5 (13%)	1 (4%)
INFLAMMATION, CHRONIC			1 (4%)
INFLAMMATION, CHRONIC FOCAL		1 (3%)	
INFLAMMATION, CHRONIC SUPPURATIVE	2 (5%)		
CALCIFICATION, FOCAL		1 (3%)	
HYPERPLASIA, NOS	2 (5%)		
HYPERPLASIA, EPITHELIAL		1 (3%)	1 (4%)
*SEMINAL VESICLE	(50)	(50)	(50)
CYST, NOS			1 (2%)
INFLAMMATION, SUPPURATIVE	12 (24%)	13 (26%)	16 (32%)
INFLAMMATION, ACUTE SUPPURATIVE	1 (2%)	1 (2%)	
INFLAMMATION, CHRONIC	1 (2%)		1 (2%)
INFLAMMATION, CHRONIC SUPPURATIVE	3 (6%)		
CALCIFICATION, FOCAL	1 (2%)		
HYPERPLASIA, EPITHELIAL	1 (2%)		1 (2%)
HYPERPLASIA, FOCAL			1 (2%)
#TESTIS	(49)	(50)	(50)
HEMORRHAGE		1 (2%)	
NECROSIS, FOCAL		1 (2%)	
CALCIFICATION, NOS		9 (18%)	4 (8%)
CALCIFICATION, FOCAL	10 (20%)	11 (22%)	15 (30%)
ATROPHY, NOS	18 (37%)	40 (80%)	23 (46%)
ATROPHY, FOCAL			1 (2%)
HYPERPLASIA, INTERSTITIAL CELL	8 (16%)	1 (2%)	3 (6%)
*VAS DEFERENS	(50)	(50)	(50)
HEMORRHAGE	1 (2%)		
NECROSIS, FAT	1 (2%)		
*SCROTUM	(50)	(50)	(50)
NECROSIS, FAT			1 (2%)
<b>NERVOUS SYSTEM</b>			
#CEREBRUM	(47)	(50)	(49)
HEMORRHAGE	1 (2%)		

TABLE C1. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>NERVOUS SYSTEM (Continued)</b>			
#BRAIN	(47)	(50)	(49)
HEMORRHAGE	2 (4%)	3 (6%)	4 (8%)
GLIOSIS	1 (2%)		1 (2%)
NECROSIS, FOCAL	1 (2%)		2 (4%)
PIGMENTATION, NOS	1 (2%)		
CYTOPLASMIC VACUOLIZATION			1 (2%)
#CEREBRAL WHITE MATTE	(47)	(50)	(49)
CYTOPLASMIC VACUOLIZATION	2 (4%)	4 (8%)	4 (8%)
#CEREBELLUM	(47)	(50)	(49)
HEMORRHAGE	1 (2%)		
#CEREBELLAR WHITE MAT	(47)	(50)	(49)
CYTOPLASMIC VACUOLIZATION			1 (2%)
*OLFACTORY SENSORY EP	(50)	(50)	(50)
DEGENERATION, NOS		1 (2%)	3 (6%)
<b>SPECIAL SENSE ORGANS</b>			
*EYE/CRYSTALLINE LENS	(50)	(50)	(50)
CALCIFICATION, FOCAL		1 (2%)	
*NASOLACRIMAL DUCT	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE	4 (8%)	3 (6%)	
METAPLASIA, SQUAMOUS	4 (8%)	8 (16%)	9 (18%)
*EAR CANAL	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE	2 (4%)		1 (2%)
<b>MUSCULOSKELETAL SYSTEM</b>			
*STERNUM	(50)	(50)	(50)
HYPERPLASIA, NOS			1 (2%)
*SKELETAL MUSCLE	(50)	(50)	(50)
DEGENERATION, NOS		1 (2%)	
*MUSCLE OF HEAD	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE	1 (2%)		
<b>BODY CAVITIES</b>			
*MEDIASTINUM	(50)	(50)	(50)
HEMORRHAGE			1 (2%)
INFLAMMATION, NECROTIZING		1 (2%)	
*PERITONEUM	(50)	(50)	(50)
NECROSIS, FAT		3 (6%)	
*PERITONEAL CAVITY	(50)	(50)	(50)
HEMORRHAGE	1 (2%)		
NECROSIS, FAT	1 (2%)	1 (2%)	
*PLEURA	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE	1 (2%)		
FIBROSIS, FOCAL	1 (2%)		1 (2%)
*SUBPLEURAL TISSUE	(50)	(50)	(50)
INFLAMMATION, FOCAL	1 (2%)		
INFLAMMATION, CHRONIC FOCAL		1 (2%)	1 (2%)
FIBROSIS			1 (2%)
FIBROSIS, FOCAL	2 (4%)		3 (6%)

**TABLE C1. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	<b>CONTROL (CHAMBER)</b>	<b>LOW DOSE</b>	<b>HIGH DOSE</b>
<b>ALL OTHER SYSTEMS</b>			
*MULTIPLE ORGANS	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE	1 (2%)	2 (4%)	4 (8%)
FIBROSIS			1 (2%)
CALCIFICATION, FOCAL			1 (2%)
LEG			
CONGENITAL MALFORMATION, NOS			1
<b>SPECIAL MORPHOLOGY SUMMARY</b>			
NONE			
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			

**TABLE C2. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
<b>INTEGUMENTARY SYSTEM</b>			
*SKIN	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE			1 (2%)
HYPERKERATOSIS			1 (2%)
ACANTHOSIS	1 (2%)	3 (6%)	1 (2%)
<b>RESPIRATORY SYSTEM</b>			
*NASAL CAVITY	(50)	(50)	(50)
FOREIGN BODY, NOS	1 (2%)	1 (2%)	7 (14%)
HEMORRHAGE		1 (2%)	
INFLAMMATION, SUPPURATIVE	3 (6%)	5 (10%)	20 (40%)
INFLAMMATION, CHRONIC FOCAL			1 (2%)
DEGENERATION, NOS			1 (2%)
HYPERPLASIA, EPITHELIAL	1 (2%)		4 (8%)
HYPERPLASIA, FOCAL			1 (2%)
ACANTHOSIS			1 (2%)
METAPLASIA, SQUAMOUS	1 (2%)	2 (4%)	11 (22%)
*MAXILLARY SINUS	(50)	(50)	(50)
ATROPHY, FOCAL			1 (2%)
*LARYNX	(50)	(50)	(50)
FOREIGN BODY, NOS			2 (4%)
INFLAMMATION, SUPPURATIVE	8 (16%)	9 (18%)	12 (24%)
INFLAMMATION, ACUTE/CHRONIC	1 (2%)		
INFLAMMATION, CHRONIC FOCAL			2 (4%)
HYPERPLASIA, EPITHELIAL	4 (8%)	2 (4%)	
HYPERPLASIA, FOCAL			1 (2%)
ACANTHOSIS	1 (2%)	1 (2%)	5 (10%)
METAPLASIA, SQUAMOUS		2 (4%)	
*SUBMUCOSA OF LARYNX	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE	1 (2%)		1 (2%)
#TRACHEA	(50)	(48)	(44)
INFLAMMATION, SUPPURATIVE		3 (6%)	2 (5%)
INFLAMMATION, ACUTE/CHRONIC	1 (2%)	1 (2%)	
HYPERPLASIA, EPITHELIAL			1 (2%)
METAPLASIA, SQUAMOUS			1 (2%)
#TRACHEAL SUBMUCOSA	(50)	(48)	(44)
INFLAMMATION, SUPPURATIVE	1 (2%)		
#LUNG/BRONCHUS	(48)	(48)	(50)
INFLAMMATION, SUPPURATIVE	1 (2%)		
#LUNG/BRONCHIOLE	(48)	(48)	(50)
INFLAMMATION, SUPPURATIVE		1 (2%)	
HYPERPLASIA, EPITHELIAL			1 (2%)
HYPERPLASIA, FOCAL		1 (2%)	
#LUNG (Continued)	(48)	(48)	(50)
FOREIGN BODY, NOS		1 (2%)	
CONGESTION, NOS		2 (4%)	2 (4%)
HEMORRHAGE	8 (17%)	12 (25%)	7 (14%)
BRONCHOPNEUMONIA, FOCAL	1 (2%)		
PNEUMONIA, ASPIRATION	1 (2%)		
INFLAMMATION, SUPPURATIVE	4 (8%)	1 (2%)	1 (2%)
PNEUMONIA INTERSTITIAL CHRONIC	1 (2%)		
INFLAMMATION, CHRONIC FOCAL	2 (4%)	5 (10%)	2 (4%)
INFLAMMATION, FOCAL GRANULOMATOUS		1 (2%)	1 (2%)
CRANIOUROMA, FOREIGN BODY			6 (12%)
FIBROSIS, DIFFUSE	1 (2%)		
CALCIFICATION, FOCAL	1 (2%)		

**TABLE C2. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>RESPIRATORY SYSTEM (Continued)</b>			
#LUNG (Continued)	(48)	(48)	(50)
FOREIGN MATERIAL, NOS	1 (2%)		
PIGMENTATION, NOS	1 (2%)	1 (2%)	
CYTOPLASMIC VACUOLIZATION	1 (2%)		
BASOPHILIC CYTO CHANGE			1 (2%)
ALVEOLAR MACROPHAGES	5 (10%)	16 (33%)	10 (20%)
HYPERPLASIA, ALVEOLAR EPITHELIUM	4 (8%)	5 (10%)	6 (12%)
METAPLASIA, SQUAMOUS			1 (2%)
HISTIOCYTOSIS			1 (2%)
#LUNG/ALVEOLI	(48)	(48)	(50)
FIBROSIS			1 (2%)
FIBROSIS, FOCAL	3 (6%)	2 (4%)	3 (6%)
FIBROSIS, MULTIFOCAL	1 (2%)	1 (2%)	2 (4%)
<b>HEMATOPOIETIC SYSTEM</b>			
#BONE MARROW	(49) (48)	(48)	
HYPOPLASIA, NOS	1 (2%)		1 (2%)
ATROPHY, NOS	1 (2%)	1 (2%)	
HYPERPLASIA, NOS	1 (2%)	1 (2%)	
#SPLEEN	(49) (49)	(47)	
FIBROSIS		2 (4%)	3 (6%)
FIBROSIS, FOCAL		6 (12%)	3 (6%)
NECROSIS, FOCAL		1 (2%)	
CALCIFICATION, FOCAL			1 (2%)
PIGMENTATION, NOS	3 (6%)	3 (6%)	1 (2%)
HEMOSIDEROSIS		1 (2%)	
ATROPHY, NOS			1 (2%)
HYPERPLASIA, LYMPHOID	6 (12%)		5 (11%)
HEMATOPOIESIS	1 (2%)		
#SPLENIC CAPSULE	(49) (49)	(47)	
FIBROSIS, FOCAL		1 (2%)	
#LYMPH NODE	(46) (46)	(47)	
CONGESTION, NOS	1 (2%)		
INFLAMMATION, ACUTE/CHRONIC	2 (4%)	1 (2%)	1 (2%)
INFLAMMATION, CHRONIC	1 (2%)		
PLASMACYTOSIS	1 (2%)		
#MANDIBULAR L. NODE	(46) (46)	(47)	
HEMORRHAGE	1 (2%)		
INFLAMMATION, SUPPURATIVE		1 (2%)	
HYPERPLASIA, LYMPHOID	1 (2%)	1 (2%)	1 (2%)
#BRONCHIAL LYMPH NODE	(46) (46)	(47)	
HEMORRHAGE	1 (2%)	1 (2%)	
#LIVER	(50) (49)	(49)	
HYPERPLASIA, RETICULUM CELL		1 (2%)	
HEMATOPOIESIS	1 (2%)		
#ADRENAL	(48) (49)	(48)	
HEMATOPOIESIS	1 (2%)		
#THYMUS	(24) (26)	(29)	
ATROPHY, NOS	3 (13%)		1 (3%)
<b>CIRCULATORY SYSTEM</b>			
*MULTIPLE ORGANS	(50) (50)	(50)	
PERIVASCULITIS	1 (2%)		
*NASAL CAVITY	(50) (50)	(50)	
THROMBOSIS, NOS	1 (2%)		
#HEART	(49) (49)	(48)	
INFLAMMATION, CHRONIC FOCAL			1 (2%)
PERIVASCULITIS	1 (2%)		
METAPLASIA, CARTILAGINOUS			1 (2%)
#HEART/ATRIUM	(49)	(49)	(48)
THROMBOSIS, NOS			2 (4%)

**TABLE C2. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>CIRCULATORY SYSTEM (Continued)</b>			
#MYOCARDIUM	(49)	(49)	(48)
INFLAMMATION, INTERSTITIAL	1 (2%)		1 (2%)
INFLAMMATION, SUPPURATIVE			2 (4%)
INFLAMMATION, CHRONIC		1 (2%)	1 (2%)
INFLAMMATION, CHRONIC FOCAL		1 (2%)	1 (2%)
FIBROSIS	10 (20%)	9 (18%)	11 (23%)
FIBROSIS, FOCAL	4 (8%)		2 (4%)
FIBROSIS, MULTIFOCAL			1 (2%)
FIBROSIS, DIFFUSE		1 (2%)	
#ENDOCARDIUM	(49) (49)	(48)	
FIBROSIS, FOCAL	1 (2%)		
#CARDIAC VALVE	(49) (49)	(48)	
METAPLASIA, CARTILAGINOUS	1 (2%)	6 (12%)	1 (2%)
*CORONARY ARTERY	(50) (50)	(50)	
INFLAMMATION, FOCAL			1 (2%)
METAPLASIA, CARTILAGINOUS	1 (2%)		
*PULMONARY ARTERY	(50) (50)	(50)	
CALCIFICATION, NOS	6 (12%)	3 (6%)	2 (4%)
CALCIFICATION, FOCAL	4 (8%)	4 (8%)	2 (4%)
#PANCREAS	(47) (48)	(46)	
PERIARTERITIS	1 (2%)	2 (4%)	
<b>DIGESTIVE SYSTEM</b>			
#SALIVARY GLAND	(48)	(47)	(48)
ATROPHY, NOS		1 (2%)	
#LIVER	(50)	(49)	(49)
HEMORRHAGE		1 (2%)	
INFLAMMATION, SUPPURATIVE			1 (2%)
FIBROSIS	1 (2%)		
INFECTION, BACTERIAL		1 (2%)	
DEGENERATION, LIPOID			1 (2%)
NECROSIS, FOCAL		4 (8%)	2 (4%)
NECROSIS, CENTRAL	2 (4%)		1 (2%)
CYTOPLASMIC CHANGE, NOS	3 (6%)		
CYTOPLASMIC VACUOLIZATION	7 (14%)	6 (12%)	9 (18%)
BASOPHILIC CYTO CHANGE	23 (46%)	16 (33%)	15 (31%)
EOSINOPHILIC CYTO CHANGE	5 (10%)	1 (2%)	
CLEAR-CELL CHANGE	1 (2%)	1 (2%)	
HEPATOCTOMEGALY	2 (4%)	2 (4%)	1 (2%)
ANGIECTASIS		1 (2%)	
#HEPATIC CAPSULE	(50)	(49)	(49)
FIBROSIS, FOCAL		1 (2%)	
#PORTAL TRACT	(50)	(49)	(49)
FIBROSIS	2 (4%)	3 (6%)	8 (16%)
FIBROSIS, FOCAL	1 (2%)		
FIBROSIS, DIFFUSE	1 (2%)		
#LIVER/CENTRILOBULAR	(50)	(49)	(49)
DEGENERATION, NOS	2 (4%)		
#LIVER/HEPATOCTYTES	(50)	(49)	(49)
CYTOPLASMIC VACUOLIZATION		1 (2%)	1 (2%)
HYPERPLASIA, NODULAR	1 (2%)		
#BILE DUCT	(50)	(49)	(49)
HYPERPLASIA, NOS	21 (42%)	26 (53%)	33 (67%)
HYPERPLASIA, FOCAL	1 (2%)		
#PANCREAS	(47)	(48)	(46)
FIBROSIS, MULTIFOCAL		1 (2%)	
NECROSIS, FAT	1 (2%)		
ATROPHY, NOS	1 (2%)		
#PANCREATIC ACINUS	(47)	(48)	(46)
ATROPHY, NOS	3 (6%)	7 (15%)	6 (13%)
ATROPHY, FOCAL	4 (9%)	1 (2%)	1 (2%)



TABLE C2. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>DIGESTIVE SYSTEM (Continued)</b>			
#ESOPHAGUS	(45)	(34)	(44)
HYPERPLASIA, EPITHELIAL		1 (3%)	
#STOMACH	(49)	(48)	(47)
ULCER, NOS		1 (2%)	
INFLAMMATION, SUPPURATIVE	2 (4%)		
NECROSIS, FOCAL		1 (2%)	
HYPERPLASIA, EPITHELIAL	1 (2%)		
ACANTHOSIS	2 (4%)		1 (2%)
#GASTRIC SUBMUCOSA	(49)	(48)	(47)
CALCIFICATION, FOCAL	1 (2%)		
#COLON	(45)	(45)	(42)
PARASITISM	2 (4%)	3 (7%)	3 (7%)
<b>URINARY SYSTEM</b>			
#KIDNEY	(50)	(50)	(49)
INFLAMMATION, SUPPURATIVE	1 (2%)	1 (2%)	
FIBROSIS, DIFFUSE		1 (2%)	
NEPHROPATHY	40 (80%)	42 (84%)	34 (69%)
NEPHROSIS, NOS	2 (4%)		
NECROSIS, FOCAL		1 (2%)	
#KIDNEY/CORTEX	(50)	(50)	(49)
CALCIFICATION, FOCAL	2 (4%)		
#KIDNEY/MEDULLA	(50)	(50)	(49)
CALCIFICATION, NOS		1 (2%)	
CALCIFICATION, FOCAL		2 (4%)	
#RENAL PAPILLA	(50)	(50)	(49)
CALCIFICATION, NOS		1 (2%)	
#KIDNEY/TUBULE	(50)	(50)	(49)
DEGENERATION, NOS	1 (2%)	1 (2%)	1 (2%)
NECROSIS, NOS		1 (2%)	
NECROSIS, DIFFUSE		1 (2%)	
CALCIFICATION, NOS		1 (2%)	
CALCIFICATION, FOCAL		1 (2%)	
PIGMENTATION, NOS	5 (10%)	1 (2%)	2 (4%)
#KIDNEY/PELVIS	(50)	(50)	(49)
DILATATION, NOS			1 (2%)
INFLAMMATION, SUPPURATIVE	1 (2%)		
CALCIFICATION, NOS	1 (2%)	9 (18%)	5 (10%)
CALCIFICATION, FOCAL	5 (10%)	6 (12%)	11 (22%)
HYPERPLASIA, EPITHELIAL		2 (4%)	
HYPERPLASIA, FOCAL	1 (2%)	1 (2%)	
#URINARY BLADDER	(44)	(46)	(40)
INFLAMMATION, SUPPURATIVE		1 (2%)	
HYPERPLASIA, EPITHELIAL	2 (5%)	1 (2%)	
#U. BLADDER/MUCOSA	(44)	(46)	(40)
ULCER, NOS		1 (2%)	
CALCIFICATION, FOCAL		1 (2%)	
#U. BLADDER/SUBMUCOSA	(44)	(46)	(40)
EDEMA, NOS		2 (4%)	
#U. BLADDER/SEROSA	(44)	(46)	(40)
CALCIFICATION, FOCAL	1 (2%)		
<b>ENDOCRINE SYSTEM</b>			
#PITUITARY	(48)	(47)	(46)
CYST, NOS	6 (13%)	10 (21%)	6 (13%)
CYTOMEGALY	1 (2%)		
HYPERPLASIA, NOS	3 (6%)	2 (4%)	3 (7%)
HYPERPLASIA, FOCAL		1 (2%)	2 (4%)
ANGIECTASIS	1 (2%)		
#ANTERIOR PITUITARY	(48)	(47)	(46)
HYPERPLASIA, NOS	1 (2%)		

TABLE C2. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>ENDOCRINE SYSTEM (Continued)</b>			
#ADRENAL	(48)	(49)	(48)
DEGENERATION, LIPOID ATROPHY, NOS	2 (4%)	1 (2%)	
ANGIECTASIS	1 (2%)		1 (2%)
#ADRENAL CORTEX	(48)	(49)	(48)
HEMORRHAGE	1 (2%)	1 (2%)	
CYTOPLASMIC VACUOLIZATION	4 (8%)	1 (2%)	3 (6%)
CYTOMEGALY	1 (2%)	6 (12%)	11 (23%)
HYPERPLASIA, NOS		1 (2%)	
HYPERPLASIA, FOCAL		1 (2%)	1 (2%)
#ADRENAL MEDULLA	(48)	(49)	(48)
HYPERPLASIA, NOS	1 (2%)		
HYPERPLASIA, FOCAL	2 (4%)	2 (4%)	3 (6%)
#THYROID	(45)	(35)	(37)
CYST, NOS			1 (3%)
HYPERPLASIA, C-CELL	7 (16%)	6 (17%)	5 (14%)
ANGIECTASIS			1 (3%)
#PARATHYROID	(32)	(19)	(20)
HYPERPLASIA, NOS		1 (5%)	
<b>REPRODUCTIVE SYSTEM</b>			
*MAMMARY GLAND	(50)	(50)	(50)
GALACTOCELE	1 (2%)		
HYPERPLASIA, NOS	2 (4%)	1 (2%)	
HYPERPLASIA, FOCAL			1 (2%)
*LACTIFEROUS DUCT	(50)	(50)	(50)
HYPERKERATOSIS	1 (2%)		
*CLITORAL GLAND	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE	1 (2%)		
METAPLASIA, SQUAMOUS	1 (2%)		1 (2%)
#UTERUS	(49)	(50)	(47)
HEMORRHAGE		2 (4%)	
INFLAMMATION, SUPPURATIVE	3 (6%)	1 (2%)	2 (4%)
METAPLASIA, SQUAMOUS		1 (2%)	
#UTERUS/ENDOMETRIUM	(49)	(50)	(47)
PIGMENTATION, NOS			1 (2%)
HYPERPLASIA, CYSTIC		9 (18%)	6 (13%)
HYPERPLASIA, STROMAL		1 (2%)	
#OVARY	(48)	(50)	(46)
CYST, NOS	1 (2%)	4 (8%)	2 (4%)
CALCIFICATION, FOCAL		1 (2%)	
ATROPHY, NOS	4 (8%)		
<b>NERVOUS SYSTEM</b>			
#CEREBRUM	(49)	(50)	(49)
HEMORRHAGE		1 (2%)	
CYTOPLASMIC VACUOLIZATION		1 (2%)	
#BRAIN	(49)	(50)	(49)
HYDROCEPHALUS, NOS	1 (2%)		
HEMORRHAGE		3 (6%)	1 (2%)
INFLAMMATION, MULTIFOCAL			1 (2%)
GLIOSIS		1 (2%)	
NECROSIS, NOS			1 (2%)
NECROSIS, FOCAL			1 (2%)
MALACIA			1 (2%)
CALCIFICATION, FOCAL		1 (2%)	
CYTOPLASMIC VACUOLIZATION		1 (2%)	
#CEREBRAL CORTEX	(49)	(50)	(49)
GLIOSIS	1 (2%)		
#CEREBRAL WHITE MATTE	(49)	(50)	(49)
CYTOPLASMIC VACUOLIZATION	15 (31%)	5 (10%)	15 (31%)

**TABLE C2. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>NERVOUS SYSTEM (Continued)</b>			
#CEREBELLUM	(49)	(50)	(49)
HEMORRHAGE			1 (2%)
#MEDULLA OBLONGATA	(49)	(50)	(49)
HEMORRHAGE	1 (2%)	1 (2%)	
*OLFACTORY SENSORY EP	(50)	(50)	(50)
DEGENERATION, NOS	1 (2%)	2 (4%)	3 (6%)
<b>SPECIAL SENSE ORGANS</b>			
*EYE/CRYSTALLINE LENS	(50)	(50)	(50)
CALCIFICATION, NOS		1 (2%)	
*NASOLACRIMAL DUCT	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE	8 (16%)	8 (16%)	1 (2%)
METAPLASIA, SQUAMOUS	3 (6%)	9 (18%)	
<b>MUSCULOSKELETAL SYSTEM</b>			
*SKELETAL MUSCLE	(50)	(50)	(50)
DEGENERATION, NOS	1 (2%)		
<b>BODY CAVITIES</b>			
*PERITONEAL CAVITY	(50)	(50)	(50)
NECROSIS, FAT	1 (2%)		
*PLEURA	(50)	(50)	(50)
HEMORRHAGE	1 (2%)		
FIBROSIS, FOCAL			1 (2%)
*SUBPLEURAL TISSUE	(50)	(50)	(50)
INFLAMMATION, CHRONIC		1 (2%)	
INFLAMMATION, CHRONIC FOCAL		2 (4%)	1 (2%)
FIBROSIS		1 (2%)	
FIBROSIS, FOCAL		3 (6%)	
FIBROSIS, MULTIFOCAL		1 (2%)	
<b>ALL OTHER SYSTEMS</b>			
*MULTIPLE ORGANS	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE			2 (4%)
OMENTUM			
INFLAMMATION, NECROTIZING	1		
<b>SPECIAL MORPHOLOGY SUMMARY</b>			
NONE			

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
 \* NUMBER OF ANIMALS NECROPSIED



## **APPENDIX D**

# **SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MICE IN THE TWO-YEAR INHALATION STUDIES OF PROPYLENE OXIDE**

**TABLE D1. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
<b>INTEGUMENTARY SYSTEM</b>			
*SKIN	(50)	(50)	(50)
EPIDERMAL INCLUSION CYST	1 (2%)		
ABSCESS, NOS		1 (2%)	
INFLAMMATION, ACUTE/CHRONIC	1 (2%)		
INFLAMMATION, CHRONIC FOCAL	1 (2%)		
INFLAMMATION, GRANULOMATOUS		1 (2%)	
HYPERKERATOSIS	1 (2%)		
*SUBCUT TISSUE	(50)	(50)	(50)
HEMORRHAGE		1 (2%)	
ABSCESS, NOS		1 (2%)	
<b>RESPIRATORY SYSTEM</b>			
*NASAL CAVITY	(50)	(50)	(50)
INFLAMMATION, SEROUS		13 (26%)	2 (4%)
INFLAMMATION, SUPPURATIVE		8 (16%)	4 (8%)
INFLAMMATION, ACUTE	1 (2%)		4 (8%)
INFLAMMATION, ACUTE/CHRONIC	1 (2%)	13 (26%)	38 (76%)
ANGIECTASIS			3 (6%)
METAPLASIA, SQUAMOUS		1 (2%)	
*NASAL TURBINATE	(50)	(50)	(50)
HEMORRHAGE			1 (2%)
*LARYNX	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE			6 (12%)
#TRACHEA	(48)	(46)	(48)
INFLAMMATION, SUPPURATIVE			3 (6%)
INFLAMMATION, ACUTE SUPPURATIVE			1 (2%)
INFLAMMATION, ACUTE/CHRONIC	1 (2%)		
#LUNG	(50)	(50)	(50)
CONGESTION, NOS	2 (4%)	1 (2%)	2 (4%)
CONGESTION, ACUTE		1 (2%)	
HEMORRHAGE		1 (2%)	
LOBAR PNEUMONIA, NOS		1 (2%)	
LYMPHOCYTIC INFLAMMATORY INFILTR		2 (4%)	
INFLAMMATION, INTERSTITIAL	1 (2%)	2 (4%)	
INFLAMMATION, SUPPURATIVE			3 (6%)
BRONCHOPNEUMONIA SUPPURATIVE			1 (2%)
INFLAMMATION, NECROTIZING			4 (8%)
INFLAMMATION, ACUTE SUPPURATIVE			1 (2%)
INFLAMMATION, ACUTE/CHRONIC	3 (6%)	1 (2%)	8 (16%)
PNEUMONIA INTERSTITIAL CHRONIC	1 (2%)		
INFLAMMATION, FOCAL GRANULOMATOUS	1 (2%)		
INFLAMMATION PROLIFERATIVE		2 (4%)	
HISTIOCYTOSIS	1 (2%)		
#LUNG/ALVEOLI	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE			1 (2%)

TABLE D1. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>HEMATOPOIETIC SYSTEM</b>			
#BONE MARROW	(47)	(49)	(48)
HYPERPLASIA, GRANULOCYTIC		4 (8%)	5 (10%)
#SPLEEN	(48)	(50)	(47)
CONGESTION, NOS		1 (2%)	
INFARCT, NOS	1 (2%)		
HYPERPLASIA, LYMPHOID		1 (2%)	
HEMATOPOIESIS	1 (2%)	3 (6%)	
#SPLENIC FOLLICLES	(48)	(50)	(47)
ATROPHY, NOS		1 (2%)	
#LYMPH NODE	(44)	(48)	(42)
MULTIPLE CYSTS		1 (2%)	
INFLAMMATION, ACUTE/CHRONIC	1 (2%)	1 (2%)	1 (2%)
HYPERPLASIA, PLASMA CELL		1 (2%)	
#MANDIBULAR L. NODE	(44)	(48)	(42)
CYST, NOS			1 (2%)
ANGIECTASIS			1 (2%)
HYPERPLASIA, LYMPHOID		3 (6%)	2 (5%)
#BRONCHIAL LYMPH NODE	(44)	(48)	(42)
INFLAMMATION, FOCAL GRANULOMATOUS			1 (2%)
HYPERPLASIA, LYMPHOID	2 (5%)	1 (2%)	1 (2%)
#MESENTERIC L. NODE	(44)	(48)	(42)
CONGESTION, NOS	1 (2%)	1 (2%)	2 (5%)
HYPERPLASIA, PLASMA CELL	1 (2%)		
HYPERPLASIA, LYMPHOID	1 (2%)		
#COLON	(49)	(48)	(45)
HYPERPLASIA, LYMPHOID	1 (2%)		1 (2%)
#CECUM	(49)	(48)	(45)
HYPERPLASIA, LYMPHOID		1 (2%)	
<b>CIRCULATORY SYSTEM</b>			
#HEART	(50)	(50)	(50)
INFLAMMATION, ACUTE/CHRONIC		1 (2%)	2 (4%)
PERIVASCULITIS	2 (4%)		2 (4%)
CALCIFICATION, FOCAL			1 (2%)
#CARDIAC VALVE	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE		1 (2%)	
PIGMENTATION, NOS	3 (6%)		2 (4%)
#KIDNEY	(50)	(50)	(50)
EMBOLUS, SEPTIC		1 (2%)	
<b>DIGESTIVE SYSTEM</b>			
*TOOTH	(50)	(50)	(50)
CONGENITAL MALFORMATION, NOS	2 (4%)	1 (2%)	3 (6%)
*PULP OF TOOTH	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE		1 (2%)	
ABSCESS, NOS	3 (6%)	2 (4%)	3 (6%)
#SALIVARY GLAND	(50)	(50)	(49)
INFLAMMATION, ACUTE/CHRONIC	14 (28%)	23 (46%)	6 (12%)
#LIVER	(50)	(50)	(50)
CYST, NOS			1 (2%)
INFLAMMATION, SUPPURATIVE			1 (2%)
INFLAMMATION, NECROTIZING	1 (2%)	1 (2%)	
INFLAMMATION, ACUTE NECROTIZING	2 (4%)		
INFLAMMATION, ACUTE/CHRONIC	9 (18%)	6 (12%)	8 (16%)
INFLAMMATION PROLIFERATIVE		1 (2%)	
NECROSIS, FOCAL	1 (2%)	3 (6%)	2 (4%)
METAMORPHOSIS FATTY		2 (4%)	
CYTOLOGIC DEGENERATION	1 (2%)		
ANGIECTASIS		1 (2%)	

**TABLE D1. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>DIGESTIVE SYSTEM (Continued)</b>			
#PANCREAS	(48)	(49)	(46)
AGENESIS		1 (2%)	
ATROPHY, FOCAL			1 (2%)
#STOMACH	(49)	(48)	(48)
INFLAMMATION, ACUTE/CHRONIC	2 (4%)		
HYPERKERATOSIS	1 (2%)		
<b>URINARY SYSTEM</b>			
#KIDNEY	(50)	(50)	(50)
HYDRONEPHROSIS		1 (2%)	
GLOMERULONEPHRITIS, NOS		1 (2%)	
INFLAMMATION, SUPPURATIVE		1 (2%)	
PYELONEPHRITIS, ACUTE		4 (8%)	
INFLAMMATION, ACUTE/CHRONIC	15 (30%)	13 (26%)	4 (8%)
FIBROSIS, FOCAL	1 (2%)		
NEPHROSIS, NOS	1 (2%)		
CALCINOSIS, NOS	1 (2%)		
ATROPHY, NOS		1 (2%)	
#KIDNEY/CAPSULE	(50)	(50)	(50)
CYST, NOS	1 (2%)		
#KIDNEY/CORTEX	(50)	(50)	(50)
CYST, NOS		1 (2%)	
#KIDNEY/TUBULE	(50)	(50)	(50)
CAST, NOS	1 (2%)		
CALCIFICATION, FOCAL			1 (2%)
#URINARY BLADDER	(47)	(46)	(48)
INFLAMMATION, SUPPURATIVE		5 (11%)	
INFLAMMATION, ACUTE/CHRONIC		1 (2%)	
*URETHRA	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE		1 (2%)	
<b>ENDOCRINE SYSTEM</b>			
#ADRENAL	(50)	(43)	(49)
CYST, NOS		1 (2%)	
INFLAMMATION, ACUTE/CHRONIC		1 (2%)	
HYPERPLASIA, NOS	2 (4%)		
#ADRENAL/CAPSULE	(50)	(43)	(49)
HYPERPLASIA, NOS	3 (6%)		
#ADRENAL CORTEX	(50)	(43)	(49)
HYPERPLASIA, NOS	1 (2%)		
HYPERPLASIA, FOCAL		1 (2%)	
#THYROID	(43)	(48)	(46)
HYPOPLASIA, NOS			1 (2%)
HYPERPLASIA, FOCAL		3 (6%)	
HYPERPLASIA, CYSTIC	1 (2%)		
<b>REPRODUCTIVE SYSTEM</b>			
*PREPUCE	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE	1 (2%)		
#PROSTATE	(47)	(49)	(43)
INFLAMMATION, SUPPURATIVE		3 (6%)	
*SEMINAL VESICLE	(50)	(50)	(50)
DISTENTION	2 (4%)		
#TESTIS	(48)	(49)	(49)
INFLAMMATION, ACUTE/CHRONIC			1 (2%)



**TABLE D1. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>NERVOUS SYSTEM</b>			
#BRAIN/MENINGES	(49)	(50)	(50)
INFLAMMATION, SUPPURATIVE			1 (2%)
#BRAIN	(49)	(50)	(50)
MINERALIZATION	3 (6%)	4 (8%)	1 (2%)
INFLAMMATION, NOS			1 (2%)
INFLAMMATION, SUPPURATIVE			1 (2%)
INFLAMMATION, ACUTE FOCAL			1 (2%)
CORPORA AMYLACEA	23 (47%)	21 (42%)	25 (50%)
<b>SPECIAL SENSE ORGANS</b>			
*NASOLACRIMAL DUCT	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE			1 (2%)
*EAR	(50)	(50)	(50)
ULCER, NOS		1 (2%)	
<b>MUSCULOSKELETAL SYSTEM</b>			
*BONE	(50)	(50)	(50)
FIBROUS OSTEODYSTROPHY	2 (4%)		
*COCCYX	(50)	(50)	(50)
HEALED FRACTURE	1 (2%)		
*STERNUM	(50)	(50)	(50)
NECROSIS, FOCAL		1 (2%)	
<b>BODY CAVITIES</b>			
NONE			
<b>ALL OTHER SYSTEMS</b>			
*MULTIPLE ORGANS	(50)	(50)	(50)
INFLAMMATION, ACUTE/CHRONIC		1 (2%)	
BACTERIAL SEPTICEMIA		1 (2%)	
<b>SPECIAL MORPHOLOGY SUMMARY</b>			
NO LESION REPORTED	1		1

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
 \* NUMBER OF ANIMALS NECROPSIED

**TABLE D2. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
<b>INTEGUMENTARY SYSTEM</b>			
*SUBCUT TISSUE	(50)	(50)	(50)
ABSCESS, NOS			1 (2%)
<b>RESPIRATORY SYSTEM</b>			
*NASAL CAVITY	(50)	(50)	(50)
DILATATION, NOS			1 (2%)
INFLAMMATION, SEROUS	2 (4%)	6 (12%)	2 (4%)
INFLAMMATION, SUPPURATIVE		16 (32%)	19 (38%)
INFLAMMATION, ACUTE			1 (2%)
INFLAMMATION, ACUTE/CHRONIC		13 (26%)	17 (34%)
HYPERPLASIA, EPITHELIAL			1 (2%)
ANGIECTASIS			3 (6%)
METAPLASIA, SQUAMOUS			2 (4%)
*NASAL TURBINATE	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE	1 (2%)		1 (2%)
*LARYNX	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE			2 (4%)
#TRACHEA	(48)	(49)	(47)
INFLAMMATION, SUPPURATIVE			2 (4%)
#TRACHEAL SUBMUCOSA	(48)	(49)	(47)
INFLAMMATION, ACUTE			1 (2%)
#LUNG	(50)	(50)	(50)
CONGESTION, NOS	1 (2%)	2 (4%)	3 (6%)
HEMORRHAGE	1 (2%)	1 (2%)	1 (2%)
BRONCHOPNEUMONIA, NOS			1 (2%)
LYMPHOCYTIC INFLAMMATORY INFILTR		3 (6%)	
INFLAMMATION, INTERSTITIAL			1 (2%)
INFLAMMATION, SUPPURATIVE			4 (8%)
INFLAMMATION, NECROTIZING			2 (4%)
BRONCHOPNEUMONIA, ACUTE			1 (2%)
INFLAMMATION, ACUTE SUPPURATIVE			2 (4%)
INFLAMMATION, ACUTE/CHRONIC	3 (6%)	1 (2%)	
INFLAMMATION PROLIFERATIVE		1 (2%)	
PIGMENTATION, NOS	1 (2%)		
<b>HEMATOPOIETIC SYSTEM</b>			
#BONE MARROW	(47)	(49)	(45)
HYPERPLASIA, GRANULOCYTIC		3 (6%)	11 (24%)
#SPLEEN	(48)	(49)	(44)
INFLAMMATION, SUPPURATIVE		1 (2%)	
PIGMENTATION, NOS			4 (9%)
HEMOSIDEROSIS			1 (2%)
HYPERPLASIA, PLASMA CELL		1 (2%)	
HYPERPLASIA, LYMPHOID	3 (6%)	4 (8%)	
HEMATOPOIESIS		2 (4%)	4 (9%)
#SPLENIC FOLLICLES	(48)	(49)	(44)
ATROPHY, NOS			1 (2%)
#LYMPH NODE	(46)	(48)	(37)
INFLAMMATION, ACUTE/CHRONIC			4 (11%)
HISTIOCYTOSIS			1 (3%)
PLASMACYTOSIS			2 (5%)
HYPERPLASIA, LYMPHOID	1 (2%)		

**TABLE D2. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>HEMATOPOIETIC SYSTEM (Continued)</b>			
#MANDIBULAR L. NODE	(46)	(48)	(37)
CYST, NOS			1 (3%)
PIGMENTATION, NOS			1 (3%)
ANGIECTASIS			1 (3%)
HYPERPLASIA, RETICULUM CELL			1 (3%)
HYPERPLASIA, LYMPHOID	2 (4%)	3 (6%)	2 (5%)
#CERVICAL LYMPH NODE	(46)	(48)	(37)
HYPERPLASIA, LYMPHOID		1 (2%)	
#BRONCHIAL LYMPH NODE	(46)	(48)	(37)
INFLAMMATION, SUPPURATIVE		2 (4%)	
ABSCESS, NOS		1 (2%)	
ANGIECTASIS			1 (3%)
HYPERPLASIA, PLASMA CELL		2 (4%)	
HYPERPLASIA, LYMPHOID	2 (4%)	1 (2%)	
#MESENTERIC L. NODE	(46)	(48)	(37)
ANGIECTASIS		1 (2%)	
HYPERPLASIA, LYMPHOID	2 (4%)		
#RENAL LYMPH NODE	(46)	(48)	(37)
HYPERPLASIA, LYMPHOID	1 (2%)		
#LIVER	(50)	(50)	(49)
LEUKEMOID REACTION		1 (2%)	1 (2%)
HEMATOPOIESIS	1 (2%)	1 (2%)	2 (4%)
#PANCREAS	(48)	(49)	(42)
HYPERPLASIA, LYMPHOID	1 (2%)		
#PITUITARY	(46)	(48)	(38)
HEMATOPOIESIS		1 (2%)	
#ADRENAL	(48)	(48)	(48)
HEMATOPOIESIS			3 (6%)
<b>CIRCULATORY SYSTEM</b>			
*NASAL CAVITY	(50)	(50)	(50)
THROMBOSIS, NOS			1 (2%)
#HEART	(50)	(50)	(48)
FIBROSIS, FOCAL			1 (2%)
PERIVASCULITIS	1 (2%)	2 (4%)	5 (10%)
CALCIFICATION, NOS		2 (4%)	
#CARDIAC VALVE	(50)	(50)	(48)
PIGMENTATION, NOS	3 (6%)		1 (2%)
#PANCREAS	(48)	(49)	(42)
PERIVASCULITIS			1 (2%)
#ADRENAL	(48)	(48)	(48)
THROMBOSIS, NOS			1 (2%)
<b>DIGESTIVE SYSTEM</b>			
*TOOTH	(50)	(50)	(50)
CONGENITAL MALFORMATION, NOS		1 (2%)	2 (4%)
*PULP OF TOOTH	(50)	(50)	(50)
ABSCESS, NOS	1 (2%)	1 (2%)	1 (2%)
#SALIVARY GLAND	(49)	(48)	(47)
INFLAMMATION, ACUTE/CHRONIC	15 (31%)	18 (38%)	6 (13%)
#LIVER	(50)	(50)	(49)
CYSTIC DUCTS		1 (2%)	
INFLAMMATION, SUPPURATIVE		1 (2%)	2 (4%)
INFLAMMATION, NECROTIZING		1 (2%)	
INFLAMMATION, ACUTE/CHRONIC	11 (22%)	18 (36%)	9 (18%)
NECROSIS, FOCAL			3 (6%)
CALCIFICATION, NOS		1 (2%)	1 (2%)
#PANCREAS	(48)	(49)	(42)
DILATATION/DUCTS		1 (2%)	
INFLAMMATION, SUPPURATIVE		1 (2%)	
ABSCESS, NOS	1 (2%)		

**TABLE D2. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>DIGESTIVE SYSTEM (Continued)</b>			
*PHARYNX	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE			3 (6%)
#STOMACH	(49)	(50)	(44)
ULCER, NOS		4 (8%)	
HYPERPLASIA, EPITHELIAL		4 (8%)	
<b>URINARY SYSTEM</b>			
#KIDNEY	(50)	(50)	(49)
INFLAMMATION, SUPPURATIVE		1 (2%)	
PYELONEPHRITIS, ACUTE		1 (2%)	4 (8%)
INFLAMMATION, ACUTE/CHRONIC	12 (24%)	19 (38%)	4 (8%)
FIBROSIS			1 (2%)
CALCINOSIS, NOS	1 (2%)		
ATROPHY, NOS			1 (2%)
#KIDNEY/TUBULE	(50)	(50)	(49)
DEGENERATION, NOS	1 (2%)		
#KIDNEY/PELVIS	(50)	(50)	(49)
DILATATION, NOS		1 (2%)	
#URINARY BLADDER	(44)	(47)	(42)
INFLAMMATION, SUPPURATIVE			1 (2%)
INFLAMMATION, ACUTE/CHRONIC	3 (7%)		
HYPERPLASIA, EPITHELIAL	1 (2%)		
METAPLASIA, SQUAMOUS			1 (2%)
<b>ENDOCRINE SYSTEM</b>			
#PITUITARY	(46)	(48)	(38)
CONGESTION, NOS	2 (4%)	5 (10%)	
HYPERPLASIA, FOCAL		3 (6%)	
#ADRENAL	(48)	(48)	(48)
ANGIECTASIS	1 (2%)		1 (2%)
#ADRENAL/CAPSULE	(48)	(48)	(48)
HYPERPLASIA, NOS			1 (2%)
#ADRENAL CORTEX	(48)	(48)	(48)
CYST, NOS		1 (2%)	
#THYROID	(45)	(50)	(43)
FOLLICULAR CYST, NOS		1 (2%)	
INFLAMMATION, ACUTE/CHRONIC	1 (2%)		
CRYSTALS, NOS	1 (2%)		
HYPERTROPHY, FOCAL	1 (2%)		1 (2%)
HYPERPLASIA, FOCAL		2 (4%)	
HYPERPLASIA, C-CELL	1 (2%)		
<b>REPRODUCTIVE SYSTEM</b>			
*MAMMARY GLAND	(50)	(50)	(50)
DILATATION/DUCTS		1 (2%)	
*VAGINA	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE			1 (2%)
#UTERUS	(48)	(50)	(48)
INFLAMMATION, SUPPURATIVE	1 (2%)	3 (6%)	8 (17%)
ABSCCESS, NOS		2 (4%)	1 (2%)
#UTERUS/ENDOMETRIUM	(48)	(50)	(48)
CYST, NOS		1 (2%)	
INFLAMMATION, SUPPURATIVE	1 (2%)		2 (4%)
HYPERPLASIA, NOS	24 (50%)	13 (26%)	1 (2%)
HYPERPLASIA, CYSTIC	1 (2%)		1 (2%)
METAPLASIA, SQUAMOUS			1 (2%)
#FALLOPIAN TUBE	(48)	(50)	(48)
INFLAMMATION, CHRONIC SUPPURATIVE			1 (2%)

**TABLE D2. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
<b>REPRODUCTIVE SYSTEM (Continued)</b>			
#OVARY	(48)	(46)	(37)
CYST, NOS	3 (6%)	6 (13%)	6 (16%)
MULTIPLE CYSTS	1 (2%)	1 (2%)	
HEMORRHAGIC CYST	3 (6%)	3 (7%)	1 (3%)
INFLAMMATION, NOS			1 (3%)
LYMPHOCYTIC INFLAMMATORY INFILTR	1 (2%)		
INFLAMMATION, SUPPURATIVE			1 (3%)
ABSCESS, NOS	1 (2%)	3 (7%)	
#OVARY (Continued)			
INFLAMMATION, CHRONIC	1 (2%)		
CALCIFICATION, NOS			2 (5%)
ATROPHY, NOS	6 (13%)	8 (17%)	20 (54%)
HYPERPLASIA, EPITHELIAL		1 (2%)	
<b>NERVOUS SYSTEM</b>			
#BRAIN/MENINGES	(50)	(50)	(48)
INFLAMMATION, SUPPURATIVE			1 (2%)
#BRAIN	(50)	(50)	(48)
MINERALIZATION	4 (8%)	2 (4%)	3 (6%)
CONGESTION, NOS	1 (2%)		1 (2%)
HEMATOMA, NOS	1 (2%)		
INFLAMMATION, SUPPURATIVE			1 (2%)
ABSCESS, NOS		1 (2%)	
INFLAMMATION, ACUTE/CHRONIC	1 (2%)		
CORPORA AMYLACEA	29 (58%)	20 (40%)	14 (29%)
<b>SPECIAL SENSE ORGANS</b>			
*NASOLACRIMAL DUCT	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE			1 (2%)
INFLAMMATION, ACUTE/CHRONIC	1 (2%)		
<b>MUSCULOSKELETAL SYSTEM</b>			
*BONE	(50)	(50)	(50)
FIBROUS OSTEODYSTROPHY	1 (2%)		1 (2%)
*STERNUM	(50)	(50)	(50)
FIBROUS OSTEODYSTROPHY	38 (76%)	33 (66%)	7 (14%)
<b>BODY CAVITIES</b>			
*THORACIC CAVITY	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE			1 (2%)
*PERITONEUM	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE		2 (4%)	
*PERITONEAL CAVITY	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE			2 (4%)
INFLAMMATION, CHRONIC SUPPURATIVE			1 (2%)
ADHESION, NOS			1 (2%)
*PLEURA	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE		1 (2%)	
*EPICARDIUM	(50)	(50)	(50)
INFLAMMATION, CHRONIC FOCAL			1 (2%)

**TABLE D2. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	CONTROL (CHAMBER)	LOW DOSE	HIGH DOSE
ALL OTHER SYSTEMS			
*MULTIPLE ORGANS	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE		1 (2%)	4 (8%)
INFLAMMATION, ACUTE/CHRONIC	4 (8%)	1 (2%)	1 (2%)
BACTERIAL SEPTICEMIA		3 (6%)	
TOE			
DEFORMITY, NOS	1		
SITE UNKNOWN			
MULTILOCULAR CYST			1
SPECIAL MORPHOLOGY SUMMARY			
NO LESION REPORTED		1	
AUTO/NECROPSY/HISTO PERF	1		2

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY

\* NUMBER OF ANIMALS NECROPSIED

**APPENDIX E**

**ANALYSES OF PRIMARY TUMORS IN RATS AND MICE  
IN THE TWO-YEAR INHALATION STUDIES OF  
PROPYLENE OXIDE**

TABLE E1. ANALYSIS OF PRIMARY TUMORS IN MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE

	Chamber Control	200 ppm	400 ppm
<b>Skin: Keratoacanthoma</b>			
Overall Rates (a)	1/50 (2%)	1/50 (2%)	5/50 (10%)
Adjusted Rates (b)	3.5%	3.2%	15.3%
Terminal Rates (c)	1/29 (3%)	1/31 (3%)	3/29 (10%)
Life Table Tests (d)	P=0.051	P=0.747N	P=0.114
Incidental Tumor Tests (d)	P=0.068	P=0.747N	P=0.154
Cochran-Armitage Trend Test (d)	P=0.049		
Fisher Exact Tests		P=0.753N	P=0.102
<b>Subcutaneous Tissue: Fibroma</b>			
Overall Rates (a)	3/50 (6%)	2/50 (4%)	3/50 (6%)
Adjusted Rates (b)	10.3%	5.8%	10.3%
Terminal Rates (c)	3/29 (10%)	0/31 (0%)	3/29 (10%)
Life Table Tests (d)	P=0.583N	P=0.460N	P=0.665
Incidental Tumor Tests (d)	P=0.518N	P=0.409N	P=0.665
Cochran-Armitage Trend Test (d)	P=0.588		
Fisher Exact Tests		P=0.500N	P=0.661
<b>Skin or Subcutaneous Tissue: Fibroma</b>			
Overall Rates (a)	3/50 (6%)	2/50 (4%)	4/50 (8%)
Adjusted Rates (b)	10.3%	5.8%	13.8%
Terminal Rates (c)	3/29 (10%)	0/31 (0%)	4/29 (14%)
Life Table Tests (d)	P=0.421	P=0.460N	P=0.500
Incidental Tumor Tests (d)	P=0.483	P=0.409N	P=0.500
Cochran-Armitage Trend Test (d)	P=0.417		
Fisher Exact Tests		P=0.500N	P=0.500
<b>Hematopoietic System: Mononuclear Cell Leukemia</b>			
Overall Rates (a)	19/50 (38%)	23/50 (46%)	22/50 (44%)
Adjusted Rates (b)	48.8%	53.9%	54.1%
Terminal Rates (c)	10/29 (34%)	12/31 (39%)	11/29 (38%)
Life Table Tests (d)	P=0.376	P=0.429	P=0.411
Incidental Tumor Tests (d)	P=0.508	P=0.377	P=0.522
Cochran-Armitage Trend Test (d)	P=0.307		
Fisher Exact Tests		P=0.272	P=0.342
<b>Hematopoietic System: Leukemia</b>			
Overall Rates (a)	20/50 (40%)	26/50 (52%)	23/50 (46%)
Adjusted Rates (b)	50.1%	56.9%	55.1%
Terminal Rates (c)	10/29 (34%)	12/31 (39%)	11/29 (38%)
Life Table Tests (d)	P=0.399	P=0.324	P=0.428
Incidental Tumor Tests (d)	P=0.489	P=0.284	P=0.488
Cochran-Armitage Trend Test (d)	P=0.308		
Fisher Exact Tests		P=0.158	P=0.343
<b>Liver: Neoplastic Nodule or Carcinoma</b>			
Overall Rates (a)	1/50 (2%)	2/50 (4%)	3/49 (6%)
Adjusted Rates (b)	2.9%	6.5%	9.5%
Terminal Rates (c)	0/29 (0%)	2/31 (6%)	2/28 (7%)
Life Table Tests (d)	P=0.217	P=0.528	P=0.308
Incidental Tumor Tests (d)	P=0.276	P=0.562	P=0.412
Cochran-Armitage Trend Test (d)	P=0.216		
Fisher Exact Tests		P=0.500	P=0.301
<b>Pituitary: Adenoma</b>			
Overall Rates (a)	21/47 (45%)	15/47 (32%)	15/48 (31%)
Adjusted Rates (b)	59.9%	38.9%	44.3%
Terminal Rates (c)	13/26 (50%)	7/29 (24%)	11/29 (38%)
Life Table Tests (d)	P=0.083N	P=0.094N	P=0.093N
Incidental Tumor Tests (d)	P=0.041N	P=0.070N	P=0.056N
Cochran-Armitage Trend Test (d)	P=0.105N		
Fisher Exact Tests		P=0.144N	P=0.128N



**TABLE E1. ANALYSIS OF PRIMARY TUMORS IN MALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	Chamber Control	200 ppm	400 ppm
<b>Pituitary: Adenoma or Adenocarcinoma</b>			
Overall Rates (a)	21/47 (45%)	15/47 (32%)	16/48 (33%)
Adjusted Rates (b)	59.9%	38.9%	47.4%
Terminal Rates (c)	13/26 (50%)	7/29 (24%)	12/29 (41%)
Life Table Tests (d)	P=0.117N	P=0.094N	P=0.128N
Incidental Tumor Tests (d)	P=0.065N	P=0.070N	P=0.085N
Cochran-Armitage Trend Test (d)	P=0.150N		
Fisher Exact Tests		P=0.144N	P=0.178N
<b>Adrenal: Pheochromocytoma</b>			
Overall Rates (a)	3/48 (6%)	5/49 (10%)	4/49 (8%)
Adjusted Rates (b)	8.4%	16.7%	11.4%
Terminal Rates (c)	1/28 (4%)	5/30 (17%)	2/29 (7%)
Life Table Tests (d)	P=0.466	P=0.404	P=0.549
Incidental Tumor Tests (d)	P=0.503	P=0.393	P=0.613
Cochran-Armitage Trend Test (d)	P=0.439		
Fisher Exact Tests		P=0.369	P=0.512
<b>Thyroid: C-Cell Adenoma or Carcinoma</b>			
Overall Rates (a)	1/44 (2%)	2/41 (5%)	4/49 (8%)
Adjusted Rates (b)	3.7%	8.0%	14.3%
Terminal Rates (c)	1/27 (4%)	2/25 (8%)	4/28 (14%)
Life Table Tests (d)	P=0.126	P=0.473	P=0.187
Incidental Tumor Tests (d)	P=0.126	P=0.473	P=0.187
Cochran-Armitage Trend Test (d)	P=0.148		
Fisher Exact Tests		P=0.473	P=0.216
<b>Pancreatic Islets: Islet Cell Adenoma</b>			
Overall Rates (a)	1/47 (2%)	3/49 (6%)	1/47 (2%)
Adjusted Rates (b)	2.7%	8.9%	3.7%
Terminal Rates (c)	0/29 (0%)	2/31 (6%)	1/27 (4%)
Life Table Tests (d)	P=0.600	P=0.343	P=0.754N
Incidental Tumor Tests (d)	P=0.549N	P=0.392	P=0.709N
Cochran-Armitage Trend Test (d)	P=0.611		
Fisher Exact Tests		P=0.324	P=0.753
<b>Pancreatic Islets: Islet Cell Adenoma or Carcinoma</b>			
Overall Rates (a)	2/47 (4%)	4/49 (8%)	1/47 (2%)
Adjusted Rates (b)	6.1%	12.1%	3.7%
Terminal Rates (c)	1/29 (3%)	3/31 (10%)	1/27 (4%)
Life Table Tests (d)	P=0.423N	P=0.380	P=0.502N
Incidental Tumor Tests (d)	P=0.360N	P=0.422	P=0.453N
Cochran-Armitage Trend Test (d)	P=0.406N		
Fisher Exact Tests		P=0.359	P=0.500N
<b>Testis: Interstitial Cell Tumor</b>			
Overall Rates (a)	29/49 (59%)	36/50 (72%)	35/50 (70%)
Adjusted Rates (b)	77.8%	89.7%	80.8%
Terminal Rates (c)	21/29 (72%)	27/31 (87%)	21/29 (72%)
Life Table Tests (d)	P=0.205	P=0.260	P=0.253
Incidental Tumor Tests (d)	P=0.277	P=0.191	P=0.375
Cochran-Armitage Trend Test (d)	P=0.151		
Fisher Exact Tests		P=0.129	P=0.180
<b>All Sites: Mesotheliomas</b>			
Overall Rates (a)	1/50 (2%)	2/50 (4%)	3/50 (6%)
Adjusted Rates (b)	3.4%	5.4%	7.7%
Terminal Rates (c)	1/29 (3%)	1/31 (3%)	1/29 (3%)
Life Table Tests (d)	P=0.253	P=0.535	P=0.338
Incidental Tumor Tests (d)	P=0.209	P=0.469	P=0.324
Cochran-Armitage Trend Test (d)	P=0.222		
Fisher Exact Tests		P=0.500	P=0.309

**TABLE E1. ANALYSIS OF PRIMARY TUMORS IN MALE RATS IN THE TWO-YEAR INHALATION  
STUDY OF PROPYLENE OXIDE (Continued)**

---

- (a) Number of tumor-bearing animals/number of animals examined at the site
- (b) Kaplan-Meier estimated tumor incidences at the end of the study after adjusting for intercurrent mortality
- (c) Observed tumor incidence at terminal kill
- (d) Beneath the control incidence are the P values associated with the trend test. Beneath the dosed group incidence are the P values corresponding to pairwise comparisons between that dosed group and the controls. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The incidental tumor test regards these lesions as nonfatal. The Cochran-Armitage and Fisher's exact test compare directly the overall incidence rates. A negative trend or lower incidence in a dosed group is indicated by (N).

**TABLE E2. ANALYSIS OF PRIMARY TUMORS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE**

	Chamber Control	200 ppm	400 ppm
<b>Nasal Cavity: Papillary Adenoma</b>			
Overall Rates (a)	0/50 (0%)	0/50 (0%)	3/50 (6%)
Adjusted Rates (b)	0.0%	0.0%	9.7%
Terminal Rates (c)	0/35 (0%)	0/32 (0%)	3/31 (10%)
Life Table Tests (d)	P=0.031	(e)	P=0.100
Incidental Tumor Tests (d)	P=0.031	(e)	P=0.100
Cochran-Armitage Trend Test (d)	P=0.037		
Fisher Exact Tests		(e)	P=0.121
<b>Hematopoietic System: Mononuclear Cell Leukemia</b>			
Overall Rates (a)	11/50 (22%)	20/50 (40%)	15/50 (30%)
Adjusted Rates (b)	27.9%	52.3%	40.3%
Terminal Rates (c)	7/35 (20%)	14/32 (44%)	10/31 (32%)
Life Table Tests (d)	P=0.173	P=0.035	P=0.202
Incidental Tumor Tests (d)	P=0.456	P=0.113	P=0.469
Cochran-Armitage Trend Test (d)	P=0.224		
Fisher Exact Tests		P=0.041	P=0.247
<b>Hematopoietic System: Leukemia</b>			
Overall Rates (a)	14/50 (28%)	23/50 (46%)	21/50 (42%)
Adjusted Rates (b)	32.6%	55.6%	49.1%
Terminal Rates (c)	7/35 (20%)	14/32 (44%)	10/31 (32%)
Life Table Tests (d)	P=0.094	P=0.053	P=0.110
Incidental Tumor Tests (d)	P=0.355	P=0.190	P=0.392
Cochran-Armitage Trend Test (d)	P=0.091		
Fisher Exact Tests		P=0.048	P=0.104
<b>Pituitary: Adenoma</b>			
Overall Rates (a)	25/48 (52%)	18/47 (38%)	14/46 (30%)
Adjusted Rates (b)	60.5%	48.9%	43.6%
Terminal Rates (c)	18/34 (53%)	13/31 (42%)	12/30 (40%)
Life Table Tests (d)	P=0.041N	P=0.193N	P=0.052N
Incidental Tumor Tests (d)	P=0.023N	P=0.123N	P=0.036N
Cochran-Armitage Trend Test (d)	P=0.021N		
Fisher Exact Tests		P=0.126N	P=0.027N
<b>Pituitary: Adenoma or Carcinoma</b>			
Overall Rates (a)	25/48 (52%)	20/47 (43%)	14/46 (30%)
Adjusted Rates (b)	60.5%	52.9%	43.6%
Terminal Rates (c)	18/34 (53%)	14/31 (45%)	12/30 (40%)
Life Table Tests (d)	P=0.043N	P=0.314N	P=0.052N
Incidental Tumor Tests (d)	P=0.020N	P=0.200N	P=0.036N
Cochran-Armitage Trend Test (d)	P=0.022N		
Fisher Exact Tests		P=0.234N	P=0.027N
<b>Thyroid: C-Cell Adenoma</b>			
Overall Rates (a)	1/45 (2%)	1/35 (3%)	4/37 (11%)
Adjusted Rates (b)	3.0%	4.8%	16.7%
Terminal Rates (c)	1/33 (3%)	1/21 (5%)	4/24 (17%)
Life Table Tests (d)	P=0.056	P=0.658	P=0.095
Incidental Tumor Tests (d)	P=0.056	P=0.658	P=0.095
Cochran-Armitage Trend Test (d)	P=0.072		
Fisher Exact Tests		P=0.687	P=0.125
<b>Thyroid: C-Cell Carcinoma</b>			
Overall Rates (a)	1/45 (2%)	1/35 (3%)	3/37 (8%)
Adjusted Rates (b)	3.0%	4.8%	10.3%
Terminal Rates (c)	1/33 (3%)	1/21 (5%)	2/24 (8%)
Life Table Tests (d)	P=0.149	P=0.658	P=0.234
Incidental Tumor Tests (d)	P=0.103	P=0.658	P=0.155
Cochran-Armitage Trend Test (d)	P=0.156		
Fisher Exact Tests		P=0.687	P=0.238

**TABLE E2. ANALYSIS OF PRIMARY TUMORS IN FEMALE RATS IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	Chamber Control	200 ppm	400 ppm
<b>Thyroid: C-Cell Adenoma or Carcinoma</b>			
Overall Rates (a)	2/45 (4%)	2/35 (6%)	7/37 (19%)
Adjusted Rates (b)	6.1%	9.5%	26.6%
Terminal Rates (c)	2/33 (6%)	2/21 (10%)	6/24 (25%)
Life Table Tests (d)	P=0.017	P=0.523	P=0.031
Incidental Tumor Tests (d)	P=0.011	P=0.523	P=0.019
Cochran-Armitage Trend Test (d)	P=0.023		
Fisher Exact Tests		P=0.592	P=0.041
<b>Mammary Gland: Fibroadenoma</b>			
Overall Rates (a)	7/50 (14%)	13/50 (26%)	13/50 (26%)
Adjusted Rates (b)	19.2%	36.4%	38.7%
Terminal Rates (c)	6/35 (17%)	10/32 (31%)	11/31 (35%)
Life Table Tests (d)	P=0.058	P=0.080	P=0.067
Incidental Tumor Tests (d)	P=0.061	P=0.081	P=0.059
Cochran-Armitage Trend Test (d)	P=0.092		
Fisher Exact Tests		P=0.105	P=0.105
<b>Uterus: Endometrial Stromal Polyp</b>			
Overall Rates (a)	3/49 (6%)	8/50 (16%)	8/47 (17%)
Adjusted Rates (b)	8.1%	24.1%	21.5%
Terminal Rates (c)	2/35 (6%)	7/32 (22%)	4/31 (13%)
Life Table Tests (d)	P=0.073	P=0.082	P=0.095
Incidental Tumor Tests (d)	P=0.131	P=0.085	P=0.209
Cochran-Armitage Trend Test (d)	P=0.074		
Fisher Exact Tests		P=0.106	P=0.087
<b>Uterus: Endometrial Stromal Sarcoma</b>			
Overall Rates (a)	0/49 (0%)	4/50 (8%)	2/47 (4%)
Adjusted Rates (b)	0.0%	11.5%	6.5%
Terminal Rates (c)	0/35 (0%)	2/32 (6%)	2/31 (6%)
Life Table Tests (d)	P=0.196	P=0.057	P=0.212
Incidental Tumor Tests (d)	P=0.301	P=0.139	P=0.212
Cochran-Armitage Trend Test (d)	P=0.208		
Fisher Exact Tests		P=0.061	P=0.237
<b>Uterus: Endometrial Stromal Polyp or Sarcoma</b>			
Overall Rates (a)	3/49 (6%)	12/50 (24%)	10/47 (21%)
Adjusted Rates (b)	8.1%	34.1%	27.4%
Terminal Rates (c)	2/35 (6%)	9/32 (28%)	6/31 (19%)
Life Table Tests (d)	P=0.031	P=0.010	P=0.034
Incidental Tumor Tests (d)	P=0.077	P=0.019	P=0.079
Cochran-Armitage Trend Test (d)	P=0.032		
Fisher Exact Tests		P=0.013	P=0.029

(a) Number of tumor bearing-animals/number of animals examined at the site

(b) Kaplan-Meier estimated tumor incidences at the end of the study after adjusting for intercurrent mortality

(c) Observed tumor incidence at terminal kill

(d) Beneath the control incidence are the P values associated with the trend test. Beneath the dosed group incidence are the P values corresponding to pairwise comparisons between that dosed group and the controls. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The incidental tumor test regards these lesions as nonfatal. The Cochran-Armitage and Fisher's exact test compare directly the overall incidence rates. A negative trend or lower incidence in a dosed group is indicated by (N).

(e) No P value is presented because no tumors were observed in the 200-ppm and control groups.

**TABLE E3. ANALYSIS OF PRIMARY TUMORS IN MALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE**

	Chamber Control	200 ppm	400 ppm
<b>Lung: Alveolar/Bronchiolar Adenoma</b>			
Overall Rates (a)	14/50 (28%)	12/50 (24%)	8/50 (16%)
Adjusted Rates (b)	31.6%	31.8%	27.6%
Terminal Rates (c)	12/42 (29%)	9/34 (26%)	8/29 (28%)
Life Table Tests (d)	P=0.336N	P=0.553	P=0.373N
Incidental Tumor Tests (d)	P=0.183N	P=0.418N	P=0.339N
Cochran-Armitage Trend Test (d)	P=0.095N		
Fisher Exact Tests		P=0.410N	P=0.114N
<b>Lung: Alveolar/Bronchiolar Adenoma or Carcinoma</b>			
Overall Rates (a)	15/50 (30%)	14/50 (28%)	8/50 (16%)
Adjusted Rates (b)	33.9%	37.2%	27.6%
Terminal Rates (c)	13/42 (31%)	11/34 (32%)	8/29 (28%)
Life Table Tests (d)	P=0.287N	P=0.438	P=0.302N
Incidental Tumor Tests (d)	P=0.150N	P=0.538N	P=0.270N
Cochran-Armitage Trend Test (d)	P=0.066N		
Fisher Exact Tests		P=0.500N	P=0.077N
<b>Hematopoietic System: Malignant Lymphoma, Mixed Type</b>			
Overall Rates (a)	1/50 (2%)	3/50 (6%)	0/50 (0%)
Adjusted Rates (b)	2.4%	8.4%	0.0%
Terminal Rates (c)	1/42 (2%)	2/34 (6%)	0/29 (0%)
Life Table Tests (d)	P=0.481N	P=0.240	P=0.574N
Incidental Tumor Tests (d)	P=0.310N	P=0.352	P=0.574N
Cochran-Armitage Trend Test (d)	P=0.378N		
Fisher Exact Tests		P=0.309	P=0.500N
<b>Hematopoietic System: Lymphoma, All Malignant</b>			
Overall Rates (a)	5/50 (10%)	5/50 (10%)	4/50 (8%)
Adjusted Rates (b)	11.2%	12.7%	9.9%
Terminal Rates (c)	3/42 (7%)	2/34 (6%)	0/29 (0%)
Life Table Tests (d)	P=0.556N	P=0.523	P=0.621N
Incidental Tumor Tests (d)	P=0.215N	P=0.435N	P=0.316N
Cochran-Armitage Trend Test (d)	P=0.432N		
Fisher Exact Tests		P=0.630	P=0.500N
<b>Hematopoietic System: Lymphoma or Leukemia</b>			
Overall Rates (a)	6/50 (12%)	5/50 (10%)	4/50 (8%)
Adjusted Rates (b)	13.2%	12.7%	9.9%
Terminal Rates (c)	3/42 (7%)	2/34 (6%)	0/29 (0%)
Life Table Tests (d)	P=0.429N	P=0.605N	P=0.490N
Incidental Tumor Tests (d)	P=0.129N	P=0.284N	P=0.208N
Cochran-Armitage Trend Test (d)	P=0.309N		
Fisher Exact Tests		P=0.500N	P=0.370N
<b>Nasal Cavity: Hemangioma</b>			
Overall Rates (a)	0/50 (0%)	0/50 (0%)	5/50 (10%)
Adjusted Rates (b)	0.0%	0.0%	17.2%
Terminal Rates (c)	0/42 (0%)	0/34 (0%)	5/29 (17%)
Life Table Tests (d)	P=0.002	(e)	P=0.011
Incidental Tumor Tests (d)	P=0.002	(e)	P=0.011
Cochran-Armitage Trend Test (d)	P=0.006		
Fisher Exact Tests		(e)	P=0.028
<b>Nasal Cavity: Hemangiosarcoma</b>			
Overall Rates (a)	0/50 (0%)	0/50 (0%)	5/50 (10%)
Adjusted Rates (b)	0.0%	0.0%	15.6%
Terminal Rates (c)	0/42 (0%)	0/34 (0%)	4/29 (14%)
Life Table Tests (d)	P=0.003	(e)	P=0.015
Incidental Tumor Tests (d)	P=0.004	(e)	P=0.021
Cochran-Armitage Trend Test (d)	P=0.006		
Fisher Exact Tests		(e)	P=0.028

TABLE E3. ANALYSIS OF PRIMARY TUMORS IN MALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)

	Chamber Control	200 ppm	400 ppm
<b>Nasal Cavity: Hemangioma or Hemangiosarcoma</b>			
Overall Rates (a)	0/50 (0%)	0/50 (0%)	10/50 (20%)
Adjusted Rates (b)	0.0%	0.0%	32.4%
Terminal Rates (c)	0/42 (0%)	0/34 (0%)	9/29 (31%)
Life Table Tests (d)	P<0.001	(e)	P<0.001
Incidental Tumor Tests (d)	P<0.001	(e)	P<0.001
Cochran-Armitage Trend Test (d)	P<0.001		
Fisher Exact Tests		(e)	P=0.001
<b>Circulatory System: Hemangiosarcoma</b>			
Overall Rates (a)	2/50 (4%)	2/50 (4%)	5/50 (10%)
Adjusted Rates (b)	4.8%	5.5%	15.6%
Terminal Rates (c)	2/42 (5%)	1/34 (3%)	4/29 (14%)
Life Table Tests (d)	P=0.078	P=0.624	P=0.110
Incidental Tumor Tests (d)	P=0.141	P=0.648N	P=0.142
Cochran-Armitage Trend Test (d)	P=0.146		
Fisher Exact Tests		P=0.691	P=0.218
<b>Circulatory System: Hemangioma or Hemangiosarcoma</b>			
Overall Rates (a)	2/50 (4%)	2/50 (4%)	10/50 (20%)
Adjusted Rates (b)	4.8%	5.5%	32.4%
Terminal Rates (c)	2/42 (5%)	1/34 (3%)	9/29 (31%)
Life Table Tests (d)	P<0.001	P=0.624	P=0.002
Incidental Tumor Tests (d)	P=0.002	P=0.648N	P=0.003
Cochran-Armitage Trend Test (d)	P=0.005		
Fisher Exact Tests		P=0.691	P=0.014
<b>Liver: Adenoma</b>			
Overall Rates (a)	8/50 (16%)	6/50 (12%)	5/50 (10%)
Adjusted Rates (b)	18.6%	16.7%	15.9%
Terminal Rates (c)	7/42 (17%)	5/34 (15%)	4/29 (14%)
Life Table Tests (d)	P=0.454N	P=0.546N	P=0.522N
Incidental Tumor Tests (d)	P=0.297N	P=0.434N	P=0.298N
Cochran-Armitage Trend Test (d)	P=0.226N		
Fisher Exact Tests		P=0.387N	P=0.277N
<b>Liver: Carcinoma</b>			
Overall Rates (a)	6/50 (12%)	10/50 (20%)	5/50 (10%)
Adjusted Rates (b)	13.5%	24.4%	14.5%
Terminal Rates (c)	4/42 (10%)	5/34 (15%)	3/29 (10%)
Life Table Tests (d)	P=0.475	P=0.138	P=0.575
Incidental Tumor Tests (d)	P=0.320N	P=0.348	P=0.532N
Cochran-Armitage Trend Test (d)	P=0.443N		
Fisher Exact Tests		P=0.207	P=0.500N
<b>Liver: Adenoma or Carcinoma</b>			
Overall Rates (a)	14/50 (28%)	16/50 (32%)	9/50 (18%)
Adjusted Rates (b)	31.0%	39.0%	26.3%
Terminal Rates (c)	11/42 (26%)	10/34 (29%)	6/29 (21%)
Life Table Tests (d)	P=0.433N	P=0.231	P=0.444N
Incidental Tumor Tests (d)	P=0.124N	P=0.516	P=0.184N
Cochran-Armitage Trend Test (d)	P=0.153N		
Fisher Exact Tests		P=0.414	P=0.171N

(a) Number of tumor-bearing animals/number of animals examined at the site

(b) Kaplan-Meier estimated tumor incidences at the end of the study after adjusting for intercurrent mortality

(c) Observed tumor incidence at terminal kill

(d) Beneath the control incidence are the P values associated with the trend test. Beneath the dosed group incidence are the P values corresponding to pairwise comparisons between that dosed group and the controls. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The incidental tumor test regards these lesions as nonfatal. The Cochran-Armitage and Fisher's exact test compare directly the overall incidence rates. A negative trend or lower incidence in a dosed group is indicated by (N).

(e) No P value is presented because no tumors were observed in the 200-ppm and control groups.

**TABLE E4. ANALYSIS OF PRIMARY TUMORS IN FEMALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE**

	Chamber Control	200 ppm	400 ppm
<b>Lung: Alveolar/Bronchiolar Adenoma</b>			
Overall Rates (a)	4/50 (8%)	7/50 (14%)	6/50 (12%)
Adjusted Rates (b)	10.1%	20.9%	43.5%
Terminal Rates (c)	3/38 (8%)	4/29 (14%)	3/10 (30%)
Life Table Tests (d)	P=0.007	P=0.160	P=0.009
Incidental Tumor Tests (d)	P=0.134	P=0.322	P=0.141
Cochran-Armitage Trend Test (d)	P=0.318		
Fisher Exact Tests		P=0.262	P=0.370
<b>Hematopoietic System: Malignant Lymphoma, Histiocytic Type</b>			
Overall Rates (a)	1/50 (2%)	3/50 (6%)	0/50 (0%)
Adjusted Rates (b)	2.6%	8.2%	0.0%
Terminal Rates (c)	1/38 (3%)	0/29 (0%)	0/10 (0%)
Life Table Tests (d)	P=0.601	P=0.251	P=0.764N
Incidental Tumor Tests (d)	P=0.223N	P=0.504	P=0.764N
Cochran-Armitage Trend Test (d)	P=0.378N		
Fisher Exact Tests		P=0.309	P=0.500N
<b>Hematopoietic System: Malignant Lymphoma, Mixed Type</b>			
Overall Rates (a)	4/50 (8%)	4/50 (8%)	1/50 (2%)
Adjusted Rates (b)	9.9%	9.9%	3.6%
Terminal Rates (c)	2/38 (5%)	1/29 (3%)	0/10 (0%)
Life Table Tests (d)	P=0.448N	P=0.554	P=0.566N
Incidental Tumor Tests (d)	P=0.048N	P=0.420N	P=0.105N
Cochran-Armitage Trend Test (d)	P=0.146N		
Fisher Exact Tests		P=0.643N	P=0.181N
<b>Hematopoietic System: Lymphoma, All Malignant</b>			
Overall Rates (a)	12/50 (24%)	10/50 (20%)	7/50 (14%)
Adjusted Rates (b)	26.5%	25.2%	29.4%
Terminal Rates (c)	5/38 (13%)	2/29 (7%)	0/10 (0%)
Life Table Tests (d)	P=0.336	P=0.566N	P=0.359
Incidental Tumor Tests (d)	P=0.003N	P=0.047N	P=0.006N
Cochran-Armitage Trend Test (d)	P=0.127N		
Fisher Exact Tests		P=0.405N	P=0.154N
<b>Nasal Cavity: Hemangioma</b>			
Overall Rates (a)	0/50 (0%)	0/50 (0%)	3/50 (6%)
Adjusted Rates (b)	0.0%	0.0%	20.7%
Terminal Rates (c)	0/38 (0%)	0/29 (0%)	0/10 (0%)
Life Table Tests (d)	P=0.004	(e)	P=0.012
Incidental Tumor Tests (d)	P=0.091	(e)	P=0.336
Cochran-Armitage Trend Test (d)	P=0.037		
Fisher Exact Tests		(e)	P=0.121
<b>Nasal Cavity: Hemangioma or Hemangiosarcoma</b>			
Overall Rates (a)	0/50 (0%)	0/50 (0%)	5/50 (10%)
Adjusted Rates (b)	0.0%	0.0%	32.2%
Terminal Rates (c)	0/38 (0%)	0/29 (0%)	1/10 (10%)
Life Table Tests (d)	P<0.001	(e)	P<0.001
Incidental Tumor Tests (d)	P=0.008	(e)	P=0.062
Cochran-Armitage Trend Test (d)	P=0.006		
Fisher Exact Tests		(e)	P=0.028
<b>Circulatory System: Hemangioma</b>			
Overall Rates (a)	1/50 (2%)	0/50 (0%)	4/50 (8%)
Adjusted Rates (b)	2.6%	0.0%	24.0%
Terminal Rates (c)	1/38 (3%)	0/29 (0%)	0/10 (0%)
Life Table Tests (d)	P=0.008	P=0.554N	P=0.014
Incidental Tumor Tests (d)	P=0.153	P=0.554N	P=0.366
Cochran-Armitage Trend Test (d)	P=0.082		
Fisher Exact Tests		P=0.500N	P=0.181

**TABLE E4. ANALYSIS OF PRIMARY TUMORS IN FEMALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	Chamber Control	200 ppm	400 ppm
<b>Circulatory System: Hemangiosarcoma</b>			
Overall Rates (a)	0/50 (0%)	1/50 (2%)	3/50 (6%)
Adjusted Rates (b)	0.0%	3.4%	16.6%
Terminal Rates (c)	0/38 (0%)	1/29 (3%)	1/10 (10%)
Life Table Tests (d)	P=0.009	P=0.446	P=0.030
Incidental Tumor Tests (d)	P=0.050	P=0.446	P=0.176
Cochran-Armitage Trend Test (d)	P=0.060		
Fisher Exact Tests		P=0.500	P=0.121
<b>Circulatory System: Hemangioma or Hemangiosarcoma</b>			
Overall Rates (a)	1/50 (2%)	1/50 (2%)	7/50 (14%)
Adjusted Rates (b)	2.6%	3.4%	36.7%
Terminal Rates (c)	1/38 (3%)	1/29 (3%)	1/10 (10%)
Life Table Tests (d)	P<0.001	P=0.701	P<0.001
Incidental Tumor Tests (d)	P=0.017	P=0.701	P=0.096
Cochran-Armitage Trend Test (d)	P=0.010		
Fisher Exact Tests		P=0.753	P=0.030
<b>Liver: Adenoma</b>			
Overall Rates (a)	1/50 (2%)	3/50 (6%)	2/49 (4%)
Adjusted Rates (b)	2.6%	10.3%	13.3%
Terminal Rates (c)	1/38 (3%)	3/29 (10%)	1/10 (10%)
Life Table Tests (d)	P=0.074	P=0.214	P=0.171
Incidental Tumor Tests (d)	P=0.125	P=0.214	P=0.332
Cochran-Armitage Trend Test (d)	P=0.391		
Fisher Exact Tests		P=0.309	P=0.492
<b>Liver: Carcinoma</b>			
Overall Rates (a)	2/50 (4%)	4/50 (8%)	1/49 (2%)
Adjusted Rates (b)	5.1%	9.8%	10.0%
Terminal Rates (c)	1/38 (3%)	1/29 (3%)	1/10 (10%)
Life Table Tests (d)	P=0.439	P=0.282	P=0.569
Incidental Tumor Tests (d)	P=0.331N	P=0.548	P=0.687N
Cochran-Armitage Trend Test (d)	P=0.415N		
Fisher Exact Tests		P=0.339	P=0.508N
<b>Liver: Adenoma or Carcinoma</b>			
Overall Rates (a)	3/50 (6%)	7/50 (14%)	3/49 (6%)
Adjusted Rates (b)	7.7%	19.5%	23.0%
Terminal Rates (c)	2/38 (5%)	4/29 (14%)	2/10 (20%)
Life Table Tests (d)	P=0.099	P=0.100	P=0.140
Incidental Tumor Tests (d)	P=0.397	P=0.217	P=0.438
Cochran-Armitage Trend Test (d)	P=0.558		
Fisher Exact Tests		P=0.159	P=0.651
<b>Pituitary: Adenoma</b>			
Overall Rates (a)	8/46 (17%)	6/48 (13%)	1/38 (3%)
Adjusted Rates (b)	20.9%	19.4%	4.8%
Terminal Rates (c)	7/37 (19%)	5/29 (17%)	0/10 (0%)
Life Table Tests (d)	P=0.271N	P=0.561N	P=0.298N
Incidental Tumor Tests (d)	P=0.125N	P=0.475N	P=0.124N
Cochran-Armitage Trend Test (d)	P=0.027N		
Fisher Exact Tests		P=0.354N	P=0.030N
<b>Pituitary: Adenoma or Carcinoma</b>			
Overall Rates (a)	9/46 (20%)	6/48 (13%)	1/38 (3%)
Adjusted Rates (b)	23.5%	19.4%	4.8%
Terminal Rates (c)	8/37 (22%)	5/29 (17%)	0/10 (0%)
Life Table Tests (d)	P=0.201N	P=0.461N	P=0.249N
Incidental Tumor Tests (d)	P=0.085N	P=0.377N	P=0.100N
Cochran-Armitage Trend Test (d)	P=0.014N		
Fisher Exact Tests		P=0.257N	P=0.017N



**TABLE E4. ANALYSIS OF PRIMARY TUMORS IN FEMALE MICE IN THE TWO-YEAR INHALATION STUDY OF PROPYLENE OXIDE (Continued)**

	Chamber Control	200 ppm	400 ppm
<b>Mammary Gland: Adenosquamous Carcinoma</b>			
Overall Rates (a)	0/50 (0%)	0/50 (0%)	3/50 (6%)
Adjusted Rates (b)	0.0%	0.0%	14.5%
Terminal Rates (c)	0/38 (0%)	0/29 (0%)	1/10 (10%)
Life Table Tests (d)	P=0.013	(e)	P=0.047
Incidental Tumor Tests (d)	P=0.079	(e)	P=0.236
Cochran-Armitage Trend Test (d)	P=0.037		
Fisher Exact Tests		(e)	P=0.121
<b>Mammary Gland: All Adenocarcinoma</b>			
Overall Rates (a)	0/50 (0%)	3/50 (6%)	3/50 (6%)
Adjusted Rates (b)	0.0%	8.1%	14.5%
Terminal Rates (c)	0/38 (0%)	1/29 (3%)	1/10 (10%)
Life Table Tests (d)	P=0.025	P=0.105	P=0.047
Incidental Tumor Tests (d)	P=0.362	P=0.290	P=0.236
Cochran-Armitage Trend Test (d)	P=0.101		
Fisher Exact Tests		P=0.121	P=0.121

(a) Number of tumor-bearing animals/number of animals examined at the site

(b) Kaplan-Meier estimated tumor incidences at the end of the study after adjusting for intercurrent mortality

(c) Observed tumor incidence at terminal kill

(d) Beneath the control incidence are the P values associated with the trend test. Beneath the dosed group incidence are the P values corresponding to pairwise comparisons between that dosed group and the controls. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The incidental tumor test regards these lesions as nonfatal. The Cochran-Armitage and Fisher's exact test compare directly the overall incidence rates. A negative trend or lower incidence in a dosed group is indicated by (N).

(e) No P value is presented because no tumors were observed in the 200-ppm and control groups.



## **APPENDIX F**

### **HISTORICAL INCIDENCES OF TUMORS IN F344/N RATS AND B6C3F<sub>1</sub> MICE RECEIVING NO TREATMENT**

**TABLE F1. HISTORICAL INCIDENCE OF INTEGUMENTARY TUMORS IN MALE F344/N RATS RECEIVING NO TREATMENT (a)**

Laboratory	Keratoacanthoma (Skin)	Keratoacanthoma (Subcutaneous)
Battelle Columbus	0/240 (0%)	1/240 (<1%)
Hazleton	2/99 (2%)	0/99 (0%)
Litton	0/200 (0%)	1/200 (1%)
Mason	1/549 (<1%)	0/549 (0%)
Southern	1/389 (<1%)	1/389 (<1%)
TOTAL SD (b)	4/1,477 (0.3%) 0.90%	3/1,477 (0.2%) 0.62%
<b>Overall historical range (c)</b>		
High	2/49	1/50
Low	0/90	0/90

(a) Data as of June 28, 1982, for studies of at least 104 weeks

(b) Standard deviation

(c) Range and SD are presented for groups of 35 or more animals

**TABLE F2. HISTORICAL INCIDENCE OF NASAL CAVITY TUMORS IN MALE F344/N RATS RECEIVING NO TREATMENT (a)**

Laboratory	At Risk	Number	Diagnosis
Battelle Columbus	240	0	
Hazleton	99	0	
Litton	200	0	
Mason	549	1	Nose, NOS: squamous cell papilloma
Southern	389	0	
TOTAL	1,477	1	

(a) Data as of June 28, 1982, for studies of at least 104 weeks

**TABLE F3. HISTORICAL INCIDENCE OF NASAL CAVITY TUMORS IN FEMALE F344/N RATS RECEIVING NO TREATMENT (a)**

Laboratory	At Risk	Number	Diagnosis
Battelle Columbus	238	0	
Hazleton	100	1	Squamous cell carcinoma
Litton	199	1	Nose, NOS: papilloma, NOS
Mason	597	1	Nose, NOS: squamous cell papilloma
Southern	389	0	
TOTAL	1,523	3	

(a) Data as of June 28, 1982, for studies of at least 104 weeks

**TABLE F4. HISTORICAL INCIDENCE OF CIRCULATORY SYSTEM TUMORS IN MALE F344/N RATS RECEIVING NO TREATMENT (a)**

Laboratory	Hemangioma	Hemangiosarcoma
Battelle Columbus	0/240 (0%)	0/240 (0%)
Hazleton	0/99 (0%)	1/99 (1%)
Litton	0/200 (0%)	(b) 0/200 (0%)
Mason	2/549 (<1%)	(b) 4/549 (1%)
Southern	0/388(0%)	1/388 (<1%)
TOTAL SD (c)	2/1,476 (0.1%) 0.52%	6/1,476 (0.4%) 0.98%
<b>Overall historical range (d)</b>		
High	1/50	2/50
Low	0/90	0/90

(a) Data as of June 28, 1982, for studies of at least 104 weeks

(b) In addition, one angiosarcoma was present.

(c) Standard deviation

(d) Range and SD are presented for groups of 35 or more animals.

**TABLE F5. HISTORICAL INCIDENCE OF THYROID GLAND TUMORS IN FEMALE F344/N RATS RECEIVING NO TREATMENT (a)**

Laboratory	C-Cell Adenoma	C-Cell Carcinoma	C-Cell Adenoma or Carcinoma
Battelle Columbus	2/232 (1%)	9/232 (4%)	11/232 (5%)
Hazleton	4/98 (4%)	1/98 (1%)	5/98 (5%)
Litton	9/176 (5%)	5/176 (3%)	14/176 (8%)
Mason	18/580 (3%)	22/580 (4%)	40/580 (7%)
Southern	37/386 (10%)	17/386 (4%)	52/386 (13%)
TOTAL	70/1,472 (4.8%)	54/1,472 (3.7%)	122/1,472 (8.3%)
SD (b)	3.85%	2.98%	4.34%
<b>Overall historical range (c)</b>			
High	6/50	5/50	9/50
Low	0/86	0/50	1/49

(a) Data as of June 28, 1982, for studies of at least 104 weeks  
 (b) Standard deviation  
 (c) Range and SD are presented for groups of 35 or more animals.

**TABLE F6. HISTORICAL INCIDENCE OF UTERINE TUMORS IN FEMALE F344/N RATS RECEIVING NO TREATMENT (a)**

Laboratory	Endometrial Stromal Polyp	Endometrial Stromal Sarcoma
Battelle Columbus	52/236 (22%)	0/236 (0%)
Hazleton	11/98 (11%)	1/98 (1%)
Litton	52/194 (27%)	0/194 (0%)
Mason	123/586 (21%)	3/586 (1%)
Southern	61/388 (16%)	3/388 (1%)
TOTAL	299/1,502 (19.9%)	7/1502 (0.5%)
SD (b)	8.47%	0.88%
<b>Overall historical range (c)</b>		
High	18/49	1/48
Low	2/47	0/87

(a) Data as of June 28, 1982, for studies of at least 104 weeks  
 (b) Standard deviation  
 (c) Range and SD are presented for groups of 35 or more animals.

**TABLE F7. HISTORICAL INCIDENCE OF MAMMARY GLAND TUMORS IN FEMALE B6C3F<sub>1</sub> MICE RECEIVING NO TREATMENT (a)**

Laboratory	Adenocarcinoma (NOS)	Papillary Adenocarcinoma	Adenosquamous Carcinoma
Battelle Columbus	1/300 ( 1%)	0/300 (0%)	0/300 (0%)
Hazleton	3/100 (3%)	0/100 (0%)	0/100 (0%)
IIT Research	0/74 (0%)	0/74 (0%)	0/74 (0%)
Litton	7/200 (4%)	0/200 (0%)	0/200 (0%)
Mason	7/598 (1%)	1/598 ( 1%)	0/598 (0%)
Southern	5/396 (1%)	0/396 (0%)	1/396 ( 1%)
TOTAL	23/1,668(1.4%)	1/1,668 (0.1%)	1/1,668(0.1%)
SD (b)	2.40%	0.35%	0.37%
<b>Overall historical range (c)</b>			
High	6/50	1/50	1/48
Low	0/50	0/50	0/50

(a) Data as of June 28, 1982, for studies of at least 104 weeks

(b) Standard deviation

(c) Range and SD are presented for groups of 35 or more animals.

**TABLE F8. HISTORICAL INCIDENCE OF CIRCULATORY SYSTEM TUMORS IN MALE B6C3F<sub>1</sub> MICE RECEIVING NO TREATMENT (a)**

	Hemangioma	Hemangiosaroma	Hemangioma or Hemangiosarcoma
<b>Historical Incidence at Battelle Northwest</b>			
Propylene oxide	0/50	2/50	2/50
Propylene	0/50	0/50	0/50
TOTAL	0/100 (0.0%)	2/100 (2.0%)	2/100 (2.0%)
<b>Overall Historical Incidence</b>			
TOTAL	34/2,343 (1.5%)	64/2,343 (2.7%)	97/2,343 (4.1%)
SD (b)	2.45%	2.57%	3.92%
<b>Range (c)</b>			
High	7/50	5/49	10/50
Low	0/50	0/50	0/50

(a) Data as of March 16, 1983, for studies of at least 104 weeks

(b) Standard deviation

(c) Range and SD are presented for groups of 35 or more animals.

**TABLE F9. HISTORICAL INCIDENCE OF CIRCULATORY SYSTEM TUMORS IN FEMALE B6C3F<sub>1</sub> MICE RECEIVING NO TREATMENT (a)**

	<b>Hemangioma</b>	<b>Hemangiosaroma</b>	<b>Hemangioma or Hemangiosarcoma</b>
<b>Historical Incidence at Battelle Northwest</b>			
Propylene oxide	1/50	0/50	1/50
Propylene	0/50	0/50	0/50
TOTAL	1/100 (1.0%)	0/100 (0.0%)	1/100 (1.0%)
<b>Overall Historical Incidence</b>			
TOTAL	39/2,486 (1.6%)	48/2,486 (1.9%)	87/2,486 (3.5%)
SD (b)	1.88%	2.33%	2.61%
<b>Range (c)</b>			
High	3/47	4/50	5/49
Low	0/50	0/50	0/50

(a) Data as of March 16, 1983, for studies of at least 104 weeks

(b) Standard deviation

(c) Range and SD are presented for groups of 35 or more animals.



**APPENDIX G**

**CHEMICAL CHARACTERIZATION**

**OF PROPYLENE OXIDE**

# APPENDIX G. CHEMICAL CHARACTERIZATION

---

## I. Identity and Purity Determinations Performed by the Analytical Chemistry Laboratory

### A. Lot No. UC 5/10/76

<b>1. Boiling Point:</b>	<u>Determined</u>	<u>Literature Values</u>
	34.7° -36.5° C at 758 mm Hg (Dupont 900 DTA)	35° C (Henry, 1903)
<b>2. Water Analysis (Karl Fischer):</b>		
	0.13% ± 0.02 (δ)%	
<b>3. Elemental Analysis:</b>		
Element	C	H
Theory	62.04	10.41
Determined	61.96 62.04	10.20 10.34
<b>4. Index of Refraction:</b>	<u>Determined</u>	<u>Literature Values</u>
	$n_D^{10}$ : 1.3695	$n_D^{20}$ : 1.3667 (Zimakov & Sokolova, 1953)
<b>5. Spectral Data</b>		
<b>a. Infrared</b>	<u>Determined</u>	<u>Literature Values</u>
Instrument:	Beckman IR-12	
Cell:	0.015 mm liquid cell, sodium chloride windows	
Results:	See Figure 5	Consistent with literature spectrum (Sadler Standard Spectra)
<b>b. Ultraviolet/Visible</b>	<u>Determined</u>	<u>Literature Values</u>
Instrument:	Cary 118	
Solvent:	Methanol	
Concentration:	10 mg/ml	
Results:	No absorbance between 215 and 350 nm or between 350 and 800 nm	No literature reference found




FIGURE 5. INFRARED ABSORPTION SPECTRUM OF PROPYLENE OXIDE (LOT NO. UC 5/10/76)

# APPENDIX G. CHEMICAL CHARACTERIZATION

---

## c. Nuclear Magnetic Resonance

	<u>Determined</u>	<u>Literature Values</u>
<b>Instrument:</b>	Varian HA-100	
<b>Solvent:</b>	Neat, tetramethylsilane added	
<b>Assignments:</b>	See Figure 6	Consistent with literature spectra (Elleman et al., 1965; Sadtler Standard Spectra)
<b>Chemical Shift (<math>\delta</math>):</b>	<b>Coupling Constant:</b>	
a -- d, 1.20 ppm	$J_{a-d} = 5 \text{ Hz}$	
b -- dd, 2.26 ppm	$J_{b-c} = 5.5 \text{ Hz}, J_{b-d} = 2.6 \text{ Hz}$	
c -- m, 2.58 ppm	$J_{d-c} \sim 4 \text{ Hz}$	
d -- m, 2.72-2.98 ppm		
<b>Integration Ratios:</b>		
a -- 2.61		
b -- 1.16		
c -- 1.13		
d -- 1.10		

## 6. Gas Chromatography

**Instrument:** Tracor MT 220  
**Detector:** Flame ionization  
**Inlet temperature:** 200° C  
**Detector temperature:** 270° C

### a. System 1

**Column:** Chromosorb 102 on 100/120, 1.8 m x 4 mm ID, glass  
**Oven temperature program:** 5 min at 50° C, then 50°-200° C at 10° C/min  
**Results:** Single homogeneous peak, retention time: 15.1 min

### b. System 2

**Column:** 20% SP 2100/0.1% Carbowax 1500 on 100/120 Supelcoport, 1.8 m x 4 mm ID, glass  
**Oven temperature program:** 5 min at 50° C, then 50°-150° C at 10° C/min  
**Results:** Single homogeneous peak, retention time: 1.8 min




FIGURE 6. NUCLEAR MAGNETIC RESONANCE SPECTRUM OF PROPYLENE OXIDE (LOT NO. UC 5/10/76)

# APPENDIX G. CHEMICAL CHARACTERIZATION

---

## B. Lot No. 6477-22

### 1. Water Analysis (Karl Fischer):

0.15% ± 0.002 (δ)%

### 2. Elemental Analysis:

Element	C	H
Theory	62.04	10.41
Determined	62.06 62.25	10.55 10.40

### 3. Spectral Data

#### a. Infrared

#### Determined

#### Literature Values

**Instrument:**

Beckman IR-12

**Cell:**

Silver chloride  
0.025 mm pathlength

**Results:**

See Figure 7

Consistent with literature  
spectrum

#### b. Ultraviolet/Visible

#### Determined

#### Literature Values

**Instrument:**

Cary 118

**Results:**

A 10% (v/v) solution in  
hexane had no absorbance  
in either the visible  
(350-800 nm) or ultraviolet  
(210-350 nm) range

No literature reference  
found

#### c. Nuclear Magnetic Resonance

#### Determined

#### Literature Values

**Instrument:**

Varian EM360-A

**Solvent:**

Neat, tetramethyl-  
silane internal standard

**Assignments:**

See Figure 8

Consistent with literature  
spectrum (Aldrich Library)




FIGURE 7. INFRARED ABSORPTION SPECTRUM OF PROPYLENE OXIDE (LOT NO. 6477-22)




FIGURE 8. NUCLEAR MAGNETIC RESONANCE SPECTRUM OF PROPYLENE OXIDE (LOT NO. 6477-22)



# APPENDIX G. CHEMICAL CHARACTERIZATION

## Chemical Shift ( $\delta$ ):

a -- d, 1.25 ppm  
b -- dd, 2.29 ppm  
c -- dd, 2.60 ppm  
d -- m, 2.70-3.00 ppm

## Coupling Constant:

$J_{a-d} = 5$  Hz  
 $J_{b-c} = 5.3$  Hz,  
 $J_{b-d} = 2.4$  Hz  
 $J_{c-d} = 4$  Hz

## Integration Ratios:

a --  $52/17.33 = 3.00$   
b --  $17/17.33 = 0.98$   
b --  $17/17.33 = 0.98$   
b --  $18/17.33 = 1.04$

## 4. Gas Chromatography

**Instrument:** Perkin Elmer 3920

**Detector:** Flame ionization

**Inlet temperature:** 120° C

**Detector temperature:** 270° C

**Carrier gas:** Nitrogen

### a. System 1

**Column:** 20% SP 2100/0.1% Carbowax 1500 on 100/120 Supelcoport,  
1.8 m  $\times$  4 mm ID, glass

**Carrier flow rate:** 25 ml/min

**Oven temperature program:** 4 min at 30° C, then 30°-150° C at 8° C/min

**Samples injected:** 0.6  $\mu$ l of propylene oxide (neat) to detect impurities; 1.5  $\mu$ l of a 1.0% and 0.5% (v/v) solution in isooctane to establish detector response linearity

**Results:** A major peak, retention time: 2.7 min; no impurities >0.01%

### b. System 2

**Column:** Results: Carbowax C on 80/100/0.1% SP 2100, 1.8 m  $\times$  4 mm ID, glass

**Carrier flow rate:** 50 ml/min

**Oven temperature program:** 4 min at 30° C, then 30°-200° C at 32° C/min

**Samples injected:** 0.6  $\mu$ l of propylene oxide (neat) to detect impurities; 3 and 1.5  $\mu$ l of a 1% (w/v) solution in isooctane to establish detector response linearity

**Results:** A major peak, retention time: 2.0 min; no impurities >0.01%

# APPENDIX G. CHEMICAL CHARACTERIZATION

## II. Test Chemical Stability Studies Performed at the Testing Laboratory

### Analytical Methods

1. **Purity determination:** Gas chromatographic analysis of the chemical was performed on a HP 5830A using the following conditions:

**Column:** Porapak QS 80/100 mesh, 2.35 m × 2 mm ID, glass

**Column oven temperature:** 125° C, isothermal

**Injector temperature:** 200° C

**Detector:** Flame ionization

**Detector temperature:** 275° C

**Carrier:** Helium

**Carrier flow rate:** 20 ml/min

The percent purity (percentage of total peak area contributed by propylene oxide) for each analysis is summarized in Table G1:

TABLE G1. ANALYSIS OF PROPYLENE OXIDE (Lot No. 6477-22)

Sample	Date Analyzed	Percent Purity (a)
Exposure	7/18/79	99.99
Reference	12/10/79	99.99
Exposure	12/10/79	99.99
Reference	5/02/80	99.99
Exposure	5/02/80	100.00
Reference	9/02/80	100.00
Exposure	9/02/80	100.00
Reference	12/31/80	99.99
Exposure	12/31/80	100.00
Reference	5/05/81	100.00
Exposure	5/05/81	99.99
Reference	7/29/81	99.99
Exposure	7/29/81	100.00
Reference	1/13/82	99.99
Exposure	1/13/82	99.99

(a) The purity value is derived from the percentage of the total peak area contributed by propylene oxide.

2. **Identity Determination:** The infrared absorption spectra were obtained on the neat material between NaCl plates using a Beckman Acculab 6. All spectra were consistent with those of Midwest Research Institute.

3. **Conclusion:** No notable degradation occurred throughout the 2-year studies.

## **APPENDIX H**

# **GENERATION AND MEASUREMENT OF CHAMBER CONCENTRATIONS**

## APPENDIX H. GENERATION AND MEASUREMENT

---

**I. Generation System in the 2-year Studies:** The liquid to be vaporized was contained in a 1.6-liter stainless steel reservoir that was housed in a vapor hood within the exposure room. The liquid was pumped from this reservoir to a vaporizer by a stable micrometering pump with adjustable drift-free pump rates ranging from 0.03 to 20 ml/min. Four pump/vaporizer systems were fed from the single reservoir by incorporating a manifold liquid distribution system. Clear Teflon® tubes of measured volume, preceded by a three-way valve, were attached just upstream of each pump to facilitate measurements of liquid flow rate to each vapor generator. This was accomplished by momentarily switching the three-way valve from the run to the test position. A small bubble of air was pulled by the pump from the room through the valve and into the clear tube. The progress of this bubble from one end of the tube to the other (calibrated volume) was timed with a stopwatch. Flow rate was calculated by dividing the volume by the time. The volume of the tubes was chosen so that the error due to start and stop time ambiguity (introduced by the pulsatile nature of the pumps) was less than 5%. Measurement of this flow, along with measurement of chamber dilution air flow, was used to calculate expected concentration of vapor in the chamber. This provided a method, secondary to that of the gas chromatograph, of monitoring concentration. Three-way valves and lines returning from the vaporizer to a beaker in the vapor hood facilitated filling the distribution system (Figure 9).

The vaporizer (Figure 10) comprises a stainless steel cylinder covered with a glass fiber wick from which the liquid was vaporized. This wick could be inexpensively and quickly replaced if necessitated by residue buildup. No residue was detectable on the wicks used for propylene oxide; nonetheless, wicks were replaced at least every 2 months. The vapor pressure of propylene oxide was sufficient at room temperature to generate the desired concentrations. Each cylindrical vaporizer was positioned in the fresh air duct leading directly into the exposure chamber to minimize material loss due to condensation on duct walls.




FIGURE 9. PROPYLENE OXIDE VAPOR GENERATION SYSTEM





FIGURE 10. CUTAWAY DRAWING OF THE LIQUID VAPOR GENERATOR

**II. Vapor Concentration Uniformity in the Chamber:** Uniformity of vapor concentration in the exposure chambers was measured periodically throughout the study. The vapor concentration was measured using a portable photoionization detector (PID) at 12 positions (2 positions, 1 at the front (F) and 1 at the back (B), for each of the six animal cage units per chamber). The sample point was just above and about 10 cm in from the front or back center of each cage unit (Figure 11). The data, normalized to the average concentration at all 12 sample positions for each chamber, are presented in Table H1. In no case was a sample position in a chamber found to be out of balance by more than  $\pm 10\%$  of the mean values of concentration of all sample positions within the chamber.



**FIGURE 11. SCHEMATIC FRONT VIEW OF CHAMBER  
SHOWING APPROXIMATE SAMPLE SITES  
(1F, 1B, 2F, 2B, ETC.)**

**TABLE H1. PROPYLENE OXIDE VAPOR CONCENTRATION UNIFORMITY TEST RESULTS**

Sample Location	Test Results (a)					
<b>RATS</b>						
	<b>400 ppm (b)</b>	<b>400 ppm(c)</b>	<b>200 ppm (d)</b>	<b>400 ppm (d)</b>		
1F	99	99	105	92		
1B	(e)	98	102	101		
2F	99	103	100	103		
2B	(e)	103	96	106		
3F	100	98	96	106		
3B	(e)	97	96	110		
4F	100	109	105	99		
4B	(e)	103	105	109		
5F	99	93	102	92		
5B	(e)	95	95	92		
6F	102	108	104	92		
6B	(e)	95	96	95		
Mean ± standard deviation	100 ± 1	100 ± 5	100 ± 4	100 ± 7		
	<b>200 ppm (f)</b>	<b>400 ppm (f)</b>	<b>200 ppm (g)</b>	<b>400 ppm (g)</b>		
1F	106	99	102	98		
1B	96	99	110	102		
2F	101	108	96	98		
2B	96	110	101	99		
3F	106	94	96	96		
3B	96	96	102	98		
4F	101	99	92	100		
4B	96	99	98	101		
5F	106	96	104	96		
5B	96	94	103	98		
6F	101	103	94	108		
6B	96	101	100	107		
Mean ± standard deviation	100 ± 4	100 ± 6	100 ± 5	100 ± 4		
<b>MICE</b>						
	<b>200 ppm (d)</b>	<b>400 ppm (d)</b>	<b>200 ppm (f)</b>	<b>400 ppm (f)</b>	<b>200 ppm (g)</b>	<b>400 ppm (g)</b>
1F	100	96	109	96	100	94
1B	100	97	105	98	99	98
2F	98	96	101	96	100	98
2B	100	96	101	107	101	106
3F	100	103	97	96	98	97
3B	100	99	97	105	99	102
4F	100	101	97	93	97	96
4B	103	106	97	105	100	102
5F	100	104	101	100	100	103
5B	100	104	101	103	100	102
6F	100	99	97	98	99	98
6B	100	103	97	105	104	104
Mean ± standard deviation	100 ± 1	100 ± 4	100 ± 5	100 ± 2	100 ± 2	100 ± 4

(a) Mean as percent of target concentration. Data normalized to the average concentration at all positions in each chamber.

(b) August 1979

(c) January 1980

(d) September 1980

(e) Data not taken

(f) January 1981

(g) March 1981




## APPENDIX H. GENERATION AND MEASUREMENT

---

**III. Chamber Concentration Monitoring System:** Propylene oxide concentrations in the exposure chambers, control chambers, and exposure room were automatically monitored approximately 8-12 times during each exposure period with a Hewlett-Packard® 5840A gas chromatograph equipped with a flame ionization detector. An 18-inch × 2-mm ID Porapak Q 80/100 mesh column held at 100° C was used. The calibration of the gas chromatograph was checked approximately once per month using a "bag" standard prepared by the testing facility and sampled at the end of the chamber sampling line.

During exposures, samples from each sampling location were continuously drawn by vacuum through stainless steel sample lines to near the input of an automatic multiplexed eight-port sample valve. The constant flow assured fresh samples at the eight-port valve.

Weekly concentrations are graphically presented in Figures 12-15.



**FIGURE 12. WEEKLY MEAN CONCENTRATION AND STANDARD DEVIATION (bars) IN 200-PPM RAT EXPOSURE CHAMBER FOR ENTIRE 103-WEEK STUDY**




FIGURE 13. WEEKLY MEAN CONCENTRATION AND STANDARD DEVIATION (bars) IN 400-PPM RAT EXPOSURE CHAMBER FOR ENTIRE 103-WEEK STUDY





FIGURE 14. WEEKLY MEAN CONCENTRATION AND STANDARD DEVIATION (bars) IN 200-PPM MICE EXPOSURE CHAMBER FOR ENTIRE 103-WEEK STUDY



**FIGURE 15. WEEKLY MEAN CONCENTRATION AND STANDARD DEVIATION (bars) IN 400-PPM MICE EXPOSURE CHAMBER FOR ENTIRE 103-WEEK STUDY**



## **APPENDIX I**

### **SENTINEL ANIMAL PROGRAM**

# APPENDIX I. SENTINEL ANIMAL PROGRAM

---

## A. METHODS

Rodents used in the Carcinogenesis Program of the National Toxicology Program are produced in optimally clean facilities to eliminate potential pathogens that may affect test results. The Sentinel Animal Program is part of the periodic monitoring of animal health that occurs during the toxicologic evaluation of chemical compounds. Under this program, the disease state of the rodents is monitored via viral serology on sera from extra (sentinel) animals in the test rooms. These animals are untreated, and these animals and the test animals are both subject to identical environmental conditions. The sentinel animals come from the same production source and weanling groups as the animals used for the studies of chemical compounds.

Fifteen B6C3F<sub>1</sub> mice and 15 F344/N rats of each sex are selected at the time of randomization and allocation of the animals to the various study groups. Animals of each designated sentinel group were killed at 6, 12, and 18 months on study. A total of 39 rats were examined (10 per time period except 18 months when only 9 rats were available). Nine mice were examined at 6 months, 10 at 12 months, 8 at 18 months, and 10 at 24 months. Data from animals surviving 24 months were collected from 5/50 randomly selected control animals of each sex and species. The blood from each animal was collected and clotted and the serum was separated. The serum was cooled on ice and shipped to Microbiological Associates' Comprehensive Animal Diagnostic Service for determination of the viral antibody titers. The following tests were performed:

	<u>Hemagglutination Inhibition</u>	<u>Complement Fixation</u>
Mice	PVM (pneumonia virus of mice) Reo 3 (reovirus type 3) GDVII (Theiler's encephalomyelitis virus) Poly (polyoma virus) MVM (minute virus of mice) Ectro (ectromelia virus)	M.Ad. (mouse adenovirus) MHV (mouse hepatitis virus) Sendai LCM (lymphocytic choriomeningitis virus)
Rats	PVM KRV (Kilham rat virus) H-1 (Toolan's H-1 virus)	RCV (rat coronavirus) Sendai

## B. RESULTS

Viral titers were not found in rats. In mice, no viral titers were found with the exception of one mouse that was positive for Reo 3 at a 1:20 dilution at 6 months. This result is considered to be spurious. Thus, there was no evidence for the presence of murine viruses during the conduct of this study.



## **APPENDIX J**

### **DATA AUDIT SUMMARY**

## APPENDIX J. DATA AUDIT SUMMARY

---

The experimental data and draft NTP Technical Report on the 2-year inhalation studies of Propylene Oxide in F344/N rats and B6C3F<sub>1</sub> mice were examined for completeness, consistency, and accuracy and for procedures consistent with Good Laboratory Practices. The 2-year studies were initiated by the National Cancer Institute in August 1979, prior to NTP's requirement for full compliance with Good Laboratory Practices regulations initiated in October 1981, and completed in December 1981. The studies were conducted by Battelle Pacific Northwest Laboratories, Richland, Washington, under subcontract with Tracor Jitco, Inc.

The audit of these studies was performed by Argus Research Laboratories, Inc., Clement Associates, and NTP staff in October 1983. The audit team included Chris Dippel, M.S., Curt Lunchick, M.S., Debra McCall, James Plautz, M.S., Ronald Schueler, D.V.M., Gary Boorman, D.V.M., Ph.D., and Miriam Anver, D.V.M., Ph.D. The full report of the audit is on file at the National Toxicology Program, NIEHS, and is available upon request. The audit included, but was not limited to, a review of the records of the in-life portion of the studies for 10% of the animals; records of room, chamber, and cage environment; 100% of available chemistry data except for daily exposure summaries; and 10% of the daily exposure summaries and corresponding chromatograms. All individual animal data records (IADR's) were examined for correspondence between necropsy observations and histopathologic findings. All wet tissue bags were counted, and at least 10% were reviewed for animal identification and untrimmed lesions. A complete slide/block match was performed for high dose and control groups of each sex and species.

Study animals were identified by ear tags, but records contain frequent notations of animals with missing tags (83 of 300 rats and 38 of 300 mice). Discrepancies were found in clinical observation, body weight, and mortality records relating to animal identification; these discrepancies may have been due to missing ear tags and failure to identify definitively the animals concerned. Daily observation records occasionally note that mice were observed free within the exposure chamber or "missing" without reference to location found. Although missing ear tags provided the potential for animal mixups within dose groups, the raw data that were audited gave no evidence of mixups between exposure groups. The audit did not identify other major problems with the conduct of the study or with collection and documentation of the in-life experimental data. The chemistry data were considered adequate and support the stated conclusions in the Technical Report.

Animal identification in wet tissue bags could not be confirmed for 24 of 81 rats and 21 of 90 mice because of missing ear tags. The wet tissue bag labeled low dose female mouse #545 contained the ear tag for low dose female mouse #546, and the ear tag was missing from the bag labeled low dose female mouse #546. It seems probable that these two mice were interchanged. The slide/block match was good with a single questionable match in rats and mice each. There was good correlation of gross observations at necropsy with histologic diagnoses. Only two discrepancies in rats and a single discrepancy in mice involved target organs (lung).

The most important problem occurring in the 2-year inhalation studies of Propylene Oxide in rats and mice was the loss of ear tags, which caused discrepancies relating to animal identification when clinical observations, body weights, and mortality dates were recorded. Although the missing ear tags provided the potential for animal mixups within dose groups at necropsy, there was no evidence of mixups between dose groups. Therefore, these discrepancies are not believed to influence the final interpretation of these studies in rats and mice. The data examined in this audit are adequate to support the conclusion of the Technical Report.